var title_f27_27_28080="Congenital emphysema left";
var content_f27_27_28080=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F62270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F62270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Newborn with congenital lobar emphysema, left upper lobe",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A chest radiograph reveals marked hyperexpansion of left upper lobe with cardiomediastinal shift to the right.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_27_28080=[""].join("\n");
var outline_f27_27_28080=null;
var title_f27_27_28081="Clinical microbiology review: Meningeal infections";
var content_f27_27_28081=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical microbiology review: Meningeal infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/27/28081/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/27/28081/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/27/28081/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/27/28081/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/27/28081/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/27/28081/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/27/28081/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 19, 1997.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     CASE 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;This 65 year-old man with multiple myeloma presented with fever, confusion, and meningismus. What does the Gram's stain of the cerebrospinal fluid show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef55171 \" href=\"UTD.htm?29/15/29950\">",
"     picture 1",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef66918 \" href=\"UTD.htm?30/48/31502\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CASE 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;This 19 year-old female college student presented with fever, petechial rash, and headache. What does the Gram's stain of the cerebrospinal fluid show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef82672 \" href=\"UTD.htm?13/1/13342\">",
"     picture 3",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef61788 \" href=\"UTD.htm?17/4/17486\">",
"     picture 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CASE 3",
"    </span>",
"    &nbsp;&mdash;&nbsp;This unvaccinated 3 year-old boy presented with fever, headache, and somnolence. What does the Gram's stain of the cerebrospinal fluid show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef69914 \" href=\"UTD.htm?39/38/40558\">",
"     picture 5",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81383 \" href=\"UTD.htm?41/24/42382\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CASE 4",
"    </span>",
"    &nbsp;&mdash;&nbsp;This neonate was irritable, feeding poorly, and had low-grade fever. What does the Gram's stain of the cerebrospinal fluid show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef60738 \" href=\"UTD.htm?30/37/31325\">",
"     picture 6",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef72503 \" href=\"UTD.htm?34/7/34941\">",
"     picture 7",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CASE 5",
"    </span>",
"    &nbsp;&mdash;&nbsp;This 38 year-old female was receiving high-dose steroids for inflammatory bowel disease, and presented with fever, headache, and meningismus. What does the Gram's stain of the cerebrospinal fluid show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef51407 \" href=\"UTD.htm?11/10/11424\">",
"     picture 8",
"    </a>",
"    ) Answer: (",
"    <a class=\"graphic graphic_picture graphicRef59105 graphicRef70892 graphicRef54066 \" href=\"UTD.htm?23/21/23893\">",
"     picture 9A-C",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CASE 6",
"    </span>",
"    &nbsp;&mdash;&nbsp;This 25 year-old man with AIDS presented with fever and headache. What does the Gram's stain of the cerebrospinal fluid show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef65656 \" href=\"UTD.htm?41/53/42846\">",
"     picture 10",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef77420 graphicRef52295 graphicRef64083 \" href=\"UTD.htm?20/25/20883\">",
"     picture 11A-C",
"    </a>",
"    ).",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1270 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-ED3CA7AB47-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_27_28081=[""].join("\n");
var outline_f27_27_28081=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      CASE 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CASE 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CASE 3",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CASE 4",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CASE 5",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CASE 6",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/1270\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1270|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/24/42382\" title=\"diagnostic image 1\">",
"      Gram stain CSF 3 with answer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1270|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/15/29950\" title=\"picture 1\">",
"      Gram stain CSF 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/48/31502\" title=\"picture 2\">",
"      Gram stain CSF 1 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/1/13342\" title=\"picture 3\">",
"      Gram stain CSF 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/4/17486\" title=\"picture 4\">",
"      Gram stain CSF 2 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/38/40558\" title=\"picture 5\">",
"      Gram stain CSF 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/37/31325\" title=\"picture 6\">",
"      Gram stain CSF 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/7/34941\" title=\"picture 7\">",
"      Gram stain CSF 4 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/10/11424\" title=\"picture 8\">",
"      Gram stain CSF 5",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/54/14176\" title=\"picture 9A\">",
"      Gram stain CSF 5A with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/35/10815\" title=\"picture 9B\">",
"      Gram stain CSF 5B with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/19/6462\" title=\"picture 9C\">",
"      Gram stain CSF 5C with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/53/42846\" title=\"picture 10\">",
"      Gram stain CSF 6",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/49/799\" title=\"picture 11A\">",
"      Gram stain CSF 6A with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/38/11885\" title=\"picture 11B\">",
"      Gram stain CSF 6B with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/37/19039\" title=\"picture 11C\">",
"      Gram stain CSF 6C with answer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_27_28082="Drug eruption purpura";
var content_f27_27_28082=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F80847&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F80847&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Maculopapular drug eruption with lower extremity purpura",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD0uC8STCq+1x1U8GpWuAo4OCKreVHJjKg1HPaqR8rOv0NaGliZ79YxkkVXOvOjfu8Gsy5sGznezfU1WWILmgDq7LV2uSA6j8KvsRtLVy1mChBA5FdHDIJYlx2oAYSSTS8IhPHNO78DjuaNu4+1MYxeFxgYpUyx4pzLgYqaGP060AAOyIngY9q5Lw863niS+1GXmO3Hlx/Xvit/xRejT9GuJeAQuB9TWH4UtXXTIoAPnc+bIcdzUlLa51Czy3Z9E7Vl+K/EEHh/TXllZfMxhUB5Y1a1nVLXRdOeaVwFUfia8rs7e78aa613eblsojlU7Y9KGwS6k/g6zude1/8AtbVVLbj+7Q9B9K9R1Kdba2IHYVW0XTUtRuC7VUYUegrJ8Y6rb2FvJJcyBV6KM8sfYUm7DWrOJlv3a/uGY8sx61zPii/luALSF9qP/rXz29BUF3fSX1w5jLRoT+NQC2Vnxkk9cVzyrJbHTGk+pFJOdiRRKFhjGFUHAHvUYLDpyDVz7KCxG7p2pskaRLwygd8nNc85825vFcuxHyyg8FxySf6UuyVnAJ+904zUENz9ol2RHcqnBAFa9rbYKs3J7EmsjRNols4DAgDMGP0q2EDLkcf0oSMkcHJqdYiP8aQrlCa2JiYIFyeuR1rKljKORyozzXRsg3cniqV5beaMgZamVFrZmIchHDEkjj8KdAVP7ssSB0J7+1TtFwyp82DjmqrRknI4KnFNMGi1KhjZCp3J0JqVo4xGdvJqvG5LmOQ4Dfd+tWBHt27s47kUmOKIPLDIVI6GmKCpIIOBV8whCHY/L6ioZ1JkwuOv6UFsZsYLvjPIpj7lOdoJ71Kg25A79adHGHyCcHsRQK1tSAdtuOPWpGA2AnvTGV/MORwOKcRggfyoHYcrDyyo6+tSwqZG29M96jjTI6UoG3pncOMUDWpMOHx6VPHhxgc0iJvjDbhnoaswWrrzkAZzxQJuxEbdjuC/gKWSEqgJBz3xV8ptYuOpH61XuCcK/QnqKdiOZlGWNRlcAZHajTLWS71CG2Rc7myc+lWrbSdRvmzbW7smfvngfrXU6B4fudLu1ubx4SwX5URtzGrhTbepNSrGKsnqdRHEIo1RhgYwvp0qqATOWt/vK2Mnua1oZre6tSYXVh/6Caybu/gsLczTyIAoJLHjmu9nmoXUp4khNuR14NcrruqWFhGxvJVWZBhY1PzH6VzGv+MJrh5I9P8A3cbDDSsPmb6elcbPI0rlnYsx6sxyaxlPsaxh3OhuPHt7FMywwLNED8hc4bHvUbePdWl2rHbwp9WNc6qqCWZMnsTxTGl2nkD8BUOb7m8YR7HRxeJ7nJeeKCSU9N+Tj6CtPQPFDRagv239zA3AeLov1FcQSPXB/nVlXVF4OQfWo9pKLNfZwkrH0HYXyTwRl3jkjf7kyHKt7H0q+bZZW2qOo9K+eLTVLqzIa0mljXuFPB/CvUPh545W/uUsNUZVuiMRyHgSf/XrohWUnZnJUw7jqjvLY7Z/LY44/KrTR8cDNGr27QXIkX7h5qWHEqgmug49zJ1P91AWA+diFUepNRW+mMmDOyk9cCtDUI0e9sI34BkJ49hVqSyRsfNQMz0gCFs4qxC4jG3OBSyac2TtdqryWMq87jikBfjYPx2qyo7Y+uKxlS5hHHz4q1DelcCVSKYF8x85NWIlxyarxzxyLlXH0qh4h1ePS7AuTumfhEHUk0AjB8Uu+ta7a6TbHKRHzJiO3pXQTSWuhaazSMF2jJJPNUvD9oNF0yS/1Fh9tuT5khb+EdhXO63c/an+3aifLtFOYYWP3v8Aab/CpLsYPiO9m1J/tl4CqE/6LbHqT/fYf0ruPB+mmx0uGFwN5G5/cnmuR8JKPEHiRJJRuiRwQPYV6Zqs9tpMU11dOsNtGNzMf5D3oQPsVvEetWfh3SHu71sk/LFEPvSN2ArwXVtQutb1CS71CQ7z91AeEHoBU/ifXbvxLrD3syskCnbbw54jX6ep71Whtgq73BLD2rkq1L6HXRp8uo+2hWNAcZFSzJx8rEH2qWADYOwpUidW5IZcZyK5XI3s3uVEt0bDklT/ABHPWmXNrFPD5mSFHAI7mk1OYwgrFjn1P8qk061lniDOSB2APGKRpyvdjdP0sgCXePXjvWnb26KTzz3wangiGwxgkYHFT29qYiRsyD/F3NFgeoxU28Kc46ZpqmUSYIUKRzV+G3jO4L1z+NMe3DuVIK453CqSIZU8shjk5B6Cq94MBlGckdKuum0H096qsFkYlW5HX2oY0ZcZCgseucEmq9zFgFlIZWrVkhSVXxgH1FZE6lQQDx0wKVzRWepErFgcrynQ1dilE0Yz8pAqnEAeCcHGDRECJAM4wevrQxpammikw4LZ5zg00gDBAyKSNgi7u9K2GKMDgY6UihmFY4yMjtUkQA+RiMe1M8pBhsfN1JqSdPlXaeo4NMiWo6WFFUsSfaqyJwxJ47Zq0I2NsAxzj1qttOMdhzQERUAU4A4I4oUhQWJx2pyrxkcdqVVUttYfNnPtSZSJYtwVgo4P61atp2T5WBwDg0tvBld2ePSoQpDlWHDGhINGXJ5FYAqTk9BXY+H9FWG0+03yq7uPkQisLwzpy3Opo0pGyMbiK9ClVWRSiFEX8z7V10IfaZw4ipb3UUJFKBY9w45kfoqD0FR2luotWuZM/IzMm7+7itOG0R3zcckchO3/AOuuX+IXii00m0FlGVmvXIzEp4Vff0rpbsjlSbZneINTtvDtzprYfdIjPOFPLZ6V5xr+vXOsz5nO2BSdkS9APf1NQarqNxql211ey75DwB2A9BVFpR2HHtWEp82hvGCjuNIHJYce9NLBR8opHfngf/WqMtgnkntWbZYjEH72fpUZVifunFTKqsVHQ1L9nBOd/GalspRKBIB6fnT4nAGMfjmpp4ihJ61VlRgRwACak01LqMcEAkA9j0p0aMXVkYoVOVI7H2qog28sSPqaninwFGfwp2KTvufYV/a/aICGXk96w7QNHK0LjkdK623mhuEAI2E/3jx+dZes2f2adZgOM8mvSPFizB1chLqwkb+GYA/iMVodOQf1rP8AEysLEso+ZCHGPbmrtnKs9ukgIwwBFBoiQSH0pfNB7UhjB6UFMDgUrgKGX+7TWaMg7kBpSMAYIqjd3AiiYkjpzQO1yHUb6C0hd1hRWHcjpWP4fs5NVvW1nUyTaxf6lW43kd/oKjtrWTxHqBjyV0+A5mk/vf7IroGT+0ZxZ2w2WEGFcrwD/siluPRFeZ/7UkkvLsldMtwz4P8AHjufavNxZ6h40il1i9nNpppcx2ltGOXGcAk11nxY1X7F4dOmWRCS3hW3VV9DWJrmrx+HdN03S9NZGuLWMFzjIRsfzpN23Kim9jX+36T4ACxCNpbnZxEp+dz7nsK8+8S+ItS8SXnnahIqxKf3cCnCIP6n3rLuZZrmaSe4Z5ZJDlnY5JPuaWMIwXdt+WuSpVb0R106Kj7z3JY4+RkDgdc8CrEaq/IcH2FDW0ckXyDOfWoFQow+Y4HpXK2dK20HQl1lwCUXPSr0sLSwhVcqfVapz3QEBUjJC9RVHT9Vk83IQsvTnmhDab1NMWiXMmzLFlOST0P0rYtYBEFQDH8hRYgSLvwMmtSKJJE4HJpohy6FeKJfMDbR7c08KyzEqwZT1HQip4I9uQ4Py+tP8lWlEi7emGBoGkMZc5bAHoVpjpntnPSrjI67VRFIJGdx6CorlhF97hT3qhb6GfdIRGcr8uOlZdwiqpUIwPpW49ysRCsuQw4yOKzb6Qq5KrkflSY0nczUUiKR48E+lZhJdTkEMDx71vKqvEGiAyeoFVpYAj5wpPoaVilKzMIqMntTYmBzk1cltmZwVyFHOKje0IIKgg9xQVdEyBsKeoI705iuwMGP0qMOY4wjqSKFck7OlA07lm3IZGxyxHGRVgOu1VYcjt6VRik8p8jkU+RzyQBz6UEuNyw0m6JtuTg8g1VGSwAOVHNSYZUyD96oy4XBGCT1oHBWLKjdCpAwQeaagIYMOR6U5CAmAPanwghsAcCky4+ZetFOxgfyqS1hlvNSjtoUDOTge1JbI4hc47cV3XhfSksIFuJAPtEgG5v6VrThzM5q0+Q0tF0qDS7UkKGlY/ePc1oXMiW1v5sn8PPPr61Sv9Rt7SAz3cyQ26Alnc4AryTxx44k1lvs2mtJFZLwXPDSfh2Fdl1BHDyuTubfi34gG3EtrorZuW4kuD0T2X3968ulleWRpZnaSRjuZ2OSTTHY/nUZ3OM9vf1rnnNs6IQtsSHLNxnFPWItkg/WoEfZ99efc1NFcguF2rn61i5M2UEOFupXB604ws2RsB+h5qZmyoMbcjqMUzeNgKj5vUHOaV2acqKzRFeNvHf1FMD7O2R6VYKGTDE49D1zR5WIgzYdAfvelNMTgRg+Yhcg7emKje23DaqNnHGOamjcGUrDn/a44NTK+xjsJ3evrSbBIymgeMqXILfw88Cnj5mBIIbofarjxrIuV6k5I96YISeCeM5/+vT5hWPry3IRiv8ACecGrk6tNZSwEeYpUlMnkHrVCL57gg8kVq27bRg+leqeKctqyedpe7GcrWZ4cuM2YjbrGdv5VvTR/wChyRkZ2krXI2Mn2XUmTornIz60mWjr05Ue9NOQfaiBwYwx6VL1HOBSGVZWCrk9MVymoPPqWoR6dZn95IeT2Re7GtrxFepZ2xc5JzhVHVm7AVHpFk+kWY3KH1m9+Z/+mY9PYCgexLchLG2h0bSR8+Pncds9WPvV9hFpVgI1wNozn1PrSWNtFYxyTSPlvvSSufvHua848c+MDcSPbaY25Bw0nr7ClKSitSoxc3ZHP+NdQN7rEd07hhb58pP9r1Nc6GeVzJOSxY5JqB5He5UMxZzzg81I32hTl1xF6jkmuKpUuzvhR5UTg/vF5LBu2OlSvb5G/b0HUd6mi2heOQB0HWp92FB2YPbFYNm1uw6wUBDz9c0j28e/ex47n0qSAnzOQcdjVmRE27ZDjPTmkTazMO8QBiYcGM8nBqfTbBWTfxxz6ZrTjsUiAUD5Tzz0qxHbsEI+UL296LD5rIgjtZBIHhfCDqPWtC3EjTB2+ULxgHg062h2rhQT7Gpl2bsZIbscUyUy4EwDuY7j3p5jDANgkrznpVQhWbY29WxkMO9WFJKqC3Qdc8mmGxNwevHriq8yKwMZII96dJIFAJzj6VXeJJZt5OHx1HHFA473I408uMhiHVf4jWRDBOWlN6qY3Fk2HtWz5UkYwjb1zzntUTwh3DZKkdqTLva5lyRZmUQBlzyVNMuCC+w8EDrWhcFY2WXHzA44pssaPyUHTmnYTaepnmI+WMYwarzIccYBFahjVQMKQPSq0sPzM3PTpRYztcxpI/MUmPlgcEHvUJiwN5BFaksKxxErgex9aokZJiJ6jigqOhXVWYlW6dgKdvOfm6gYFSLhIyDyc/lUakFjuFI0uSo5KBO5PWmDhSTk+2KZGwVgVOTmp4irqVJOc5oGie1BdQpPIq1ERCSCRkjvVKG4VGB24PQ06e43PvAyAcUAb2isJrmGInh5ADmuw8XeILPw9bL9rkHmsv7q3T77+nHYe5rya517+znjexYNdqchiMqh/qawZriW7uXuLyZ555Dl5JDljW8J8qOatDnkaWv65f6/cCW/cCNOI4F4WMf1PuaymLDpipGI58sH61G4zy35VEp33HGnbYYzegAOKQEkcjj3OKf5WB8vT1NNZCPmXgdOai5ooMjYIXwFIz1NKwKg8Ag9eOlIeF55PqOaeisPmTJx+dIvlsNTco3ROA2e5xVqKcSDDoA3TIpjNG6r58ZKg8sBg/jTJAkSqdNdpR/tjGD6D2oAukMqiRf3mDyyinx+SyHau4t970qO1vCFbzYjHxznoaVnRyzRkHpkr6e4/rQDZCybCF4APYdjShCCG5yOh71L5YkXaxG7Hy56N7A9qbEW2FJAc56HqKBWHouThvvdvenlBuJbjimquGGeF61Kccbjn680FWsfUtmuZcnvVi9u0txsGXlPRB1rON8Qnl2o3P3kPQfT1qIAwB3UGW5YErnqT6/SvXPBsTjeYpvM2785IHbNcZ4hje3mjkHXOc1vSX0vmfYrEIZsbppG5CH1PqazvFMIi0SSaa4eRuNu4Ac+1JlxRo6PdC4tUkz1Fa6gyAbQCfSuZ8Oq0ejRh8KwGTn3qW61OQTR2Fo/+k3PGf8Anmg6tSKsS28K3WoS6ld/8etoWWBT0LDq3vjoKsG7t7Gxl1TUpREZecsecdlUVi+Ides9OsjZxASMF2qgPA+prznWNRn1FzJeTPIVGFGflT6ColNRLjTcjV8VeLLjWXMEBMFiP+WYOC/uxrj55MKxROegFPUvIm2MFQeMkc01LRhIXlcvjpntXJUqXO2nSSKLPLEUCRbnbgNjpmptPsZ0kMjTs2f4Ccirs8ccpWJx2yDnFX7aDKgrjaB+dc7kdVrIqTxO0RWIgP6movJuDJul4jXoQf1rYwsMe2QEntxVdiWkwPTPTrRYSfYihPmN8kpI7jNaMEfHOfYHnFUIbbY+UJyxyeODV6BHEu45wO1MU/It8mPYwOPSnRR+UCWbIHPPangrkKwOW9KdtCkZ78VRkTggrknqM5FIVBdSDgDvUUlwsQwQc9KkVyyEqQQehoCzRMpLMwyCvtVe4eaOQFAuw1JuBUFD8w60b451K5BI6ikUvMLWZbgHgq2ealO3f05I4PrULTJHMqMMNnHFWlAABGMUCYRKFBD/AM6aVRsFWGOn41LLbiaMEnGOhplvbCBdrkHjigdlYpzwk5zVZ1O0KQc+vStS6xJHg49eKp4LICMlaCbEEkbEjn5ccCq8qEcHp1q43QqRyeAaqM/3k5GD+VMRRnTk5AGemPSs0wiOTdjOPWtW5OSM9az7kMSq8HJIpFWuVblQSpXn6VWmUo4Pbpmp8eXkMM4PFQSN+59i1ItaBCV3MWOSOcVLHPgs+BwO1ZoLAtyee9OMjJHnsaAL0ciCX5uT1PtWVf6k2WhgYA55bP8AKoLu8ZEMa/eYcn0HpVCLOAANzE/gKpCbJFGG3MM96mL56cD2qGM54bpmrCxruyfu49abdgUdRBIMAjGO3NN3AknOT39KliUZPAC+uOtEkYf7q7RnGcVDd2bKIFkAJyTj+EHgU5IklBydjA/XNTW9qcNlMkcZIzU3kqFGPlI4wO9TcqyKiwLzhvqSO1Sw28YVnEypF1Oe1WvKEit5eSR0HempaMvzTcEeg6GmK3coyh5W2rny/U9T/wDWpUB3ZVVBAxgVflhm3fIgz1BHWmqCwCTpk9mUYpXBRKbSsHBkTPbKmosKCZIyd+M1faFGjcYII6etVtvl5GCOP0poUoCwyiWIpNnd0DDr+NRyylWy33hwff3oni2opXODzuA6VE77M7ucgcnvVLUxtyl2OTzshmGccZ9akclSMjAP41UtZAtyo3ZRhg4H3auSuqRsM5x3pNWNIu59MwKqxho1OzphhyKxRdXWo6jcC1mWCADYZcZbAPO38a09UuhBp85Xhyu1fYnvWNpO2S7jt7b/AFcceCfXmvVvc8RI1rGzjt4THCpEZ5ZmOWc+pNZXiMC7uLS0JxGXy30HJrevpVgt8DHAwK838S64yzeXbY8wZBc9FBpN2Kimy/4g8RW+lxyJESznhUUcn2FcnH4huLSGdlP/ABMbr/WSf8817Ivp71hXlxI7s6H95nHmN1/Cs8OGyQ5kCj5sGsJVbbHRTo9zVku5XYtMSc9waaUSYYc54zjtVK3Y3CnfEwVjj6VfijdCBEoCgY9MVyync640wSNki+VeTwKkKMPlYjZjp/jU6h9g8wrg9KbtBJLg56ZrK5qlbciVM/MyqWxj6fSlt2kXDAFQeoPX61KUAZUJzmrIQmMjHy0FNk4y45XPv7VWeM53rgDpQJmfMbbh6EdqURsSQck544p3uJKwKyllAYlx19CKvxBhGXIIA6HbnFQW0AEm5uB3yavou1dqk5bkN1FCYpWGxxq4G7nPcdamC7Rz24BqJXMbbZgobruA6ip1Tdyv3fXNVcykmRhdxKlc+9MtyhJYBgCeSamIHPP6UxsBTk5x0JoBMcWAPzH73Sq8ZYXh2j5T196fKzLCWi5PakLykgpjkdDwaRSQ+dDOwK4BB5+lXozhQOwrGNw7HnKAelXYrhdqgudxoTHKLsX1YsMZx9KfJIu0BjjHc1U8wZXJwTTiQ2c9KZKQzGCx3EZOaRcnPI49acy7lG1iKhuGwuCD7gdqAauMkUbcKRnrn1qnKuG3E9ueKtlACG6nFVrgfMSOKAsZ906qcseKYI8jsOKsSxCRce/WmynA/SgHsZ10hIwoyfaqA0rUbtF+x2c8yucBwvyk/XpXaaB4d+2XcTXriO3CmRlz8zDsuPU16drtxDpukW1hHCgdkDKi8BB2/Kt6dG+rOepiOTSOp4BeeH9Y04g3unzx7hwvB/lWLeRS26b545I8nChlIya9b1e+8tmluJegLMznr9a8s8S6vNrl8rtlLeIbYkz09T9TTqU4wRNKpKb1MEgu4yScnrV61TaxLKFUjjd6UxVK4GcLjkj+VEgDKuS6jPGea52zrjuTSqkmBuAC85piFANo6HkZ70u9AvlkEj1PGamI3IPkAx0PpUtmqdh9oAzOxdsY4BqYmHB2k7h0yaoNHKVIAYZOc05QEATJ39TxSDmL8Vw0TMPNwOhVepNWgUWGSZznHQE4yewFY4dA2R94frQrzvIsgOMdPYUbDvfVmlHewyTD7T5rXIP3tvy4rRYxOUbkhurDtWVbWo5IbaSM5xyaurC4OWJ2d+etJyuCkmyZYCj7kYPHnn1pJo4HViBhyOcfzpHwhLZyhGDiqzqPKEm5jk9fX2pqxoiJodgLKenTNQy/ePQnvjtVhmZwcLhTxg1WmZlfHB24FNDaIiHddijvVSVcAxuNp9+fyq3LvTDqMKOvNRStE6mXq+MY7U0ZyjcqpGrYI+WVeme9XYJS5O4dTg1Cwie2EuCBnBqvBKI5JPM5zV6MwSaZ9D+IbsujIpIGOT61Z8IAW2mzXL9ZWwufQVgaqWwFBy7kKM+9ReIfEUenWcdjYsGeNNmew9TXot2PMSvoi/4n8QRwqy+Z8x7dxXml9qBlkfZkZ5/yKrXdxNPMZJGaRzzUcUYUFjy3U/4VzTqXOmFOwgBbqPnxwvpTlVCyIiA/N82OimpIwArE8c8AGnW8beYz9cjGPSueUrnTFEyxAsMsc9eDjNWEEceVI+XqWz3qk6yIwEmRnkYqUxtIuzeAW6g1kzblLeXWM+eqOM8Bf6e9TJDBLExiyDwDk81XAEcJ3HLL0JNJbb45QyuQ+eQR1pBylqWx3PGUY7epB7fWpRKInEIVnJ7YzV/TEWWM5YO3r6U+4EETbYlIkP8AEKaFfWxXggEZYhfvDimmYrKFZSc8YWrSMWBBABwcMx4FMgt5PM3K6E4x+PfFNgtdWPePz878hR2IwKBK1ugAO5Aeg7VYIztPUjv6VXuER3Byqvn73pTRNhEmJmG4EL2Bq0jkgjGMdcdM1BFDzu3ZYjoORUpwEyv1HpQNpdCOQ+YcxuQy/wCeaiZGeLOct6joabEGa4LYUf3sdasH5SABx2FAmuV2IFLs6hcKoGSD60jDdKCXKt7VIyZHHBJ5+lQuyiba2enHNAuo9UWNdy856g81HazhmI298U7zNoG0nB7VEqAOSDgnqD3osHNfRl7zolb5iCTUiyEFjwy9hVBlVxyBuH5VKhLLjdtHYjtTC6Locb1UjBxkiklwM4/EZqEOSAQc9uajZyjHjdn16CnYT8iQyDBIHFVZTlgcc0wmTcxAGPQ1ctNG1G7kRLa0mfzD8r7SFH1J4FUot7EuSjuZpJMixxjLN90Ack1s2Oh3KKtxcwy8cj5eBXQaX4Zj0u8jkkuEuLsL84QZWP2z3NdjbsLiLa5JI45ropUEtZHJWrvaJwGm+YdTtyi5dHzhuhx607xZq72/m3MmJbuZiFDHAVR1J9AK0vFgsNB/0i8u44S+WWPOXb6AV4p4q8RTaveOUzHbAbUjHUjPetJyUDCnBzE8Q69PqUixkAIPvFOjH/CueLFzkn5RTmZ+gICnqKAjuNqEbvywK5JNyd2d0IqKsiTcxXcMgD16mngPJyAQw9elRrFKGywzjtUm9kcIYyT25qJGyJ47UhGckEnr6VYgUBQrMC3UCo44nkONxUegq0trlcHnFZsGyFyxAOAQecDjFQmI7SwlPXnPOKnMQJG35R7d6c8L+WrLEWY9DnnNLUtFeOIhgzoB/dUd/c1etYWJ3HJPvUllaMuXJJ6HJ7GtNCEiyQ5fp8tJ6g5dCADBGFyw4JXkfjUlwgaIsPlx97bz+lSJCoYsCCOh9fxqQKVJ3AA+x60E6GUsUgO6KTcncHtU20xQZPzL1xVyARRFhjKk5Oe1JcOefK2ndyOetCNYy1sZKETKFwQB155HpVWTcgO1T0wuelbP2ZJSJI9yn17Vk3kUu5wcrzyPX6VSZqpXK4k2hVIDDHIz0qtcuox5Q7HoM5FDDa4GeMipooPMdtwAx0xVA0VROFiZSuBnBGO1V5ExNvXIHtVi8jaKRiBlT3NVjIEU4fI6c1UTmqHr+v6k1tdKQvlyIDtU8lSR1+tcbPdCSRizZJPJPr3JqO5uZbmVnmY5JySfeoDIplCtjaOo9a6akzlp0tCVH8xykZAx3x1qdw4UKgHPTIzUPnAKWX7pOMkY59qbbTSPOylGJxxt6D8a5pSudMYPcuRJtQKzANjqRVuBti+ueQTVHyGm2vLu3DkA9qlUrIzJFu3YwT2FZtmnLcWRSr/O5ck8Ec4qcyDghNxA4x1pFCqArHceBwOacxMBLNjJPKdcUrlqNyX76HIBwM7cdKAzBF3AjPA46VctCQvyAjI5yM806FJLgMJkCuD8rL2oFawy1uHjfa52+hHerxeKeIZLebnBIHemm2VYwsgJxzux3qGNC0pKMSvbjrTsK6ZeEYWHJAweCT0pkUiI5jxtxyD2b3qVXklhaIMFbGM45qNgRNFGWUADJyOppi6akpJGcElTyBRM6iMHYGJ/Co/OEcioVJYknp0FPWICPAGATk555pitYcxAj3Iu04qrGTPkuxKnnaOMVK0uX8tQWI5p7IRgZwMcUD2EjhUMzJgH+VCMVI4yW71GpZjgAqakaTK4PJHIx3oRDGu+GO4dOaqXQEsu5WzgcjvT53jC+YxBzxVd5gYjsyMjAoBXI2kMZ25JAPegT5bgcj3qCXLKTu56Cqwm2Bt3XpTQSskaEshIABwTU1rwdu7kn7o5NWPCvh+/16UpZxts/jmI4X6e9ej6TpGg+HtqtKlxdj73lAMc+7VvCi3ucs66jojmdH8NahqDL5NqVU9ZJTtH5da6+H4e2r2EyaheSLOw+V4uBGfXHetO28QNKTFaWckYHygsnWpHh1C6JMkjqvoBgGt40Yo5Z15S8jF0nQdJ0hB58Ul1dKcebMQQT6gdBW21/PLG8cVs/lDrtHGKda6bLbXInISUjgrKuQfr6VNeXM8UVxKUVWZAnB6DtitEktjJzcnqc0GTzHMS4yc1meKPEX/COaUZ4gr3cmUgVum/uT7Cl1zV7bQrH7Td7tucIi/edq8R8Ta7c65qTT3BwPupGPuovoKic1E1p03Mg1nVbjULl5724a5uJDl5X6n2HoPast0L/wCyvrinAAZ3NzS7nxyMccelcc5OWrO6MLLQfHCOAVz24FDIyHaFFSQnIAy3TnAqYunOfmwOCTzWdzRRK1v533pFCuOqg5A/HvU8DwsxLIc0olGwgMW5+uKAwIUyHHptH86ls0US4kqgZWP/APVUjksQV4Ht2qpA2XOWHpjHNSrMUQEIzL64pC9mOSB/OU7wF9D2rTSIYBkAVz69xVOHy5ZVJQq2PvHvVpS4U5BKZ6jmgHFli4jHlHnI9AO9QGSRCOuOhA7Vbt282NSpKn3H9KUW+9nMoOc8EGkQnbcgBKpuBDDvx1o+0o6fL9/0bg1ZKqwJBBXpg8Y9qozkJkBQxU546CgNGJHIzPgqd3XHrTniBLZHyr6/wmoYZ4y4KHGOo7irMt0ELEYwRjJPHNBWt9BlpIAzRuCFJwDVie3jniA2/nWfbsFJVtwUHnd1FXluo0AKnAPU0Dd09DHu9Jwr+WwLds1lwg2zlHJ3fwkjp7V0l7L5sTbD84GK5m6naYtHJ95W+lUtTSMm0Nn82VXGxgoYKZMfLk9s+vtVXUbZbeWONVnjmVf36TKF2vnkDvjGOtbtsYNS0O009tUg0+4tJHeWK4yEn3HIkyAfmA4war+JriO5ls4Y7prw29uIXumBHnMCTkZ5IAOAT1xWq0Mpu+haJWSNwuSx7Z60hTYoYx4x6d6kYrEV2g+Y/XA71YtY5PMdpmG08KMfrUykOMLIYzouC5AYj7p7U60jC/M5dScAqe/vViNFdQUQMT/eGDT5WUSAGPJP93tUNmqS2JSBLJtjbdtXJAHNELAOVZQOOnc1PBbxRKZGYYI4FWvs8BdsqQ23AJPWpFoin5MiOHRQwbjOPu1ILOO7uNzEMVHbr+NXFQxxhlztz0qxbwopeRGUF/4h0p2GpWKcYEMqKu4DoB2JrTslCKVxtJ6imOYpFx/dPOB1NZ+o3FyJVWJeCeCKYvi0L12zbtm8EDkj0qrOXXG3cGHzYA61FbrOZEkmYrnnBH3fatNJFkHBIYUD5WhLUbsvKcSNU+5ZSFBBAHPr/wDqqrdFkykaKznlgeKlslVVyqkEDA560yWrq5ZTYVHf0x3qJp4w7RsOT05qk8svmfuME7vmB7CpprZpJtwxgjk+lActt2SJ8iFY1+br6UgLlRkAseCc9KjlRlRRExwePpTQp2FEfDA8mgRPFwTk544IqMsG3hQcD8jUT/6PBtG5nHr3pBIzMC4Cjtg0ybdht7h48YyMdu1VGUGBQnVOoPerrRq24g4z1NQvGVkggjUvLK4WNVGck00rsL2Rl3NxsIjjR3kboqDLE/Suk8M/D7WdXmhuL+IWdifmKycPJ7Y7CvYPBfg200OwWW5iQ3knzSPIOSfT2A7Ctu7vIYQVhG76dq66dFLWR5tbFcztA5y30RbWzW3MjeSowIk+RMfQdfxqRbaGEYjjjVR0wAKtSzySknnFQ+WW5Zsiuixy3ZGJGziNMketWoJrpfuuqr24zVaW4jtyFLZbso5JqXT7ebUkLyExW4OFRT8znvn0FDEy2bh5m2q7M4OH2Lkfn2rH8U6hFYaa015IEiT5mbPYdq15JjHHPFYNHbWkAJlnbucc4rwD4leK38QXSQWpIsIDiP1kP94/4VE5qCuzSlTc3oYPjLxJLr+oCTb5VtH8kUXoPU+pNc0+0/KuTz1qSVSHIBJbvj+VQsuHUqVGPTrXJKXM7s9SNOysNkx3JLDjgVMhQKAQQ3fPpRFL5Ybbwc8ZIqF5CQS2AT6g81mzZRLnmoAPnAwcE5xigghmchXycAk8fnUEh8vaywK7EdKu24EsW1wE9hz+lQyuVoEVlwSy7T0A4xUxiDLGoJIbvioDO0UyKkJKDoxHFWh8j+ZJIwHUDsKksZPGY22hlQkcH1qzAtwrARgSA9T6VG9s94qhApUHIIq1B/ocRE0nXpnikPoSCwxMrZzjlsmrDqUicwqSPY1US7eUOISwcDbtbpVnT4pVg/fFg39080EyTtdlyAMAvckdO4qyvzqwXHPFZMEsjzF1wYlB5Ht71btrhbkFkYA9x6fhTMZRadxyI8bNucYOTg0yZe2zAI45qW6EodVVM8d+lQTq7YWM89xnikK1zNaIQsMoemM9KidC4YH7pPQ9DV2e4j8tTImWU4G7jBqk86qi4G4Z5oKux7DEYJf2GO1DEPEVJ5HIIPU1EshkjdT1zls9s1CqHLR9R/Cc80FIhE85ukXHOfmA9KluoAUM6AeYOq1YwpkAK5ORk1KZkS4U+WrohG5W+63sfaqQpPXQ09KS/XQbI6VcWVs5aQ3Ad41kkJPyn5uwHGK5nxP/AGg16ranPFPOsWA0bow25OPu8VqXur2sKiZtC0lmIwMo/wDjWHe3Ud5qCvDZW9ogjwUtwQrHrk571qjHZ3ZvmJJ7fYC6J13DirkEaoAZNqoO3vVazJIJEbIo42v3rQhkXLDbz9KyudLVhnkMNwD4B5JH+eKfDB5CldzMWGCR/OnQvIZMIuY+hz2/CpYrpHuTCY2LAYJHQUbifMhY4V2FVB6Zw3bilsVKqmwAseOfT6U+Rijr5alxjn1plqqB2ZSX9BnkGkOOqNZogV3IeTwR3zUb24aJkIO3r8vHNNtXRpizM3mgYz/hVueQ7WQDaSOmKohpplCP5kLFScDoPbsKlgMU0cczqUHUBuv41DBZrbP5wcln+XaeRn1xT7VMNLE8nzZyBnp9KV9TRR63LFwqCP5VGB6c01Yx9mbbkfLyRzSvC8cZWTJU8Hnk0tnF5aA5LADuetMp7EMiIkQfDFgOPf2qGPUUV1VQyluNpHer08W4rk/IDnFUbhk83cuGI70MFZk1ugdt5BX296kuJXiKkD5e9IroYsgkjHGOtVHlZwxP3O5oZNuZ6lm3nEm7C/MOagbzPnYL3/OooXI2lc8H1xkVNLuAwRnJ+mBQgsk9Bgn/AHmwjnFNu1O+MpgMcYOKccctjBFODqEO8jI5pomVlqGF2DecqOp/pXonw+0N7W4/tJ40fUXTEayLkQJ/8UaxfB/h57uaO+vIyEU5hhI5Y/3j6e1emWdsYoipO1T1Vf6nvXZSp21Z52JrK3Khbk3EjET3Rkf/AJ5xioorGWUnI2j/AGjV9GRBtiQBR1I71IJdmNx+XGfpXSedcpyWscOBI5Ynj0ArN1VZY3jEDkwuOVzhgR1GafqN8hBbdkZwqjqT7Vd07SZtQSF7lsWqAsSOC5PYeg96LDWmrKXh3SRqjSSSssUCniJT87H/AGj6V1V7+7sWgEYhfbtj2jg/T0rM+zxW11fyRkxIjJtxxg7eorlPiF4zk0bR/Ljl8y/lGIlHVf8AaP0qW+rBJzdkcj8WPE/kJ/wj2mOAi/8AHzIp+8euzP8AOvIbqYRqdm3eeKuXBkmmZ5GJLEkk8k1k3zjeVU7iOvpmuGpPnkevRpKCsim0hBODg5xz3qESbDlSP9oECnFyRwO/SkEkRYKz7W7qBSOpRCF18w54Ue2KI9sk5wBy2Tk0p+zgOHLEKeq8CmbQGWQMEHZcc1LNEjX8o5VwpkPoeAPepCGEitFH8xHrxVYXbeXsmOGUY2pwSKsGVJbUDY8YPA7Gs2UkS+cY5V3kbmHpxTktlkXcDuLHp2ot4FSLfIenTdyKmXoETCBhnOO9SJroiSyRoSQ7pjoOMCrN1FHOii4AQjkZ6msKVJ3eRSxLIflwOmaswLe3LeVLt2IA27OWxQPk1vcuTWa2482Ni4Y8c1btL2GSDkscHnB71n3FpP5cc0aOwbggnsKqwpnfCEdVPGR1U0IpxutTSmuovtcKwyeUrE8AcN6g1cIhikXaAueh7E+lcvc2qQtvXeCxwGbqD6ZqGO+c5WWRkUMOWIODVNEygmd2CpOQWAx36VSu3Rlyw2kelZ1jeXLkBzlT3U8Zppmn+0yFGV4v7vp60jmdNxZDO+bgpKqsg5BNNuAIAWfADdCe1OldRcll+majdfPgYu+7GeMdKRbsx1vPBIrbWPmAYwOc0w8hm6H09KyLSCeK+3SLtU/xVppOpm5HPY+tMlrsTQk4cnJfGBSRj93uk45waYXWJyVPBp1xIGRd4HXgVVjNyIp4XnUDy2lG8BAqk5PoPf2p8sUNq62slpdW98q5k848ZP8As4yBjGK6LR9Sgi0uIxm4e5sY5isKRFlLv92VmHTaM9axdanSS7tIYppZzaWywvPKpDSNknODzgZwM1tGOhjKd2aZi2oMEZIweadbou4mJvvHnnPPpQIiMAYJbBIPORTnCxFihxgZwBx+Nc7PQQpjZnXa7bs/MOlSWkTlyS33T246UW0Mj/O2SrdCp7VPbCSN2VSTFknceue9BaWli4Nwtw4jBkXnHXikiWI7gwx0JPbP1qCG63yvBHuZwctu449qnW2jR5AH5PUZzTIUbblgNmNSo8wg9cc5pTJKRJ9oUf7AHQ1VB2IGnyqhsDnp6YrRHltGJASxC5OemaaFJElnxDwoO3kDHbtRDboJHdcktyM9vpUaI7xq6kiUHp6ip5U2qfKI3ZyRmgluzKsoEzSRs2GAHPeoGR2DAOV2jvxn8afPcNsyYwGz261WaZ3k3R4OR909qRokOaWVE2NyoHzc9Kqo5zuUKoztOfT/ABqzejdEwQBS3ORVXK+Xgr856570FJ6aEuWUlicqRjj0puCGwh6VAWIYEnEargD3qw20MNvXHShIluw+PJGMVLKrEj09OtLGACS3pk0+GKa4nSOGNndvugd60jExlNbsiucJGflzJ2+tdt4Y+Hsr+Vd6ncQOTh1jRiQv19TTtD8MW9vcmXVX8y6TDQhPmVGx09Cfeultpfs0uQzmPjc0ZwFP8q66dFLVnn1sQ5aROhtNKMaqqyBAOPkXrVv7FHH95pGH1qlpWoTC6ihnUlZjhGbhh9RW/dJLsxHEoGfmYnoP61uefJtsyrgW1vFuAIYc53GseGCfVrxEeWRLLBYsCFL47D/Gr1vZPq80uCUtUYgt1DH0FJdxmxubXKlYw+wFT0BHWqQLQtjSLCJf3FupYDryT+ZqjPEbUkRvJED1VWIFWr/U1sIt0s0WB/EWA/EivPPEPjg38rWmho19OM7pE+WNfq3QChAk3ua3iTWorO1c3FwzIh3YLnOe1eJ6/qU+sak1zOQN3QD+EdgKfq99c3Ujm5uBM5P8H3VHov8AjVFEAIJ4U+veuOtUv7qPQo0uVczARfIN3Bx161m3iiIOFi3MeenIq/fSeSvyDLdSM81zr30xJJZtpzwR0Fcx3U4N6leaSBIiqgs+fmJHAPtiqYYjdkYJ/iHf/CkuJQ7kEjaTyB3pplRgoJ257471obqI8K7HaWAK8k1PFH867SCCOcjqKgjcrEwTJOecrU+5lUMhCkdRjpUstIvyqHjj8pwSOrDtUdxMz7ASpA4JB61V80RxKluQXkbkAdfpUSoyzIrod5yQM4/GoSuWbUF+DKqM+UI5zwFx7VblvoFdUYnBHUelYXCAR4UcZI9asIrSKFKKWUdO+KXKTYu31xLbtiJQ0I7r1xU+nX0oMTFBtIwH6GsTYYHUTDA9c9fcVMtw8WxEfjB2kHmixW+h18d8cmGaJFUggEnI+oqGS1L5yo2MoCSx+naudF0NgilbeG5OWxk+3p9K07O9NpG0cTNMOoSRsAjvz61LiTtsUNSvJbdTE67ghwSfbpWKirOGeV9rDGGb17YrY166F7M5AKuvGB0YfX1rGSVUTZIisucqp6596tbAbFpPciCNYT8w5yxGR9a3Ps6TL5pCxuBuJU1xolKBWYlZF7/yFbWn37LlZc7yflz3B6ipaJnHmWhekdRGz4Vl/vGojPuTMQALDketTgxS2rYAUEkYxWbezC2O1DhcY49akwtrYYs5LkuhPzbSafsAzsbP90+lUJZZFg3ngn+ftToJ9qgjJycHPrVWHIkuxIEHlttbOAT0qaZTOqbu2OAep9aiMjOAWX2xipYiRgsMGtIo5ZysdV4ZnSXTEs7e8ggKw3K3MEkojMjuPkfn7wxx7Vk+ILmNZbNHuo7mW2tlhuJ0OVdwThQf4sDAzWhZJLH4ftptP0q01CTzJPPla3ErxkHhSOuMc5re0jQ01Vvt2qaTaWkFvbJKkccexo7gsQVYg85GDtPSuunG5yVJ2M+CFmAY8qeAOm2rASNFUsFVs8qO9RxLvQFXOCeM/wCFTpbRXWVfcNuQGHrXnntW7ldWZ45FIOQc/J0HpUkcjqD5IBydpLHA/wD1VZNk1pETHISoHO/nIpkEHlt5isRGw4yMgetBaaexFhVfd5O1S213HY4/l71YjghRgRxnnGaUmSeLyoSVbdncR1Gf1Bqa5ij8rcx5HUrzmqsS5W0I7qQmeElAVHXvinuN4ILbFXkjHBqARKCrOWw/RvSnRsnmuGA+bgn2o6hdW0LyOkSId3J+6RTJZVc4fgMfpVMuSymLGzpj6Us1wFUs67tvZRTI5RJ8H5sHah4FRKQkmSeW5xTnnLkCNT6mjY8iHeAHY8HGKm2o+ay1C4Dq+7nnjnt7VUY4c9/apxHI3MnGOMdqZGEbev8AEeCTVqJDqJIci7/mIAQHp61at4VV92dzH0pbC1kuJo4LeJpJGPyog3M30FeoeFPAAQLca0Az9RbjoP8AePf6dK2hSbOWpXUdzj/D/ha/1lg0KCKDPzTSfd/Ad67aXSNP0SG3062LNd3h/e3DDMnlj7xH90HgCuzvXg0rS5riRNsMKFtqLk4A6ADr9K5TSdV81Gnu7Pypbs7nmkILIvVUx2rrp01E86pXlUfkONqq/KMiTG0ZNb2jQ208clvsjNqBtIbrIe5qiHgdSN6Nn3Bqe1kjhw0bYYEMF9CK0sZN3RYltbi2uZQPI8pMeUS3zMPTHqKQWk86OyvPC+PuK5AcGrT38U4UkMzflgilFyeqKWI6D/GgjUpWtnqNhAsdteAIoIEbKCo/rWR4h14aTLpp1y4t4RJMHAB6quc8fpVbX/HNtp1xLZ6dA+raqowYYD+7jP8Atv0A9hzXE2mm3F9qj634km+1ao/CL/yzgXsqD2oSGl3HTWVjr2u6jOsl1c2SyAwJMWEYBHIA74NY3i7UorGL+yLMRxqP9YIlwPZf8a3PFOtf2Rp+6Jt13LxEhPT/AGjXmAZ5JGeQ7pGJZix5JNY16vKuVbnVQpc3vMI1LOWk49KkMOUUucqp3cj+VOgU5GSF559qJo2Z1wxVSeSa4Gz0IxuUb+4gjL7uZCM8DmsUW7XccjxpkseucCuhna3jiZpFjBJ6kdfTNZF3qBWBo7aLDA4JAxSOumtNDEeznSRhsOAMF8cj6VEV2IgdAXAzn0NWHmneMIwIUklscfrTGnR3VYwTIx5HTNUmzW1tysXdpxlwpJwo65qzOvlDarBiRzzgZpnlqCyn5GHJBPU1J5QZF+ZAo5JXp+OaGCQ23BLhMqTg7WzjAqMqyPllBI6MOpqe2EXJlIAbIAzjFN+cNyMLn5cHqKENpktvcAneQxCDneMg/wD16e8wZSxJO7kuo5FRODHCTllye4qF2dQMKVyAemOtFriLFy4l/cs5/djAyOnH8qrEM5RZZIw6fKSR1B7imu5BAhZGK9ctg59KcyjzFZiM9dw6D2NVYS3FkKLOHjUtg7TtPGRUzyyNMccIDk54Gcf1qrOQHOQPLYYY4xgjvmkjKu6A4YEHg9DRYetyS4V2diysMfMpHXPcVHBJHIgZAQQcN5g696iLAMUCsGZ+7EgjtSSF5I1QA4A4Poo60WEyZ5hIzRkBcZ2kDrUouPn5JJA5JPT6VTjLbTJMG2DkMO/GKRQFRgBjHytk/eB/lSaJNqFmaE4nwVGcH1qS5tpp7IuQvnKe3pWKpKbCXOxSSWB5z6GtKzkklljdZmATOVJ4IqGrCkM8t0t0Vz05Kn9KfDhAVkGG6g1Zu2a4jCKvfDY6ilMe5UPGaEc03pqRb90gGR25p8JMh5Bz2FV2QGbdyMU25FzczQadp4b7deHapA/1S93PpxXRTjc4qk7Hc+ENFtNa+xxfZ7qW2kEzz3UNy0S74zgQjb1zzmu/nt4IYbVbKAwWzxB1iLE85IOc9/eqvhnSrHw74csbSKW5EaEsBDgAOOCxz/EavXky3M/mB5X+UAmXGfwxxiu6EbHFKV3c5CERjCOUViDgA9fX6VJCv2eOMWxD5OWBOTiofLLbI8YfOSRwB9avrCqyLJBj5RtPua8hI+hkyVjK0R3xjJGME/pTEgVEbzGIC84HY46VDBLslJklLdsdhU9zKxjwBkNkUyNU7FMyAurI4DngY7exqXEiLuVhwcHdzVbCrdRrIO2APX60+5lclsAqm4ZAGCKSKluh3lCUh8sFYYCk9/enD50+5swenvVKWR40KKwVQ2WLe9OVpNnB4PQf/XpjBQ0bs4yfmyTTt2S8irgtxzRNtjVQe5wfemTlGk+/g8celCQnPqRSzPbwTTRRF8D5QDyTUWn3dzNaK99Gsc+chF7VYmMSrjdhccAetFtG19KkMEe+UjCqOprSMG9jGdRbsfPKWAHQnkjNdR4V8E3+sFJSv2e1P/LaQdf90d61PDvh7S9HZLjV1e/v+qwIv7pD7k9T+ldi+t380Y+zi3to+gA+Y4/lXXCh1Z59XEvaJr+HvDmm6BCRaIDK/wB+Z+Wb8ew9hV+51vTbE4muIw3TbnJ/KuMmFxct/pNzM49N20fkKgW2ji+5GAPUda6FFHG7y1Z0d74pjuCn2azlkVMnLjap4x3rBtF2RKjYZh19KZlduCOtAbDZjP500rAkXAluy7TGgPqOKTYqH91LImPQ5H61XMjDtk0gkO75qALJvr2AnYYHX/ZXaaytRlvtTDRXNy8FofvRQsQz+xbjA+lW5ZF5wOfXPSqznODjBp2GRWdtbWdt5NnFHFH1wgxk+p9aj1G7t7Gzlu7ltsMa5YY6+w9zUp5yMHPbivNvHGsi/vRZwv8A6JbnGQeHk7n6DoKzqT5Fc0pwc3YyNW1CfVr97mcFQfuoDwo7CmIgwO+e1RRqWGTwPrVhMBcjt+JFeZKTk7s9KMbKyHIME/Jt4yWPeqmqea0ZNsAzKOo7VTvJ7l3KxgxIOrseTWdd6wyxmK2Y7ifmfP8AKpaOqnSe5aS2VRHJfOzuf4c1n6imyU7SQhHJHJNVxdzoAWl3seQCeabLOdzZP3hyTzQkdcYtasrPJN5zcHccABj0p8bKgBZS7n0HT3pQVyxBJXoo6kmkG6OQgHLHl+5FUO1wmXDhnG05yBntTFYNMw2kA8gZ4qw0eSNrOV7LnqPekICZ2gE9cn1PakmFiujBZyjHMfYjoKueWrrvdNoVgDzkEVVz+83BcMDjA4zVt9qQYRzubr0OaYiC7nyBtAZBnOeMiq0iyTIqlhsxjBOMD0NPZfNZtoU7Rt9B+NQzb42KyJJnG/68VaRDbHeZHBNGzReZt/hwelOuHjlkJC7YnXnBxjjriq4kJ+ZOj8Z7ir9rbMAjIcBuSMZwaTdgsiq6KyKVX7y9Qc1BcKYsKWKSqAQR0Pvmp7gyIJFwFViDkdzUdwFkdSX+VeMEZGPrQmNplu3ZVyhcyb1BzjgVFeRtBOjDpjJAP5/UGqscgjUBT8hwMt0BzU5uTLguxGxsNgZqXe+gLUZKwePexClRyPXnoKRY/mYthl46noPXPeopFEjD7y45A7cVMV8xSpwVOM47fSmRJajJYhtYI/y7gcN0yfap7JJPNdsEEHHB6f8A1qhkVyzx9ZU4X6/1qzZowxkkFQTz9KdrmTdjS035csSSrdquSRspJHGT0rPtZNi7U5AGfxq3NdokTOzBVUE7j296Ix1OSrPW5Uvp47K2kmmOEQdB1PoPxrufhtoElnaNquoIBqN6AcEcxJ2UelY/gjw2+uXEWsarCV02M7rS3ccyt/z0YenpXqkSBSpZAwHO09D7V30oW1PNqTuzRsTKNPiW0ubeAhm3q5ALeh5qtfrM0yGaaKVtvDIQR9OO9TfaoRhf7PtwO3LUk06uVKW6xADBVen/AOutTI4pvNRyXbYB0I7ipoiFjO1hvyCcdM1Qhu1uImR2YSKRuUjr6VIsqiEowCuTkheteOj6Ke1mNnbbNIpYFvvDPpVmNHdkIfAAyAao3xE8SOmRKPmqW0uDkHO8noD2pddR30uPiXbelpjgYwAabfXSIHZwV28sKbeTBZwX25z3/wA9ahlZHkZhjk9+9VYm99WOjYTbQ3RvmPvU9w+0KUxt/kBVSOTys8cnsabcyiKBmdwnckmmo32M5SS3J5J45mXzAcjkVXlnjj3NnDe/b61Hptjfak4ezgYRn/ltLlV+o9fwrsNG8OWdqyS3Wby5U5BkXCL9F/xzXRCi3uc1SvFOyOesNGv9SiV4o/Jt8/62UdfdR1Ndp4e0220rLQoWuCMNPJy59h6D2Fau8sgGwntTSrL1Qgj3zXVGCicc6jnuXiBOnOc+lQm3miYtC3GOh6VEkpjIyMGr0d0m3DDHb2qzFlUXbqdssZA9ael2pPyNx6VOxjfGPmz3qGe0jYE4A4+hpgKZlIwCKRic/KwNVjauDlTxSBZE75pXAuBmxx+fpSiQ/wAec/Sqiu6j5lP4U4SZGcc0XEWg45JG4noKYSCpAX35qJWJYjH60jsio7yMEjRSzMewFFwMPxnq40rSWWI4u7rMceDyq/xN+FeXRjPI+bFafiPVH1bUpJ/+WQ+SNT2XtVOFeB2HTniuCvPmZ6NCHJHzFQE4I69/alkeYGMQqvzHJOeopxZkKoFBJOcg5AHvVWebygEidfNc5Bdsk1zXOyEbk2oW5mQ7cFmHGT933rCbTWtIzkLnrn0+tbDxTpATHIA33mfHArEuL24kJUSE/N1xyaLnVTi+hQkjy6tMV2g5GOMmn29pLI/lCSNEIyGJ5Iq9FaI7tJO3ydADz+NUZxHDKywkZwOGPNFzoEaz8kDynLYPzKT1HfmnuwOHCHd2JHIFOjUM+8sS+BgVE8UrXG92IJGfYe1MBkkysoJGS+ATjvTEY5ZRxnPOO3Y1I5DNj5VLcZ6HNVpk8pw3RlGAM96aZLJN7K2SQTnoRwaVm2o2Sw6KVAzjPU0fNuBzz1YnsfT6VGjsxO1Vz3xnJpgkDKqkmIsChAIPRj9Kju5ZH2vtc44Zs8UYKqrgrg8ccnNPs3eIspXc2MKO1A7FNgqEgZJOQOMZHfNWLS+dLfyvLbCklf8A61QyOsvU7WB79j6f/WpsbN5pEmRxkqOhpvUXKhs8jyyMN0jJnJbr+lKzEosfOQcDPUgmnBFZArbwwBLY6Ef1rTijjaCOSIqFxyCefwqb2DYzRCiXBR03x5xjtz3pDD5dzIyEhUHc53VejtZTI0qDMeM7SRVdlaKZ2Vx8xHyZzt9aXMTJLcryK7tH5TcO2cAenWpoNwcOFUMq59vbNFzsMmVDB04BUc5oiZ7htq5VQRk461a1MZOw948gNyCSc+oPqKkhQFAozu9+uKm+ytuIYYVc/M3c1PApHHG4nj1rSKOSrIIMxls44/zmr/hLQH8U3QubhGGgwPz2N247D/YH61H4c0KXxVcOil00WF8XEwODcsOsaH+76mvXbS2jtIYobaNYoIlCxoowFH0rqpU7as8ytV5tETw4SNUjCKijaFA4A9KsRjYyl13J3UHqPrUakMQSDn8qeFYHAPHpXQc5sWtvFcReZDpx25wN05APr1qC/jMUgjNv5Jxkrv3/AI5pbefy4rfzEkKxs0TEDgq39aZqTbXjhQSZiQIWddrHv0pCZ5qNv2ggE/LziokvkWWSAKQy/wAZ7n601gSTubafQds1DMcqdhAbGGzzXkI+iuupI0pZScnBHIA5FFlOkKllBT1z1P1qsJlVTwrHG0EnpTGl3ttToO/rVKLZDmluXpHR8feZ85yemaemWZdoOevNa3hrwpqOrEMALW3brLIOv0HevS9E8J6Vpce4ILm4XrJNzz7DoK6KeHb3OSpiox0R5bb6Rq10v/EvsnlZv+WsvyInvnqfwroNG8HyWmJr6CG/vAch58mNP91Bx+Jr0s+XjbtAx/d/wqAhJCyg/L6etdMacYnHOtKe5zMjalH99UC99kYwKj+0XGBvkIPp5YrqWhjYdeAcYNNezjcHgEH2q7GXMc6ly4ILzbvoMVYS4Unkkk++auy6bGzcqFHpVdtLQt8qgEdCDQF0NLKT2+tIGySBhl9aa2lyL/y0YfQ02SylH/LaTHvQFyZd645YjpThMyr3/HmqghmjGBJu+poV5AcNg+poFcuGQEYDYH8qTjPbI96iyM/MOPanqwJ64pgSFzgBupNRNt75z7c0pbJPzbvqKR8gjGSAOaQAVGAe2c1yPj7WPJh/su3Y+ZIMzY7Dsv49a6LWNQh0zT5LuTOUHyKf4mPQV5LdXL3VzJPMxaWRssc9zWNapyqyN6FLmd2NiQA7j+NWIjvAKYYE+nWoTt2/MVwBxVdrmVQGZQqjhVXkn8q89nqRhcuzyLGMLGPNxwuePesm9lccR2+H7yDmrMExMrZPzdCoPSkd5U2yO645G0DJz2+lQzppw5SsLvzkRGUvHnl+m0+lV57WQSeZaqxDDk9fwq6byPaQsAMnQhV4z61XguZZlcRrtEh5AHFB0xXWxlSFlOPMIwe9JM8LbSqbmGOoqS5UrMoK7lGQGXjHtRGsgRSY2znjHSqRQscmwZIyR/F7emKJWkuQiqnD9MHrUsMy7QJkOR0OODTYVdbgOAFwvDEcY+tLqBXEMg3ZQ7gMg55+tNhhMhXZ97ng1JJP5rlmbG3IBx29KqI5U7t52qc5PH0xT1AnuLKa1jLOFIft6VUJyzJu2gdPXPpU1xdPOxLNkg845H5VFKWMhYbUUdTjH6U1cEDAiXedzKQMkdyB6VLZW+ZdsyYj27s9/wADRaSFCp4fbyQf8K2rpBeWQaDagGDh+fqKTbQaHP3ltbLMZI5SVb16j8O9VVKIN4wcdvX2qSeEhwHzu6KV70savG6h8FRk9PvU07BYLSNBmSVjg8AA9M0yOYLb+Q0DOo/hBOfXNKEbyS3PmA+hGfapIj5eA2MAYbdxk+lKwmOtLk+XIu/3AFWtEtgQxmQ7sAZI7dqoRxK07s5IZcNsUda2bJpGgd3YoGPC454o5TGcitPao1w8cScA5Y7vyqb7KLZI4m+YnkkjnrxVm3jLPuVflznjnNWX+cfMCGONqnrWiTehyTnYrTsT90dTjFO0DRJ/E181rbu8OmQnbd3Scbv+mSH19T2qTR9JufEt01rZuYbCI7bu+XnB7xx+rdiegr1XTdPt9LsILOwhENtCMIijj3J9T712UqXVnmV619EP0+xt7K2itbOMRW8ShY0XhVFXCmMc06MfKOOfapCpPNdRyEaoCvb14p3lhvXPb3qRF5LYIGecU+OURyB4zyDkc9D60hEymOWzige58loiRhlJVs98jv2pmozCQxRqzSJHGE81hgsfX6VeicxWcbveTxGRmIRFDd+TUd9biRDKLp53EYkBkXGUz2+h7GkJnkM1wiIS4O76dKy5bgElF6k9B/OrttZ32t3DJp0IMQOHnbiNB3ye59hXceH/AAzpWmbXl/0y8xzJKMKp/wBlf8a4adFyPWqYiMdEcho3h7VNRVGhgEVuek0o2rj1A6mu00fwjY2TI1xm9nXnMgwin2X/ABzW6Z2Y8tnt0pwkcj5FwP8AZ711Rpxjscc6spblqJ3jAGdo6DBp5mbIBLls8VAjcfMNv4VKrEAAc59au5kTLLKQeT68mlSYggknPqOKjwxGC35ik8kkZJPX1ouIuLebWHzEnHfpVhdRiUYIJ/CswxYGSKRI0P8AFggUxGg96jnkrjORxyKT7XGv3FUD1rP2hSQJAQOOeKQOp4Dp74NArIvNcq3BJ4pplBbjJX1NUGaI8F+R3zSieBDxKoz70XCxdLo/3VBP0qExM44VRkE+lV2uog331Izng0j3SdFLEGi4WLQg28liBimNH1A6/wAqrG5J5z+Zp4nx1wB29KVwJAQeMZx7UhGXA5H8jS+d83II9zXNeNtaOnaabWB8XNypHH8Cd2+p6UpSSVyoxcnZHK+NdbGo37RxyH7DbEqh7O38Tf0FYiMuA2Bn+lVpCjqgCeY46DsKehd92Xwehbrg15tSfM7nsUqSjFIe8ibcMFU9qgK7IWJl3N3WMZpZhErASgFuu8nAz9KZBlmk2Bon7K+ACfWszthGxPZ26C1MrRSMTxtJ+Y+5qK5uZ1nCpbqsYHKkdaS48+NCzsHfHGDgVHbPNekoZtmOFx1FSzWMerKs8saSllB+b5WXsKcsFxgSwkiMkcD+tX7iE2CBpgZG9hyTT49SIt2VYzCD04+alcu+nulaWJ1Qyqp57KP1qKMHyt3loW9GGCDUV3fyqzsjMuedvp9fSq0t3JLAA+Cw4znrTS0Gr9Sa5lMxJITK87ccYqe1jW7tJCnmK2eh6H6VjySbmVUyQ3Ut0FWzdTWqZRge2adgHNptwzMADhefTNOXTGubRJF37FOORj86l02/RdkM+SrODuPrWzrWow2VqEGG8wErxwPWldibadjk3gERddgYsR0PUCmTQKYw/wAwXjPNC3Mckku9mAbgk9hUTuEXABw3HXt6iquzSxbsrcS3Eabhux2Pf+la9ltmaaycrFMehX+L61k6PcrDI7rGZDkcjqTVu4uTJqAa32qy4O/1HvUO7IaZX1C2S2xGzHC/eHqRVa4thMrneY9hDtnryOtbGq2n2qGBw+5nzkKe2ayJmaOeVF3MwXC/NkU0Cd0FtOu7ylG6PdkyHrTTasXn83/WgbcjtnoalWFAkYYkM43EbfQ96sXciPEsT5LA5DDjpVRRlOViKyjSJd8jKSuFz/8AXq7BGTuI53nj2NR2lqqZydwU9OoqxbsIkkeRlVUB3Mxwqj1z6CtFG5yVZ2LaYSNUjXjrkcCl0TRZ/FVyzRtJBoyErJcqcPcEdUi9B6t+ArQ8P+GZvEKpPerLb6LjKxkFJLwe/dY/1NekwQRQQpFHEsUUahEVOFUegHYV2UqXVnlVq13ZFWxsoLC0itrOJIbaJcJGnAAq4ile52+xqUKcknDDvmlYhXBOefauk5CNcbgMkVJyFG0/1NPXGDzwOvFIVQk7TtPYigQzHOeQQaPmLZRc46g0jBg5KHnoeacGwuWGD6igRcs5ALMfamgWEsfLEiknPfGOQKbdz3ERdHMLJKg2tGOAg7KOw9aI5oZYUiuYnZkzsKNsJB6jnjFR3uWMOYRHFsxEAd2Bk9ffOaQFyG0sIIViKGYIOIohsjUfQVZ+xpO3NtGq9lC4xVu3tEtlwBj3xxVnaysWJ/LrSL5ihFplsR80aqw9RkU9rGBc7oQD6r0q6N+QSc55prSBG+Y+3HSglsonTbaTn5h7qx5pp0iBm2h2HoCSc1fCsWLY568U9tzEMeB2AGDTsF2Zg0ZAMEsWXnhjSnSUHLByeuSa1lfOQH6nBpP9W43E7e3vQF2Za6VEHAce4GSKf/ZUatitUtuOVAyTUqpGCGcgsPU8Cgm7MgaXF0ZACO56UqaZFg74wB3xWtK8GCGkXd161Cbq35PmjI/SgLszRp0RYqY1H6inDTI1AJRdvT7o4q6txCBksp56qajN6okJRyyDjGO9AXZTGnRgElRgdDikk02IY+UqOnXpVh7wAYAIXPpxURvNq4BJyfvDnNBSuQHTUbkYGeCBUUmnFQSVLAc4B/pVxrocEcn6d/Smm8Dg/KRz+VILsy9Qe302wnu7ghIoV3OT1z6D3PSvFdW1SfVr+e6lPzSt90dEXsorrviX4g+23SaXbsDDbtvlI/ik9PcAfqa4dcIN7MMn17f41yYip9lHpYSlpzMkC/Mqo2wt1PfFJbxkyuIWCwBsEd80h38MeEb8zTVhZlMiB1UdTnvXGepFaF5/J8hmbaCp6nrWRLcyx5UhZj7jgfjVmKLzchwxXHA6g1cc2/kKkbJ0xz1NI1jozPWVEhH21gwPY9jUsc8IkWZV+5jCjjNUvKkHEyZjPOWFMKxnmF/LZDn7vNSbpI3r69EsRLIAQOhHSudnlkDY35PUZ5NakGy4tniklEkh+6f8az5o3trlMYJGeGHWhMUdNCCO3dWAlIfcdzEnn86rzKqy45I6kL0FW7iAXEpOfnboQ36VTljYDe3thR3qkx2I441kfCOc/wB3PB+tbun6W8sHnyDaqKcjrms7TJIYLvcyLnAyDXV6bdi3aZpGURsMgEYUGlJkttLQ5MrAsobDr82UyfzouJheF2MR2/XI+tafiG2GYJ4VQRSfeweh71HFbWjRm4idwCArKOnNK5opJq5gpCYhkqCueOM5q1ZwRTq0d0wQt0zW7ZaVI7OjqGgblX6dKoa7pYt545ImZd3BHUA/0ouRzpu1xLO0t3vD5G82+3lweDir9nBaT3pUAKeeRyG7GnxWrW+jtHAMy55OOT68VkWwnsZE8xCu8/Mf7v0pENuV7M6O/aC2gEUJjXZjGO1c3JGs86mP3JUDHHrVy5/fhi6ZJHAB6VbthHFCry85GAcdapIy5uRFNRGeNjAbMBe/1pv2fzI1UL8vQAjnOetOO6WXLjKsduMYzV8KEKJGkk0rnbDBGMvK3oB/M9BW8IM5q1axXmVLaAu7AJ1JA+8T0AHc+gFdP4U8INcmK/16ErErBoLB/UdHm9T6L0H1rZ8LeFTZ3Eeo6wFk1AcwxA5jts/3f7z+rflXWlCeGHHuMmu2nStqzyatdy22IgrAHG4j0I4p/GcYB9OakC7eF+U+lIRgnKg1sczGpkHg8DrmpN6soVgB/nrTWx/DkYH1xQEDDPf09KYmJswwOOex7GkZcdfvDg98UoLRjb1B7UhmQsA5ANAgPONygnsc4oUZYb+VPXA7d8UpGCccjsO1JsZtqqSCemeAKAZYCacy7D9s45z8vFR3kqsYVtmk8tI/LxJ1PJPapX06ZX2uYVYdczLVeaCSD72xiRnCuGA/LpSQHQPLdcbBGoHqM1EXuM4a5XnsFqaa4BJwHCY4yhpizWODv698qaB3ZG0twEI+0bR0xioJJpud8nHptqcy2DMMOAevIqzHc6dGDlwzdvlpgVEvJuiSHg9kp32mXnfPJg9glWZNUswcRL9SVqP+07fHb3+U80gK4uMdJ5vb1pzYlUsJ5CR0y1O+22zckrjPIA5qNpbRxnd+XrTuBIkeRkvJ6Z3U7y4Ojthf9+oNlm2MzFfWkZLcFtjlvfbQBKYrUNjcaa6Q7sB9qj0HWoioHCqSPahY33/Kp+opAKwVTxJyfQU9cnBzjGeajwSD8mecZp205yAQw9KBisH2jLKfYU089ckfSlQt/CCW6j3p6RXUrEJbM31FAEQBzhQBjmsTxZq/9i6W0qsRcS5S3B9ccn8P8K6MWd5uUG3RcZJLPivF/GGtNq+rySoc28WYoRnjAPJ/E/0rOpPlRrQp88jAlkBbL5Zs9e5+tSxQK2wyjOBnbSIQQdgJbvjvTlhnKFFZV3feORyK86Wup7MVZCyuBKrBGdgMBSeKBJLJIY5Ssa+inrTbp/s9uxKq79gTgfnUCzDyY/kbOM8c4rM6Iq5FdO1uzJFJvB7AdPyqHcCysI9pXndnGDVuzhSR3e3ZWlBzye1QmOWV2DkMO5UcCg3iRzXhXePLbkjO4/54qF3d5d/3T+efQVLdxhXwMkkc5HBquv7xWIADKc46HpRYsmtp5bcs+cZIJUetWLiSOeQMu4OMnDdCaoxZLAttz2zVi5jjMinzF3Y6Lxk+tKxRHDLLHKVKjcPUcj3q00UNxA5Z9jA9PU1nx7mmdw2/B6N6Uhnc3Ksu7AGGHbFOwbjAQk4SRS4H3W7j6mr0V4Y4ngkAkQncATnr2rNlb96wTHJ+YdagdijH5SDjBHqKVhmvLMs2n+VCAfLPBz8p9qkjuVj05YSBE+eOO1VrBUutPlihJ45yB0pdG097ubbKchen4UiXJdTpNEuwxaBgysFBG7is/wAS3CmURqCWZgPZjW7BaLGTtJyFwM9/aq02mpLd+fcH5l6DsKEjk9pFSuUtEmdZpROy8HAUc4FQahNHeT5UnylPUL1PtVu8s90okBAK5banG761nahC088IiIDDnAq1EXMr3IpJmlvSUQ7FGfl9OgFTrK0z7duR0GegHrSafblGfepLMTjH862/DWiXesu32UhLYNtku9uVU91QH7ze/Qe9bwptnLVrKK1KtlaXF7eiz0+BZbkgHaeFjX++7fwj26ntXpPhzw9b6Ihl3faL912y3TDBI/uqP4V9h+NXtH0e00m0+zWMJWPdudmOWkb+8x7mtEjaBkcY7djXbCCieVUqymyMYK5ajY3KqwIPrTlUZw3BzjjvStGFyWzgf55rQxIt43YkBVhyGx+lPBK8ycoOhFTARSABl2nsc/zqDa0DkN06e1AAIww4Jwf0qCVHTJKsMcggVZDc9BnvSlt3AJz6GgRXjlMo5+YAUPGjtgkI/bjrSyQAnco2v6imgndtcA8de1AhnlMPl3HI6c05MyEBcliePenBsADOcdOOlIQsh64OeMcUAWZLe5lCCSCZiqhVJTkD61Wlgktsh0dMjOGHar80F/NsdsK4XBPmgM3uQT1qjMJYZCs4cSD+EnmhAbCzXUmeYyB29Keki5/eptPqD1qNLiBzyjE9yqnmnl0OTBbSH3bFMYuyKVlXAIPfGDThZxbhgnGec00LdODhI4lPUYzUMqXCON0wQ+yf40hFs2UCLkuppGtrUL94H2rNkjmkPMsjZPaiOxmkGCzgfU0XA1Q9lGQNuB+VMk1CyAA3Ljrgc1Hb6PAMmX5/YmtGKxtkX5Y0z9KQGRJfQN/qopGOeflwAKUTh8bFXA7E4rWaKPkeUAp5GKRrCGROEAOfvUwuZ6RzsrbHhIHo386WSGdUyTCTxkb6vR6ZATh1z9KeNNti3KYGOvQ0guY7mdB88CE/7LdBULzy7uIySMcFq6JdLtyFAiGRznNMGlQhjuiUrnIGaAuc/wDbbhCPKiRW5Gd1TLqN2wA4B78E5roJtKtyoaKPaD2z2piadGpwoGeg560mHMjgPHviC4tNDa2S4Pn3eY1AXBEf8Rz+n414/PMq5QjaE4OP5V1Pj7ULnXPEFw+nwyy2duwt4mRSVwM859ScmuSurC7it4pp7aWOGQgIzDG89ePwrmqttno4dKKuRi6jSM7CN7fxdKZ9qAA3A7uwqN4AZPmTZtOCDxzS+SQ2GBjBPBNczR6MSxbyPOSXfjjII6CpZhlyYdx2r17VHsMKZPOR8pzxxTbe5KDarDbnp6VDR0Rdi/prQHPknZIRnBpzzqmXaJMkYyveoIjCk/mMp8zP3geKlnj3Zmj3AHgj+tTsaoyrk7j5j/dYfeB6Gp7QKojkxvfGwn/Gtj7NbG02HGwjg4qrDbw/bAE3/dAwOMD6UFJlO4tg7lgFVR/DnOeO1U549rqAWO0cnqCD0rX1GAW1wJI+cgjkZwexqBreKSzSVJR5icoh6n2+lMLlV2WKRlZdkYQ5z3NULSZYLgfxIG3Lk5H4mp5wXs5BtxKz/wAR7dazgBv2KdoUYUEZ7U2gTJmcNI7LLuRsnPTH0+lULiUTMM/K+OTng/SrqoxUxvjHXnqM9qje1xb7nBDKcc0ht2JNPu2ic8kBOmByR3rr/D8ciSyuyhUf5lOOgPrXOaHpxmuUZlLREYLDiuzlXyoUVT7Umjmq1OhEUktYpXVmllc8Z7e9Su5eIiNg0oGMk8ZpwlVcRMc46+1MWNUBKjGevuacUzmlNPczpRLMfL2kKCBkd6jjiW3mlmkYbR685PYD/Ctaw0+81KVrfTYjK6/ecnbHH/vN2+gya7Xw34VttKaO4u2W6vxyHI+SI99g9f8AaPNdVKk2ctbEqOiOd0PwfNeYutXSSC1YZ+zZ2ySj0fH3F9hye+K9AtYY4YEihRI4kUKsajaFA7Adqm8vcu9f/wBf4U0jjjAI5GPWuuMVHY86U3J3YoAKk52t6HvSgHo3B9jxS/Lty2eO9GDt4IP6/lVXJuIUBXHzKcdT3pu4qcNjp1I4NSMxUA4IzzleRTSolQknaw6N6/hRcQ1kBPGMHtninZBXbIoOBjI61Fgwk7kOewpFcR8MPl65NADZYljw0eSvdT2+lOSUMBkZJqTeGUMSAfbvUEgG75cfj0/OmIlRgTkDn1PFEpVlIKjPUVGG+bjd64PAFCup68etAmMZQvXkDmnI/lyJKBnawbBHWlfvwMHt2/CkgCJPEX+4rAke3egCWe3s5JTI9xMhkO7a8eSfx71FeyKxhRVkCImwGQfMR61dubk/aZYruQXFs/OV/h9CvoR6VBqAjHkIsqyhItu4Hk8n/OKEBpeZdKwBEJTodikHFTW8ylj5q59wDVdI4GPy3jbSOD1qQRoSVF0WA9EpgtR8s8jZEcYT3c9PwqGNOd0jFjnk5/zxU4tYtoaS4fHcHrinlbCNvlcv/OkK4yNUUnYOfY8VZRJi2Rt9hj2pourVMBASB601775cIhAxxmgCdRIBlsY6cU8AkBeRzke1UDfOCPlySMZp41EA/vEYfTmgLM0G4XDfeqRDhazvt8bZPmDdjsaa1yoBy4z7HrQI0GYKowB7EGmNMwbLYOetZzXQ2nJPt6U1p2IA52+lAzVSfaOM0yS6zkq24HvjHNZkbsxxycdqxNY8QRWMptoB51weBt5VCfX39qErg9DoNU8SWunKv2qXkHGFG4g+4FcprPja5upkgsEENrImPOcfO2eDjB+X2zXN8M5mmBcE7tz8qfRif8544pBb8SwxlgpJZkPBUY4Lf3c+ldEKUephKo+het9Tt7ZII1WWJFAUp5IbAA4OAef69auWl7b30u0NAZJCPLQ/umDMOdpbjAx655rFt3WK33tGjhjkyk7SSeflXvTJoxfTNHCrsp58uddrhemfz7CqdKDWwvbSWoeJvCMd5Gp023ZdQjUfu5H+aRem7J4b65ya88ljaF3jkTJUkMG9QcY/OvTLCW702JoJJhPb8b7WUljgcgK/Vf1rnfEttYX8rXti/lzH5plZSCT3I7HHc1wYjDac0T1sFjLvkmczZzRqSsisVI6dTTpreKPLp8yHueoPoaRrYREZ5B7+lICwyDvyvt1rz7HtJgtuZSHRsgdjWhaMChhuNy4657VSmAUiVSFBGD7fX2qcgyowRhvBwcH+H1qZI0i7I1fsluYFwp255wOCKltLS3lLoUOegYnpVKxlkabyHPyAcMfXvSTt9inXzH5ZcHb0/KlYlydyO9hWG88uRtyvjZnJwef0rL1H9zBCoG2RFIPck54/Crd3d5jjddzDJzn73FYlzK8h81syEZIUjnPai5otRl/MNkojYnscj9RVKQhZIvLzIMZOe49qsvJ+6GUDSg/LzgcionQJHGjKd33uvT2q1qHNZk1qZLq644jUcema0jp7fZ2e5kHBzgVS05myREgZzwSee/Wuht2JcoF+RR1P8R9hS5TCpVsWNPjFvaJGDyeTjv8AX2qS4uxACwJLNwF9KRN0kgiVGkuJPuwxjczfgP8A9VdJpPg+5uWSTVn+ypnP2aIgyEf7T9F/Dn3rSFJyOCpiEnqczp8by3DJFDJLcOc+Wi7mP19B7nFdpp/g6SVFl1acKh5+zwN+jP3+g/Oup03TrWxgMFlBHCnbZ3+p6k/WrqrhMcAdwK6oUox1OOdeUytawQ28CQQRRxQpwsaLhR/9eplQgnaoz/SntjuDz+NBI2cf+O8VqYEZXGfm5NLkKpDjcRSjDfex04xTWG088j1NMQmB0GQRTGOG4znpSu3BAOOOtJt285BJ/MUCFLttYEHbioy3HHA9QKcJAFGVOD39qaR6ZI7ZoAcrHJDgOv51G4AOOxOQDS5BbGMEHnHpSFVJy5P1zxTQiMZVuVwPcVIM4UkBh1+lNJwx5zjjmmoRuwSV5/KqEOwvBU7e+D3pxOT8oB+lMlQ87OV6cUiYwOc9uaVgA4ycDnrkd6buBIAG7HU45px3Zw4B9CKfbsq3EcvVVcFvYUWAf5SqxjmmiRx/BgnH4gcVXlj8pisg5HPsQffvWgy4nhJldGi6BYyd3OSVx1zVTUmUyxocAopBA6DJJ2/hnFFwZxNjrN5aqqRupUNjDDNdvpt7LcQbn2gnn5RiiitJ7iiXcAsCeacfllCgAAiiis2Mm2AjGO/WkUfMQeQPWiigCRevtimg5kKnGBRRQA+aNAiNtGSDninRwQt8xjXPHaiigYzyURiVGOcY7UMAM4A6UUUAcZ4k129F9JZRMsMQ4JjGGI571jwQRlgjAspUMck/0ooreGxlIjWUy2sMhCrJLMIyy/wqDjA7VNdxRoZwihEhcnYCcSEDGX/vUUVojFiXLGPTo7oHM9wvzsewBxgelM1K3jiuYY1BLkg+aTlwT3B7UUVZmCXMl0sttOQyqxG/ozAdiap29qlxqPkTlpIgCQCemOw9B9KKKHsV9owdctkt7qeKMsVj2FcnkZ//AF1lqAZyjfMBnGevpRRXhVVaTPq8O26SuQ2UjPc+U53KrHGfpTy7KTIpw/PNFFZM6Yl6CaRpU+bG4849qsa4oSWJgMny+p+hooqA6nMQ3EhsIjuwd2Mj61bn+WxmlUAOrEA+1FFJFyMgD/VZJw3zEds1oSkSwxh1XnjgdPpRRWhnMuaWiq5CgAbSSPU1u6NbC/8AEVtprySRQOpdmiOHOO2TnA+lFFax3POrtnqunaVZaQHi063WFeNzDlm+rHk1fkQYVzkt05oorrR5z3GZywHtUmcZoopiHTKFUEZ5HNMQ56gZ9aKKBDc9elOKhhhhmiimIrsOc+jYxT3+QEL2oooAhZsOeB0zSAkpjsBmiigBj4xuwMg8Um7a4Tgq2etFFAhMkAkHkcUu4nrggjOPSiigQxHKqSOoNSMchX6Mw7UUUB1GOSvQnrillQAgc4PFFFUNCLcTRxlUkcKOwY4qOU4K4HUZNFFIk//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Purpuric lesions can occur in sites of nonvasculitic cutaneous inflammation. This is evident on one leg in this patient with a maculopapular drug eruption.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_27_28082=[""].join("\n");
var outline_f27_27_28082=null;
var title_f27_27_28083="Care after gynecologic surgery";
var content_f27_27_28083=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Care after gynecologic surgery (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?27/27/28083/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/27/28083/contributors\" id=\"au6580\">",
"       Sarah Feldman, MD, MPH",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?27/27/28083/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/27/28083/contributors\" id=\"se197\">",
"       Tommaso Falcone, MD, FRCSC, FACOG",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?27/27/28083/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/27/28083/contributors\" id=\"de1930\">",
"       Sandy J Falk, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?27/27/28083?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Women are often given instructions by their surgeon about how to care for themselves following gynecologic surgery. These instructions are intended to help avoid or recognize complications, as well as ease the recovery process. The information here is provided to help answer common questions about care after gynecologic surgery.",
"    </p>",
"    <p>",
"     More specific information about gynecologic surgery procedures is available separately.",
"    </p>",
"    <p>",
"     (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/48/34564?source=see_link\">",
"      \"Patient information: Vaginal hysterectomy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/16/6405?source=see_link\">",
"      \"Patient information: Abdominal hysterectomy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/24/8578?source=see_link\">",
"      \"Patient information: Dilation and curettage (D and C) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/28/7620?source=see_link\">",
"      \"Patient information: Permanent sterilization procedures for women (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WOUND CARE AFTER GYNECOLOGIC SURGERY",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Abdominal surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women who have an abdominal incision may be sent home with staples, stitches (sutures), or tape strips (steri-strips).",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Staples and certain types of skin sutures are usually removed within 3 to 10 days, either before you leave the hospital or in the surgeon's office. Sutures under the skin or inside the vagina do not need to be removed.",
"      </li>",
"      <li>",
"       If there is a bandage dressing on the incision, you can take it off 24 to 48 hours after surgery.",
"      </li>",
"      <li>",
"       Tape strips may be removed gently at home (if they have not fallen off) approximately one week after surgery. Soaking the strips with a warm, wet cloth or taking a shower may make the strips easier to remove.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Abdominal incisions should be kept clean by showering. It is not necessary to put soap on the incision; plain tap water is adequate. Avoid scrubbing the area.",
"    </p>",
"    <p>",
"     The way your scar looks will change over time and may not reach its final appearance for up to a year. The area may feel either numb or sensitive to touch, which is normal.",
"    </p>",
"    <p>",
"     Unless directed by the surgeon, do not apply creams, ointments, or other substances to the incision. If the incision appears red, drains more than a drop or two of blood or fluid, drains pus, or begins to open, you should call your surgeon.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Vaginal surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women who have vaginal surgery often have stitches inside the vagina. These do not need to be removed because the sutures will dissolve, usually within six weeks. It is normal to have some light vaginal bleeding or pink to brown colored vaginal discharge as the sutures dissolve. As the sutures dissolved, you may see pieces of suture thread on your underwear or toilet tissue.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      PAIN AFTER GYNECOLOGIC SURGERY",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Will I have pain?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Many gynecologic procedures are followed by some pain or discomfort. Pain or discomfort should improve over time and can be managed with pain medications, if needed. The location and severity of pain depends on the type of procedure. For example, women who have procedures that involve a skin incision (eg, abdominal hysterectomy, laparoscopy) will have pain in the area of the incision, while other procedures that are performed inside the uterus (eg, hysteroscopy, endometrial ablation) may be followed by a crampy sensation (similar to menstrual cramps).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Gas pain",
"     </span>",
"     &nbsp;&mdash;&nbsp;It is common to develop occasional crampy pain and bloating in the abdomen after surgery. This is caused by gas building up in the intestines. The discomfort is usually temporary and will resolve after passing gas or having a bowel movement. Some patients are helped by non-prescription medications (eg, simethicone [Gas-X&reg;]). If the pain and bloating are severe or do not resolve, you should call your surgeon for guidance.",
"    </p>",
"    <p>",
"     Women who have laparoscopic surgery may have shoulder pain as a result of the gas used to expand the abdomen during surgery. The shoulder pain can last up to one week.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      What should I do about pain?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some women find it helpful to avoid uncomfortable positions or activities, support their abdomen with a folded blanket or pillow, or to hold a hot water bottle over the painful area (close the bottle tightly and cover with a towel to avoid burns).",
"    </p>",
"    <p>",
"     You can take pain medications as needed, or, if you have pain that is constant and moderate to severe (in the first few days after a major surgery), it is helpful take the medication on a schedule, as prescribed (usually every four to six hours). This will help to prevent severe pain from coming back between doses.",
"    </p>",
"    <p>",
"     It is not necessary to take pain medication if there is little or no pain. If do need pain medication, take it as directed on the prescription bottle. Taking pain medications at higher doses or more often than prescribed can be dangerous.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      Types of pain medication",
"     </span>",
"     &nbsp;&mdash;&nbsp;Pain medication is available over-the-counter or by prescription. Your surgeon will give you a prescription for pain medicine if",
"     <span class=\"nowrap\">",
"      he/she",
"     </span>",
"     thinks you will need it. Possible pain medications include acetaminophen (Tylenol&reg;), ibuprofen (eg, Advil&reg;, Motrin&reg;), narcotics (eg, oxycodone, hydrocodone), or combinations of acetaminophen and a narcotic (eg, acetaminophen and oxycodone [Percocet&reg;], codeine [Tylenol&reg; 3], or hydrocodone [Vicodin&reg;]).",
"    </p>",
"    <p>",
"     If you are taking other medications, ask your healthcare provider whether it is safe to take these and pain medications at the same time.",
"    </p>",
"    <p>",
"     Do not drink alcoholic beverages, drive, or perform other activities that require concentration while taking narcotic pain medications.",
"    </p>",
"    <p>",
"     If pain becomes severe and is not relieved by the recommended dose of pain medications, call your healthcare provider.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      VAGINAL BLEEDING AFTER GYNECOLOGIC SURGERY",
"     </span>",
"    </p>",
"    <p>",
"     Some light vaginal spotting or bleeding is expected and may continue for several weeks after gynecologic surgery. Occasionally (especially in the first week after surgery), you may have an episode of heavy bleeding when you stand up or after urinating.",
"    </p>",
"    <p>",
"     Call your healthcare provider if bleeding is heavy (more than a menstrual period OR completely soaks a large pad in one hour).",
"    </p>",
"    <p>",
"     A pad may be used, but tampons should not be used until your doctor tells you it is safe. (See",
"     <a class=\"local\" href=\"#H16\">",
"      'Can I have sex? Can I use tampons?'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      ACTIVITY AFTER GYNECOLOGIC SURGERY",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Should I limit my activity?",
"     </span>",
"     &nbsp;&mdash;&nbsp;It is normal to feel tired for a day or two after surgery, especially if general anesthesia was used. If you have a major surgery, you may feel tired for longer. Taking a few short naps during the day or resting when you are tired may help.",
"    </p>",
"    <p>",
"     While rest is important, it is also important to walk around several times per day, starting on the day of surgery. This helps to prevent complications, such as blood clots, pneumonia, and gas pains. You can resume your normal daily activities as soon as you are comfortable doing them. Walking and stair climbing are fine. Gradually increase your activity level as you are able.",
"    </p>",
"    <p>",
"     Other activities (exercise, housework, sports) can be resumed gradually, as you are able and depending upon the type of surgery. Your surgeon can give you specific instructions.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Can I take a shower or bath?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Showers are permitted, but tub baths and swimming should be avoided until your doctor says it is safe to do so.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Are there limits on what I can lift?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Lifting heavy objects can increase stress on the healing tissues. Most patients are asked to avoid lifting heavy objects (&ge;13 pounds) from the floor; if the object cannot be lifted with one hand, you should ask for help. Restrictions on lifting are generally recommended for six weeks after a major abdominal or vaginal surgery (eg, hysterectomy), and for one or two weeks after smaller procedures (eg, laparoscopy).",
"    </p>",
"    <p>",
"     Women who do not have an incision (eg, hysteroscopy, D&amp;C) do not need to limit lifting.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Can I drive or travel?",
"     </span>",
"     &nbsp;&mdash;&nbsp;You should not drive a car until you can move easily and no longer require narcotic pain medications. You may ride in a car; as always, wear a seat belt when riding in or driving a car.",
"    </p>",
"    <p>",
"     Some surgeons recommend avoiding long trips by car, train, or airplane during the first two weeks after major gynecologic surgery (eg, hysterectomy). Speak to your healthcare provider if you have questions.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Can I have sex? Can I use tampons?",
"     </span>",
"     &nbsp;&mdash;&nbsp;After most types of gynecologic surgery, you should not put anything in your vagina until the tissues are completely healed. Otherwise, you may develop an infection or interfere with healing. This includes tampons, douches, fingers, and all types of sexual activity that involve the vagina.",
"    </p>",
"    <p>",
"     These activities should be avoided for two to six weeks after surgery. Ask your healthcare provider when you can resume these activities.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      When can I return to work?",
"     </span>",
"     &nbsp;&mdash;&nbsp;You may return to work when pain is minimal and you are able to perform your job. After minor procedures, you may be able to work within a day or two, while for major procedures (eg, hysterectomy), you may require four to six weeks to recover.",
"    </p>",
"    <p>",
"     Time out of work also depends upon your daily activities at work; a person who sits at work may be able to return to work sooner than someone whose job requires them to stand, walk, or lift.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      DIGESTIVE SYSTEM AFTER GYNECOLOGIC SURGERY",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      What can I eat?",
"     </span>",
"     &nbsp;&mdash;&nbsp;You may eat and drink normally after gynecologic surgery. You may have a decreased appetite for the first few days after surgery; eating small, frequent meals or bland, soft foods may help. However, if you are not able to eat or drink anything or if vomiting develops, call your healthcare provider.",
"    </p>",
"    <p>",
"     A high fiber diet may help to prevent constipation, although other treatments for constipation are also available. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/39/8817?source=see_link\">",
"      \"Patient information: High-fiber diet (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      How do I treat constipation?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Constipation is common after surgery and usually resolves with time",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     treatment. Constipation means that you do not have a bowel movement regularly or that stools are hard or difficult to pass. Constipation can be made worse by narcotic pain medications.",
"    </p>",
"    <p>",
"     If you are having vomiting in addition to constipation, or if your surgery involved the stomach or intestines, call your healthcare provider before using medications to treat constipation.",
"    </p>",
"    <p>",
"     A common approach to constipation after surgery is to take a laxative (eg, magnesium hydroxide [milk of magnesia]) or fiber supplement (eg, psyllium [Metamuci&reg;l, Hydrocil&reg;] or methylcellulose [Citrucel&reg;]); this can be taken with a stool softener (eg, docusate [Colace&reg;]).",
"    </p>",
"    <p>",
"     If the initial treatment does not produce a bowel movement within 24 to 48 hours, the next step it to take a stimulant laxative that contains senna (eg, Black Draught&reg;, ex-lax&reg;, Fletcher's Castoria&reg;, Senokot&reg;) or bisacodyl (eg, Correctol&reg;, Doxidan&reg;, Dulcolax&reg;). Read the directions and precautions on the package before using these treatments.",
"    </p>",
"    <p>",
"     If these treatments do not produce a bowel movement within 24 hours, you should call your healthcare provider for further advice.",
"    </p>",
"    <p>",
"     Once the bowels begin to move, you may want to continue using a stool softener (eg, docusate [Colace&reg;]) or a non-stimulant laxative (eg,",
"     <span class=\"nowrap\">",
"      Miralax&reg;/Glycolax&reg;)",
"     </span>",
"     on a daily basis to keep the stools soft. This treatment may be taken for as long as needed. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/10/34977?source=see_link\">",
"      \"Patient information: Constipation in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      What if I have diarrhea?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some women have a few days of soft stools after surgery, especially after taking medication for constipation. If you have watery stools more than twice a day or have blood in your stool, you should call your healthcare provider.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H22\">",
"     <span class=\"h1\">",
"      URINARY SYSTEM AFTER GYNECOLOGIC SURGERY",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h2\">",
"      Is it normal if it hurts when I urinate?",
"     </span>",
"     &nbsp;&mdash;&nbsp;If you have had vaginal surgery, you may feel a pulling sensation during urination or you may feel sore if the urine falls on vaginal stitches. It can be normal to urinate frequently after surgery. Call your surgeon if you have any of the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Burning with urination",
"      </li>",
"      <li>",
"       Needing to urinate frequently or urgently and then urinating only a few drops",
"      </li>",
"      <li>",
"       Temperature greater than 101&ordm;F or 38&ordm;C (measure with a thermometer)",
"      </li>",
"      <li>",
"       Pain on one side of your upper back that continues for more than one hour or keeps coming back",
"      </li>",
"      <li>",
"       Blood in your urine (you can check to see if this is just vaginal blood falling into the toilet by holding toilet tissue over your vagina)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h2\">",
"      What should I do if it is difficult to urinate?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most women urinate at least every four to six hours, and sometimes more frequently. If you have not urinated for six or more hours (while you are awake) or if you feel the need to urinate and it will not come out, you should call your healthcare provider.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H25\">",
"     <span class=\"h1\">",
"      FOLLOW-UP VISIT AFTER GYNECOLOGIC SURGERY",
"     </span>",
"    </p>",
"    <p>",
"     Most women are asked to make a follow up appointment with the surgeon's office two to six weeks after surgery. At this visit, your healthcare provider will usually examine your abdomen and pelvic area to be sure that the tissues are healing properly. You will hear about results if you had a biopsy or tissue removed, and you can ask questions about the procedure or your healing process.",
"    </p>",
"    <p>",
"     This appointment is a good opportunity to ask questions about the procedure you had, for example:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Were there any abnormal findings?",
"      </li>",
"      <li>",
"       Was my cervix removed?",
"      </li>",
"      <li>",
"       Were my ovaries removed? Which ovary was operated on or removed?",
"      </li>",
"      <li>",
"       Was mesh or any other permanent surgical material used?",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     You may want to keep a copy of this information, including a copy of the operative note, in your personal records.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H26\">",
"     <span class=\"h2\">",
"      What follow-up do I need after surgery?",
"     </span>",
"     &nbsp;&mdash;&nbsp;When you speak with your doctor after surgery, be sure to ask what type of gynecologic care you will need in the future. The answer will depend upon the type of surgery you had, any underlying medical problems, and your risk of certain conditions (eg, cancer).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H27\">",
"     <span class=\"h1\">",
"      WHEN TO CALL YOUR SURGEON",
"     </span>",
"    </p>",
"    <p>",
"     You should call your surgeon if you experience any of the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Abdominal pain or bloating that is severe, lasts for one hour or more, and is not relieved after taking the recommended dose of pain medication",
"      </li>",
"      <li>",
"       Shortness of breath or chest pain",
"      </li>",
"      <li>",
"       Vaginal bleeding that is heavy (heavier than a menstrual period or completely soaks a large sanitary pad) and continues for more than one hour",
"      </li>",
"      <li>",
"       Nausea or vomiting that continues for more than one day or that make it impossible to eat or drink",
"      </li>",
"      <li>",
"       Fever greater than 101&ordm;F or 38&ordm;C (measure your temperature with a thermometer)",
"      </li>",
"      <li>",
"       Skin incision changes &mdash; redness, drainage of fluid or pus, or opening of the incision",
"      </li>",
"      <li>",
"       Swelling in an extremity (leg or arm) that is much greater on one side than the other",
"      </li>",
"      <li>",
"       Foul-smelling, green, or dark yellow vaginal discharge",
"      </li>",
"      <li>",
"       Inability to empty the bladder or burning with urination",
"      </li>",
"      <li>",
"       Inability to move the bowels for three days",
"      </li>",
"      <li>",
"       Loose or watery stools two or more times a day",
"       <strong>",
"        OR",
"       </strong>",
"       bloody stools",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H28\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2413240918\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9141963\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/41/3731?source=see_link\">",
"      Patient information: Hysterectomy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/33/29202?source=see_link\">",
"      Patient information: Dilation and curettage (D and C) (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9141971\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/48/34564?source=see_link\">",
"      Patient information: Vaginal hysterectomy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/16/6405?source=see_link\">",
"      Patient information: Abdominal hysterectomy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/24/8578?source=see_link\">",
"      Patient information: Dilation and curettage (D and C) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/28/7620?source=see_link\">",
"      Patient information: Permanent sterilization procedures for women (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/39/8817?source=see_link\">",
"      Patient information: High-fiber diet (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/10/34977?source=see_link\">",
"      Patient information: Constipation in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H29\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21113?source=see_link\">",
"      Abdominal surgical incisions: Prevention and treatment of complications",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/25/32151?source=see_link\">",
"      Basic principles of medical lasers",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31321?source=see_link\">",
"      Classification, clinical features and diagnosis of inguinal and femoral hernias in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7415?source=see_link\">",
"      Complications of gynecologic laparoscopic surgery",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24631?source=see_link\">",
"      Complications of gynecologic surgery",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/18/43305?source=see_link\">",
"      Management of hemorrhage in gynecologic surgery",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27546?source=see_link\">",
"      Management of postoperative pain",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17334?source=see_link\">",
"      Overview of conventional gynecologic laparoscopic surgery",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/1/20499?source=see_link\">",
"      Pelvic examination under anesthesia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2586?source=see_link\">",
"      Postoperative ileus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39800?source=see_link\">",
"      Overview of preoperative evaluation and preparation for gynecologic surgery",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26359?source=see_link\">",
"      Preventing postoperative peritoneal adhesions",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       US Department of Health and Human Services",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.womenshealth.gov/faq/hysterectomy.cfm\">",
"      www.womenshealth.gov/faq/hysterectomy.cfm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Mayo Clinic",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://mayoclinic.com/health/pain-medications/PN00060\">",
"      file://mayoclinic.com/health/pain-medications/PN00060",
"     </a>",
"     )",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 18, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?27/27/28083?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f27_27_28083=[""].join("\n");
var outline_f27_27_28083=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WOUND CARE AFTER GYNECOLOGIC SURGERY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           PAIN AFTER GYNECOLOGIC SURGERY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           VAGINAL BLEEDING AFTER GYNECOLOGIC SURGERY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           ACTIVITY AFTER GYNECOLOGIC SURGERY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           DIGESTIVE SYSTEM AFTER GYNECOLOGIC SURGERY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H22\">",
"           URINARY SYSTEM AFTER GYNECOLOGIC SURGERY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H25\">",
"           FOLLOW-UP VISIT AFTER GYNECOLOGIC SURGERY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H27\">",
"           WHEN TO CALL YOUR SURGEON",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H28\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f27_27_28084="Cutaneous nerves of trunk";
var content_f27_27_28084=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F81709&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F81709&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 556px\">",
"   <div class=\"ttl\">",
"    Cutaneous nerves of trunk",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 536px; height: 327px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    &bull; The thoracic intercostal nerves supply the parietal pleura; lateral and anterior branches are sensory to the skin of the lateral and anterior thorax.",
"    <br>",
"     &bull; The thoracoabdominal intercostal and subcostal nerves supply the peritoneum; lateral and anterior sensory cutaneous branches supply the skin.",
"     <br>",
"      &bull; The subcostal nerve provides cutaneous branches to the superior gluteal region.",
"      <br>",
"       &bull; Other cutaneous nerves of the lower abdomen include the lateral femoral cutaneous, genitofemoral nerves, ilioinguinal and iliohypogastric nerves. The ilioinguinal and iliohypogastric nerves arise from the the lumbar plexus (L1) and provide cutaneous sensory innervation in the groin and upper hip and thigh regions.",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_27_28084=[""].join("\n");
var outline_f27_27_28084=null;
var title_f27_27_28085="NSCLC liver met CT";
var content_f27_27_28085=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58174&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58174&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Liver metastasis-CT",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 354px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT of the liver showing multiple low-density masses in a 74-year-old man with a right hilar mass. Ultrasound guided needle aspirate confirmed metastatic non-small cell lung cancer.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_27_28085=[""].join("\n");
var outline_f27_27_28085=null;
var title_f27_27_28086="Piperacillin and tazobactam sodium: Pediatric drug information";
var content_f27_27_28086=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Piperacillin and tazobactam sodium: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24216?source=see_link\">",
"    see \"Piperacillin and tazobactam sodium: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?39/20/40259?source=see_link\">",
"    see \"Piperacillin and tazobactam sodium: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F210401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zosyn&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F210402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      AJ-PIP/TAZ;",
"     </li>",
"     <li>",
"      Piperacillin and Tazobactam for Injection;",
"     </li>",
"     <li>",
"      Tazocin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1049416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Beta-lactam and Beta-lactamase Inhibitor Combination",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Penicillin (Antipseudomonal)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F12675525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Zosyn&reg; (piperacillin and tazobactam) is a combination product; each 3.375 g vial contains 3 g piperacillin sodium and 0.375 g tazobactam sodium in an 8:1 ratio. Dosage recommendations are based on the",
"     <b>",
"      piperacillin",
"     </b>",
"     component.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Limited data available, positive efficacy results, dosage regimens variable, dosing partially extrapolated from piperacillin data; further studies are needed (Kacet, 1992)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     GA &lt;36 weeks:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     PNA 0-7 days: 75 mg/kg/dose every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     PNA 8-28 days: 75 mg/kg/dose every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Meningitis: PNA 0-7 days: 200 mg/kg/dose every 12 hours of piperacillin was used in two neonates (GA: 31, 35 weeks) (Placzek, 1983)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     GA &ge;36 weeks:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     PNA 0-7 days: 75 mg/kg/dose every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     PNA 8-28 days: 75 mg/kg/dose every 6 hours",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1049409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24216?source=see_link\">",
"      see \"Piperacillin and tazobactam sodium: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Zosyn&reg; (piperacillin and tazobactam) is a combination product; each 3.375 g vial contains 3 g piperacillin sodium and 0.375 g tazobactam sodium in an 8:1 ratio. Dosage recommendations are based on the",
"     <b>",
"      piperacillin",
"     </b>",
"     component.",
"     <b>",
"      Note:",
"     </b>",
"     Some centers divide doses every 6 hours for enhanced pharmacodynamic profile.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants 1 to &lt;6 months: I.V.: 150-300 mg of piperacillin component/kg/day in divided doses every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children &ge;6 months: I.V.: 240 mg of piperacillin component/kg/day in divided doses every 8 hours; higher doses have been used for serious or pseudomonal infections: 300-400 mg of piperacillin component/kg/day in divided doses every 6 hours; maximum dose: 16 g of piperacillin component/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Appendicitis and/or peritonitis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants 2-9 months: 240 mg of piperacillin component/kg/day in divided doses every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children &ge;9 months and &le;40 kg: 300 mg piperacillin component/kg/day in divided doses every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;40 kg and Adults: I.V.: 3.375 g (3 g piperacillin/0.375 g tazobactam) every 6 hours; maximum dose: 16 g of piperacillin component/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: Nosocomial pneumonia: I.V.: 4.5 g (4 g piperacillin/0.5 g tazobactam) every 6 hours for 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-40 mL/minute: Decrease dose by 30% and administer every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute: Decrease dose by 30% and administer every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: Adults: Administer 2.25 g every 8-12 hours with an additional dose of 0.75 g after each dialysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     CAPD: Adults: Administer 2.25 g every 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in patients with hepatic cirrhosis:",
"     </b>",
"     No dosing adjustment required",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F210378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note",
"     </b>",
"     : 8:1 ratio of piperacillin sodium/tazobactam sodium",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion [premixed iso-osmotic solution]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zosyn&reg;: 2.25 g: Piperacillin 2 g and tazobactam 0.25 g (50 mL) [contains edetate disodium, sodium 128 mg (5.58 mEq)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zosyn&reg;: 3.375 g: Piperacillin 3 g and tazobactam 0.375 g (50 mL)  [contains edetate disodium, sodium 192 mg (8.38 mEq)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zosyn&reg;: 4.5 g: Piperacillin 4 g and tazobactam 0.5 g (100 mL) [contains edetate disodium, sodium 256 mg (11.17 mEq)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 2.25 g: Piperacillin 2 g and tazobactam 0.25 g; 3.375 g: Piperacillin 3 g and tazobactam 0.375 g; 4.5 g: Piperacillin 4 g and tazobactam 0.5 g; 40.5 g: Piperacillin 36 g and tazobactam 4.5 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zosyn&reg;: 2.25 g: Piperacillin 2 g and tazobactam 0.25 g [contains edetate disodium, sodium 128 mg (5.58 mEq)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zosyn&reg;: 3.375 g: Piperacillin 3 g and tazobactam 0.375 g [contains edetate disodium, sodium 192 mg (8.38 mEq)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zosyn&reg;: 4.5 g: Piperacillin 4 g and tazobactam 0.5 g [contains edetate disodium, sodium 256 mg (11.17 mEq)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zosyn&reg;: 40.5 g: Piperacillin 36 g and tazobactam 4.5 g [contains edetate disodium, sodium 2304 mg (100.4 mEq); bulk pharmacy vial]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F210362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes infusion",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1049419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: I.V. intermittent infusion: May administer over 30 minutes at a maximum concentration of 200 mg/mL (piperacillin component); however, concentrations &le;20 mg/mL are preferred. Piperacillin has been shown to inactivate aminoglycosides",
"     <i>",
"      in vitro",
"     </i>",
"     . Concurrent aminoglycoside administration with piperacillin may pose a risk of reduced antibacterial efficacy",
"     <i>",
"      in vivo",
"     </i>",
"     , particularly in patients with end-stage renal disease requiring hemodialysis. If the patient is on concurrent aminoglycoside therapy, separate piperacillin and tazobactam administration from the aminoglycoside by at least 30-60 minutes.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F210429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, sterile water for injection; LR (EDTA formulated product only);",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in peritoneal dialysis solution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amikacin (EDTA formulated product only), aminophylline, anidulafungin (EDTA formulated product only), aztreonam, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium gluconate, carboplatin, carmustine, cefepime, cimetidine, clindamycin, cyclophosphamide, cytarabine, dexamethasone sodium phosphate, dexmedetomidine, diphenhydramine, docetaxel, dopamine, enalaprilat, etoposide, etoposide phosphate, fenoldopam, floxuridine, fluconazole, fludarabine, fluorouracil, furosemide, gallium nitrate, gentamicin (EDTA formulated product only), granisetron, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydrocortisone sodium phosphate, hydrocortisone sodium succinate, hydromorphone, ifosfamide, leucovorin calcium, linezolid, lorazepam, magnesium sulfate, mannitol, meperidine, mesna, methotrexate, methylprednisolone sodium succinate, metoclopramide, metronidazole, milrinone, morphine, ondansetron, potassium chloride, ranitidine, remifentanil, sargramostim, sodium bicarbonate, telavancin (EDTA formulated product only), thiotepa, tigecycline (EDTA formulated product only), trimethoprim/sulfamethoxazole, vasopressin, vinblastine, vincristine, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Acyclovir, amiodarone, amphotericin B, amphotericin B cholesteryl sulfate complex, azithromycin, caspofungin (EDTA formulated product only), chlorpromazine, cisplatin, dacarbazine, daunorubicin, dobutamine, doxorubicin, doxorubicin liposome, doxycycline, droperidol, drotrecogin alfa, famotidine, ganciclovir, gemcitabine, haloperidol, hydroxyzine, idarubicin, minocycline, mitomycin, mitoxantrone, nalbuphine, pantoprazole (EDTA formulated product only), prochlorperazine edisylate, promethazine, streptozocin, tobramycin (EDTA formulated product only).",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Cisatracurium, vancomycin.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1049413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reconstituted piperacillin/tazobactam solution is stable for 24 hours at room temperature and 2 days when refrigerated; incompatible with LR solution and aminoglycosides (especially tobramycin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Reformulated Zosyn&reg; containing EDTA has been shown to be compatible",
"     <i>",
"      in vitro",
"     </i>",
"     for Y-site infusion with amikacin and gentamicin, but not compatible with tobramycin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Premixed solution: Store frozen; thawed solution is stable for 24 hours at room temperature or 14 days refrigerated; do not refreeze",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1049418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of sepsis, postpartum endometritis or pelvic inflammatory disease, intra-abdominal infections, including appendicitis (complicated by rupture or abscess) and peritonitis; uncomplicated or complicated infections involving skin and skin structures, the lower respiratory tract, and urinary tract caused by piperacillin-resistant, beta-lactamase-producing strains that are piperacillin/tazobactam susceptible. Tazobactam expands activity of piperacillin to include beta-lactamase producing strains of",
"     <i>",
"      S. aureus",
"     </i>",
"     ,",
"     <i>",
"      H. influenzae",
"     </i>",
"     ,",
"     <i>",
"      B. fragilis",
"     </i>",
"     ,",
"     <i>",
"      Klebsiella",
"     </i>",
"     ,",
"     <i>",
"      E. coli",
"     </i>",
"     , and",
"     <i>",
"      Acinetobacter",
"     </i>",
"     . When piperacillin and tazobactam is used to treat nosocomial pneumonia caused by",
"     <i>",
"      P. aeruginosa",
"     </i>",
"     , combination therapy with an aminoglycoside is recommended.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F210432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Zosyn&reg; may be confused with Zofran&reg;, Zyvox&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Tazact [India] may be confused with Tazac brand name for nizatidine [Australia]; Tiazac brand name for diltiazem [U.S., Canada]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F210428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain, edema, hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, anxiety, dizziness, fever, headache, insomnia, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, constipation, diarrhea, dyspepsia, nausea, stool changes, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: AST increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Abscess, local reaction, phlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, pharyngitis, rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Infection, moniliasis, sepsis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Agranulocytosis, anaphylaxis/anaphylactoid reaction, anemia, anxiety, arrhythmia, arthralgia, atrial fibrillation, back pain, bradycardia, bronchospasm,",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD), candidiasis, cardiac arrest, cardiac failure, cholestatic jaundice, circulatory failure, confusion, convulsions, coughing, depression, diaphoresis, dysuria, epistaxis, erythema multiforme, flatulence, flushing, gastritis, genital pruritus, hallucination, hematuria, hemolytic anemia, hemorrhage, hepatitis, hiccough, hypoglycemia, hypokalemia, hypotension, ileus, incontinence, inflammation, injection site reaction, interstitial nephritis, leukorrhea, malaise, melena, mesenteric embolism, myalgia, myocardial infarction, oliguria, pancytopenia, photophobia, pulmonary edema, pulmonary embolism, purpura, renal failure, rigors, Stevens-Johnson syndrome, syncope, tachycardia (supraventricular and ventricular), taste perversion, thirst, thrombocytopenia, thrombocytosis, thrombophlebitis, tinnitus, toxic epidermal necrolysis, tremor, ulcerative stomatitis, urinary retention, vaginitis, ventricular fibrillation, vertigo",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1049422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to piperacillin, tazobactam, penicillins, cephalosporins, beta-lactamase inhibitors, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1049408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients requiring restricted salt intake, and in patients with renal impairment or pre-existing seizure disorder; dosage modification required in patients with impaired renal function",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1049407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prolonged use may result in superinfection, including pseudomembranous colitis; abnormal platelet aggregation and prolonged bleeding have been reported in patients with renal failure; piperacillin therapy has been associated with an increased incidence of fever and rash in cystic fibrosis patients. Severe anaphylactic reactions, including shock, have been reported in patients receiving piperacillin and tazobactam; be prepared to treat anaphylaxis when administering Zosyn&reg;",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F210371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Penicillins may decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Penicillins may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Penicillins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F210374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F210387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. Piperacillin and tazobactam both cross the placenta and are found in the fetal serum, placenta, amniotic fluid, and fetal urine. When used during pregnancy, the clearance and volume of distribution of piperacillin/tazobactam are increased; half-life and AUC are decreased. Piperacillin/tazobactam is approved for the treatment of postpartum gynecologic infections, including endometritis or pelvic inflammatory disease, caused by susceptible organisms.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1049415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum electrolytes, bleeding time especially in patients with renal impairment; periodic tests of renal, hepatic, and hematologic function; observe for changes in bowel frequency",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1049406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins; inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls; tazobactam prevents degradation of piperacillin by binding to beta-lactamases",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1049421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Both AUC and peak concentrations are dose proportional",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely distributed into tissues and body fluids including lungs, intestinal mucosa, female reproductive tissues, interstitial fluid, gallbladder, and bile; penetration into CSF is poor when meninges are uninflamed; piperacillin and tazobactam cross the placenta; piperacillin is excreted into breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     : Children and Adults: 0.243 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Piperacillin: &sim;26% to 33%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tazobactam: 31% to 32%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Piperacillin: 6% to 9% to desethyl metabolite (weak activity)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tazobactam: &sim;22% to inactive metabolite",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Piperacillin: 71%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tazobactam: 84%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Piperacillin:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants 2-5 months: 1.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 6-23 months: 0.9 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 2-12 years: 0.7 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 0.7-1.2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metabolite: 1-1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tazobactam:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants 2-5 months: 1.6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 6-23 months: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 2-12 years: 0.8-0.9 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 0.7-0.9 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Piperacillin and tazobactam are both eliminated by renal tubular secretion and glomerular filtration. Piperacillin, tazobactam, and desethylpiperacillin are also secreted into bile.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Piperacillin: 50% to 70% eliminated unchanged in urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tazobactam: Found in urine at 24 hours, with 20% as the inactive metabolite and 80% as unchanged drug",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Children 9 months to 12 years: 5.64 mL/minute/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Hemodialysis removes 30% to 40% of a piperacillin/tazobactam dose; peritoneal dialysis removes 21% of tazobactam and 6% of piperacillin",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1049423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sodium content of 1 g piperacillin component in the combination product: 2.79 mEq",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bryson HM and Brogden RN, &ldquo;Piperacillin/Tazobactam. A Review of its Antibacterial Activity, Pharmacokinetic Properties, and Therapeutic Potential,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1994, 47(3):506-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/27/28086/abstract-text/7514977/pubmed\" id=\"7514977\" target=\"_blank\">",
"        7514977",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Flidel-Rimon O, Friedman S, Gradstein S, et al, \"Reduction in Multiresistant Nosocomial Infections in Neonates Following Substitution of Ceftazidime With Piperacillin/Tazobactam in Empiric Antibiotic Therapy,\"",
"      <i>",
"       Acta Paediatr",
"      </i>",
"      , 2003, 92(10):1205-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/27/28086/abstract-text/14632339/pubmed\" id=\"14632339\" target=\"_blank\">",
"        14632339",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Flidel-Rimon O, Friedman S, Leibovitz E, et al, \"The Use of Piperacillin/Tazobactam (in Association With Amikacin) in Neonatal Sepsis: Efficacy and Safety Data,\"",
"      <i>",
"       Scand J Infect Dis",
"      </i>",
"      , 2006, 38(1):36-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/27/28086/abstract-text/16338836/pubmed\" id=\"16338836\" target=\"_blank\">",
"        16338836",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kacet N, Roussel-Delvallez M, Gremillet C, et al, \"Pharmacokinetic Study of Piperacillin in Newborns Relating to Gestational and Postnatal Age,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1992, 11(5):365-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/27/28086/abstract-text/1630856/pubmed\" id=\"1630856\" target=\"_blank\">",
"        1630856",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pillay T, Pillay DG, Adhikari M, et al, \"Piperacillin/Tazobactam in the Treatment of",
"      <i>",
"       Klebsiella pneumoniae",
"      </i>",
"      Infections in Neonates,\"",
"      <i>",
"       Am J Perinatol",
"      </i>",
"      , 1998, 15(1):47-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/27/28086/abstract-text/9475688/pubmed\" id=\"9475688\" target=\"_blank\">",
"        9475688",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Placzek M, Whitelaw A, Want S, et al, &ldquo;Piperacillin in Early Neonatal Infection,&rdquo;",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 1983, 58(12):1006-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/27/28086/abstract-text/ 6559060 /pubmed\" id=\" 6559060 \" target=\"_blank\">",
"        6559060",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reed MD, Goldfarb J, Yamashita T, et al, &ldquo;Single-Dose Pharmacokinetics of Piperacillin and Tazobactam in Infants and Children,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1994, 38(12):2817-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/27/28086/abstract-text/ 7695268 /pubmed\" id=\" 7695268 \" target=\"_blank\">",
"        7695268",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rubino CM, Gal P, and Ransom JL, \"A Review of the Pharmacokinetic and Pharmacodynamic Characteristics of Beta-Lactam/Beta-Lactamase Inhibitor Combination Antibiotics in Premature Infants,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1998, 17(12):1200-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/27/28086/abstract-text/9877383/pubmed\" id=\"9877383\" target=\"_blank\">",
"        9877383",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12708 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-188.40.116.55-F65976BBC3-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_27_28086=[""].join("\n");
var outline_f27_27_28086=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210401\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210402\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049416\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12675525\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049409\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210378\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210362\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049419\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210429\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049413\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049418\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210432\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210428\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049422\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049408\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049407\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299884\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210371\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210374\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210387\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049415\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049406\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049421\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049423\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12708\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12708|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24216?source=related_link\">",
"      Piperacillin and tazobactam sodium: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/20/40259?source=related_link\">",
"      Piperacillin and tazobactam sodium: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_27_28087="Genomic disorders: An overview";
var content_f27_27_28087=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Genomic disorders: An overview",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/27/28087/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/27/28087/contributors\">",
"     Carlos A Bacino, MD, FACMG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/27/28087/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/27/28087/contributors\">",
"     Helen V Firth, DM, FRCP, DCH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/27/28087/contributors\">",
"     Benjamin A Raby, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/27/28087/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/27/28087/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/27/28087/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H16722192\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genomic disorders are diseases that result from the loss or gain of",
"    <span class=\"nowrap\">",
"     chromosomal/DNA",
"    </span>",
"    material. The most common and better-delineated genomic disorders are divided in two main categories: those resulting from copy number losses (deletion syndromes) and copy number gains (duplication syndromes).",
"   </p>",
"   <p>",
"    An overview of genomic disorders is presented here. Specific syndromic disorders are reviewed separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16722199\">",
"    <span class=\"h1\">",
"     COPY NUMBER VARIATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Structural genetic variation refers to a class of sequence alterations spanning more than 1000 bases (one kilobase or kb) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28087/abstract/1\">",
"     1",
"    </a>",
"    ]. This class includes quantitative variations such as copy number variations (CNVs), sequence rearrangements (such as those observed among immunoglobulins), and other less common variations, including chromosomal rearrangements that may or may not alter the genome contents and in some cases result in disease.",
"   </p>",
"   <p>",
"    CNVs, the most prevalent type of structural variation, are DNA segments spanning thousands to millions of bases whose copy number varies between different individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28087/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. These submicroscopic genomic differences in the number of copies of one or more sections of DNA result in DNA gains or losses. Copy number gains can be the result of duplications, triplications, or even multiple copy number gains. Most deletions are one copy loss (heterozygous), but in some instances the loss can affect both copies (homozygous).",
"   </p>",
"   <p>",
"    CNVs, which are most commonly inherited but can occur",
"    <em>",
"     de novo",
"    </em>",
"    , were initially thought to be rare events resulting from sporadic mutation and correlated with specific Mendelian diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28087/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. These misperceptions about their rarity and absolute disease linkage were primarily due to technical limitations precluding genome-wide assessments in large cohorts. Advances in technology have shown that deviation from the diploid state is widespread and contributes substantially to genetic diversity. Some studies have suggested that CNV differences in the human genome are as extensive as 20 percent, although this may be an overestimation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28087/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. It is estimated conservatively that most individuals carry an average of three large-scale CNVs [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28087/abstract/3\">",
"     3",
"    </a>",
"    ]. The number of known CNVs that contribute to disease pathogenesis continues to increase.",
"   </p>",
"   <p>",
"    The physical distribution of CNVs appears to be nonrandom, with both CNV hot and cold spots reported [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28087/abstract/6,8\">",
"     6,8",
"    </a>",
"    ]. CNV frequency is greatest in regions of segmental duplication (a 4- to 10-fold enrichment for CNVs), consistent with nonallelic homologous recombination as a primary mechanism for CNV mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28087/abstract/2,9-12\">",
"     2,9-12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/13/7386?source=see_link&amp;anchor=H5#H5\">",
"     \"Genetic and environmental causes of birth defects\", section on 'Nonallelic homologous recombination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CNVs are more commonly observed in gene-rich regions. CNVs appear to be enriched in specific gene families, including immune and inflammatory response genes, cell signaling and cell adhesion molecules, structural proteins, and olfactory receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28087/abstract/6\">",
"     6",
"    </a>",
"    ]. Most of these differences probably represent benign CNVs that reflect normal variation with no apparent clinical consequence [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28087/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CNVs can be pathogenic if they involve a dose-sensitive gene(s) or if they influence genomic regions through regulatory elements [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28087/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Some pathogenic CNVs cause syndromic disorders with consistent phenotypic features (eg, deletions of elastin in Williams syndrome, duplications of PMP22 in Charcot-Marie-Tooth disease type 1A [CMT1A]), while others are associated with disease susceptibility or resistance (eg, cancer, human immunodeficiency virus [HIV] infection, autoimmune disorders, autism).",
"   </p>",
"   <p>",
"    CNVs can be responsible for Mendelian diseases associated with large gains and losses of genetic material or even small losses or gains at the exonic level, as well as syndromes with more complex combinations of genetic and environmental factors. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Contiguous gene",
"      <span class=\"nowrap\">",
"       deletions/duplications",
"      </span>",
"      as seen for example in Williams-Beuren syndrome, 22q11 deletion-syndrome, Smith-Magenis syndrome, and Potocki-Lupski syndrome. These recurrent CNVs are sponsored by nonallelic homologous recombination (NAHR) at sites of low-copy repeats.",
"     </li>",
"     <li>",
"      Deletions of genes or portions of genes (exons) leading to many Mendelian-inherited genetic disorders, including disorders that are autosomal dominant (eg, Rubinstein-Taybi syndrome) and X-linked recessive (eg, Duchenne muscular dystrophy) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28087/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A deletion at the complement factor 4 (C4) locus that confers a 1.6- to 5.3-fold risk for systemic lupus erythematosus [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28087/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A deletion in FCGR3B associated with granulomatosis with polyangiitis (Wegener's) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28087/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A deletion of defensin-beta 4 (DEFB4) associated with increased risk of colonic Crohn's disease [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28087/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Increased frequency of",
"      <em>",
"       de novo",
"      </em>",
"      germ-line CNVs in patients with autism spectrum disorder (ASD) and schizophrenia [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28087/abstract/20,21\">",
"       20,21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/43/37562?source=see_link\">",
"     \"Epidemiology and pathogenesis of systemic lupus erythematosus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33097?source=see_link\">",
"     \"Pathogenesis of granulomatosis with polyangiitis (Wegener&rsquo;s) and related vasculitides\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4698?source=see_link&amp;anchor=H13#H13\">",
"     \"Terminology, epidemiology, and pathogenesis of autism spectrum disorders\", section on 'Genetic factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, some conditions are associated with multiple CNVs, which may explain their variable phenotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28087/abstract/22\">",
"     22",
"    </a>",
"    ]. As an example, in a retrospective study, array comparative genomic hybridization (CGH) was used to evaluate CNVs in 2312 children with developmental disabilities who already had one predefined CNV and in 8329 children without developmental disabilities [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28087/abstract/23\">",
"     23",
"    </a>",
"    ]. This study found that, in comparison to controls without developmental disabilities, individuals with developmental disabilities had an increased number of second site CNVs. This increase in CNVs may have played a causative role in the disabilities (eg, by causing disruption of a new gene or altering gene dosage), or may be an indirect marker of susceptibility to genomic damage. (See",
"    <a class=\"local\" href=\"#H3390507\">",
"     'Array comparative genomic hybridization'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12440911\">",
"    <span class=\"h2\">",
"     Causes of CNVs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low copy repeats are stretches of repetitive DNA sequences (segmental duplications) approximately 10 to 300 kilobases in size that share &ge;95 percent homology. Erroneous pairing of these highly homologous regions can cause misalignment and unequal recombination during meiosis. This can lead to duplication and deletion of chromosomal material resulting in CNVs. This process is known as nonallelic homologous recombination (NAHR) (",
"    <a class=\"graphic graphic_figure graphicRef67644 \" href=\"UTD.htm?40/28/41412\">",
"     figure 1",
"    </a>",
"    ), the most common mechanism for the formation of genomic rearrangements [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28087/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    NAHR can result in either deletions or duplication via the same mechanisms and due to low copy repeats mediated nonallelic homologous recombination. A classic example is the case of Charcot-Marie-Tooth Type I, a peripheral neuropathy caused by duplications of the PMP22 gene on chromosome 17p11.2. The same region when deleted leads to a different neuropathy known as Tomaculous neuropathy also known as hereditary neuropathy with liability to pressure palsies (HNPP). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/17/37143?source=see_link\">",
"     \"Microduplication syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other mechanisms include nonhomologous end joining and microhomology-mediated break-induced replication, although discussion of these is beyond the scope of this chapter [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28087/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite a great deal of knowledge about the structural details of how CNVs occur, we do not know what predisposes certain individuals to develop these changes more than other individuals.",
"   </p>",
"   <p>",
"    Of interest, in a large study of patients with developmental disabilities, parental data provided information about whether CNVs were inherited or arose de novo [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28087/abstract/23\">",
"     23",
"    </a>",
"    ]. This study suggested that CNVs were more likely to arise de novo in the syndromic disorders (eg, Williams-Beuren syndrome), whereas CNVs were more likely to be inherited in the disorders with variable phenotype (eg, intellectual disability). A potential explanation may be that reproductive fitness is reduced in individuals with the more severe syndromic disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/14/34025?source=see_link&amp;anchor=H12329278#H12329278\">",
"     \"Microdeletion syndromes (chromosomes 1 to 11)\", section on '7q11.23 deletion syndrome (Williams syndrome)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12440918\">",
"    <span class=\"h2\">",
"     Interpreting CNVs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The interpretation of CNVs has steadily improved due to use of large control databases that allow a direct comparison with apparently normal controls. Examples of these databases include the Database of Genomic Variants (DGV) or large sequencing projects such as the 1000 Genomes Project [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28087/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Other databases that include phenotypic information, as in the case of DECIPHER (",
"    <strong>",
"     D",
"    </strong>",
"    atabas",
"    <strong>",
"     E",
"    </strong>",
"    of",
"    <strong>",
"     C",
"    </strong>",
"    hromosomal",
"    <strong>",
"     I",
"    </strong>",
"    mbalance and",
"    <strong>",
"     P",
"    </strong>",
"    henotype in",
"    <strong>",
"     H",
"    </strong>",
"    umans using",
"    <strong>",
"     E",
"    </strong>",
"    nsembl",
"    <strong>",
"     R",
"    </strong>",
"    esources), are becoming valuable resources for findings detected by array-comparative genomic hybridization [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28087/abstract/29\">",
"     29",
"    </a>",
"    ].",
"    <a class=\"external\" href=\"file://decipher.sanger.ac.uk/\">",
"     DECIPHER",
"    </a>",
"    is a web-based resource that contains array and clinical data deposited by over 200 member centers around the world.",
"   </p>",
"   <p>",
"    Interpreting the pathogenicity of CNVs can be quite challenging in the presence of multiple CNVs in one individual. Some studies have shown that multiple rare CNVs, either inherited or",
"    <em>",
"     de novo",
"    </em>",
"    , can compound the clinical severity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28087/abstract/23,30\">",
"     23,30",
"    </a>",
"    ]. It is also important to highlight the presence of common CNVs in the general population. It is unclear whether many of these common polymorphisms may play a role in common disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28087/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16722227\">",
"    <span class=\"h1\">",
"     DISEASE MECHANISMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are different potential mechanisms that can lead to disease in genomic disorders secondary to deletions and duplications. The main mechanism is related to changes in dosage sensitive genes. &ldquo;Haploinsufficiency&rdquo; (&ldquo;haplo&rdquo; = half) defines the concept where loss or gain of one allele of a gene leads to abnormal protein production or function, thereby causing disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28087/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Deletions can interfere with the required gene product dose, resulting in disease. One example is Williams-Beuren Syndrome, which is caused by a microdeletion in chromosome 7q11.23 involving multiple genes, including the gene for elastin [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28087/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Having only half of the normal amount (dose) of elastin is enough to cause disruption of the arteries leading to aortic narrowing and multiple other arterial abnormalities. The deletions in Williams-Beuren syndrome, similar to what happens in many other genomic disorders, can be of different sizes. Typically the loss encompasses 1.55 Mb, but in some cases the deletion can be more extensive or even smaller. The size difference is due to the different LCRs around the critical region that can be involved in mediating the rearrangements. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18167?source=see_link&amp;anchor=H10#H10\">",
"     \"Chromosomal translocations, deletions, and inversions\", section on 'Deletions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/14/34025?source=see_link&amp;anchor=H12329278#H12329278\">",
"     \"Microdeletion syndromes (chromosomes 1 to 11)\", section on '7q11.23 deletion syndrome (Williams syndrome)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40774?source=see_link\">",
"     \"Supravalvar aortic stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of gene dosage in determining the effect of CNVs was illustrated in the sex differences from a large study of CNVs in patients with developmental disabilities [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28087/abstract/23\">",
"     23",
"    </a>",
"    ]. When compared to females, males had more of the &ldquo;variable phenotype genomic disorders&rdquo; (eg, intellectual disability) but not syndromic disorders (eg, autism spectrum disorders). Females may be protected from these more genetically multifactorial disorders due to sex chromosome bias (ie, the protection of females from weakly deleterious mutations on one X chromosome by the normal corresponding genes on the other X chromosome).",
"   </p>",
"   <p>",
"    Duplications may also disrupt a gene and alter the amount of protein produced by interfering with protein synthesis or assembly. Another mechanism includes unmasking recessive alleles [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28087/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. When a recessive allele is deleted, it could potentially uncover a pathogenic mutation in the remaining copy. This would lead to disease, because there is no working copy for the affected gene.",
"   </p>",
"   <p>",
"    Other disease mechanisms include interference with (i) imprinted genes like in the case of paternal duplications of 11p15 that lead to Beckwith-Wiedemann syndrome or (ii) with regulatory elements outside genes like in brachydactyly type A2 and duplications outside the BMP2 gene [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28087/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24473?source=see_link&amp;anchor=H1618409#H1618409\">",
"     \"Beckwith-Wiedemann syndrome\", section on 'Genetics and pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Arrays that contain single nucleotide polymorphisms (SNPs) can further aid in the identification of imprinting disorders caused by uniparental disomy. One such example is Angelman syndrome (AS) and uniparental disomy (UPD) caused by isodisomy. Isodisomies result from either nondisjunction in meiosis II or postzygotic duplication (monosomy rescue). A small number of AS cases are the result of UPD. In those cases there is absence of the maternal contribution for a region of chromosome 15 (15q11-q13). These cases are typically associated with monosomy rescue (duplication of a chromosome from a monosomic zygote), where there are two identical copies of the paternal chromosome 15 and no maternal contribution. Other examples of UPD can be seen in patients with Prader-Willi syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/8/16516?source=see_link\">",
"     \"Epidemiology and genetics of Prader-Willi syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174214015\">",
"    <span class=\"h2\">",
"     Contiguous gene syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contiguous gene syndromes can occur when large CNVs affect several contiguous genes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28087/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. For example, Williams-Beuren Syndrome is caused by a 1.5-1.8 Mb deletion on chromosome 7q11 that typically encompasses nine genes. Occasionally, molecular-phenotypic correlation is possible. For example, in WAGR syndrome, a genomic disorder consisting of",
"    <strong>",
"     W",
"    </strong>",
"    ilms tumor,",
"    <strong>",
"     A",
"    </strong>",
"    niridia,",
"    <strong>",
"     G",
"    </strong>",
"    enitourinary anomalies, and mental",
"    <strong>",
"     R",
"    </strong>",
"    etardation, clinical features are attributable to the loss of individual genes by a large deletion: deletions of",
"    <em>",
"     WT1",
"    </em>",
"    are responsible for Wilms tumor, while",
"    <em>",
"     PAX6",
"    </em>",
"    deletions are responsible for the aniridia findings. Both genes are contiguously located within the short arm of chromosome 11. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/14/34025?source=see_link&amp;anchor=H2473577#H2473577\">",
"     \"Microdeletion syndromes (chromosomes 1 to 11)\", section on '11p13 deletion syndrome (WAGR syndrome)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16722234\">",
"    <span class=\"h1\">",
"     DETECTION OF GENOMIC DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genomic disorders are typically detected by array comparative genomic hybridization (array CGH). Most laboratories confirm gains or losses detected on an array with an independent method such as fluorescence",
"    <em>",
"     in situ",
"    </em>",
"    hybridization (FISH), multiple ligation dependent probe amplification (MLPA), or quantitative PCR (Q-PCR). Parental FISH testing, and in selected cases array CGH, is warranted in all cases of detected genomic abnormalities as many are inherited and relevant for future pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28087/abstract/42\">",
"     42",
"    </a>",
"    ]. Whereas the genomic position of a loss is clear from an array, gains may be either tandem duplications or insertions. If the latter arise as a consequence of a parental insertional translocation (IT), this may have important implications for future pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28087/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3390507\">",
"    <span class=\"h2\">",
"     Array comparative genomic hybridization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Array comparative genomic hybridization (array CGH), also known as chromosome microarray or microarray-based comparative genomic hybridization, is the gold standard laboratory test for the detection of CNVs that cause genomic disorders (",
"    <a class=\"graphic graphic_figure graphicRef58888 \" href=\"UTD.htm?28/63/29687\">",
"     figure 2",
"    </a>",
"    ). Array CGH allows detection of small losses or gains of genomic material down to several kilobases (kb) and even the exon level. It is widely used in the evaluation of patients with intellectual disabilities",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    congenital malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28087/abstract/44-49\">",
"     44-49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28536?source=see_link&amp;anchor=H15538652#H15538652\">",
"     \"Cytogenetic and molecular genetic diagnostic tools\", section on 'Array comparative genomic hybridization'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    The two main platforms currently used for CNV detection are oligonucleotide arrays (oligonucleotides are stretches of DNA ranging from 25 to 60 base pairs) (",
"    <a class=\"graphic graphic_figure graphicRef58888 \" href=\"UTD.htm?28/63/29687\">",
"     figure 2",
"    </a>",
"    ), and single nucleotide polymorphism arrays (SNP arrays) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28087/abstract/50\">",
"     50",
"    </a>",
"    ]. There are approximately 10 million polymorphic SNPs throughout the human genome. Both SNPs and oligonucleotide arrays can detect copy number variations, but SNP arrays can be used in addition to determine absence of homozygosity (AOH) as seen in cases of consanguinity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28087/abstract/51\">",
"     51",
"    </a>",
"    ] and in cases of uniparental disomy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28087/abstract/52\">",
"     52",
"    </a>",
"    ] when there is inheritance of regions or entire chromosomes from one single parent instead of the normal biparental contribution. SNPs can also detect loss of heterozygosity (LOH) typically seen in somatic cancer cell changes. SNPs can also be very useful for the detection of somatic mosaicism, a situation where two or more cell lines can be present in a single individual, and triploidies, a rare instance when there could be a total of 69 chromosomes (3 haploid sets) that can be detected in the prenatal setting. Some current platforms are combining the use of array CGH and SNPs integrated in one single platform.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1726088\">",
"    <span class=\"h2\">",
"     Other molecular diagnostic techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other molecular techniques used for the detection of genomic disorders include fluorescence",
"    <em>",
"     in situ",
"    </em>",
"    hybridization (FISH) and PCR based studies like Q-PCR (quantitative PCR) and MLPA (Multiple Ligation Dependent Probe Amplification). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28536?source=see_link\">",
"     \"Cytogenetic and molecular genetic diagnostic tools\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    FISH uses larger stretches of DNA (approximately 50 to 100 kilobase probes) labeled with fluorescence reagents to target specific genome regions. The use of FISH, however, requires knowledge of what specific area is being targeted and is dependent upon a clinical diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28087/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. MLPA uses a cocktail of multiple probes available in kits and targets specific chromosomes or disease regions. A single reaction allows simultaneous hybridization of multiple probes to multiple regions or even multiple exons within a gene.",
"   </p>",
"   <p>",
"    The advantage of MLPA over FISH is the lower cost and more comprehensive coverage for copy number",
"    <span class=\"nowrap\">",
"     gains/losses",
"    </span>",
"    detection due to the use of multiple probes. However, MLPA does not provide location. FISH studies, on the other hand, can determine location if visualized in metaphase chromosome spreads. A copy number gain can be the result of chromosome duplication immediately adjacent to the area of interest, part of a marker chromosome (a structurally abnormal chromosome that makes up a partial trisomy), or the result of an insertion or translocation. Duplications that are very close to each other may be challenging to detect by metaphase FISH and are best detected by interphase FISH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1726355\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Genomic disorders are diseases that result from the loss or gain of",
"      <span class=\"nowrap\">",
"       chromosomal/DNA",
"      </span>",
"      material. The most common and better-delineated genomic disorders are divided in two main categories: those resulting from copy number losses (deletion syndromes) and copy number gains (duplication syndromes). (See",
"      <a class=\"local\" href=\"#H16722192\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=see_link\">",
"       \"Congenital cytogenetic abnormalities\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Copy number variations (CNVs)",
"      <strong>",
"      </strong>",
"      are submicroscopic genomic differences in the number of copies of one or more sections of DNA that result in DNA gains or losses (",
"      <a class=\"graphic graphic_figure graphicRef67644 \" href=\"UTD.htm?40/28/41412\">",
"       figure 1",
"      </a>",
"      ). Some pathogenic CNVs cause syndromic disorders with consistent phenotypic features. Other CNVs are associated with disease susceptibility or resistance, and the same CNV can be associated with several diverse disorders. (See",
"      <a class=\"local\" href=\"#H16722199\">",
"       'Copy number variations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The main mechanism that leads to disease in genomic disorders secondary to deletions and duplications is changes in dosage-sensitive genes. Other disease mechanisms include interference with imprinted genes and with regulatory elements outside genes. (See",
"      <a class=\"local\" href=\"#H16722227\">",
"       'Disease mechanisms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Genomic disorders are typically detected by array comparative genomic hybridization (array CGH). Most laboratories confirm gains or losses detected on an array with an independent method such as fluorescence",
"      <em>",
"       in situ",
"      </em>",
"      hybridization (FISH), multiple ligation dependent probe amplification (MLPA), or quantitative PCR (Q-PCR). (See",
"      <a class=\"local\" href=\"#H16722234\">",
"       'Detection of genomic disorders'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/1\">",
"      Feuk L, Carson AR, Scherer SW. Structural variation in the human genome. Nat Rev Genet 2006; 7:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/2\">",
"      Redon R, Ishikawa S, Fitch KR, et al. Global variation in copy number in the human genome. Nature 2006; 444:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/3\">",
"      Tuzun E, Sharp AJ, Bailey JA, et al. Fine-scale structural variation of the human genome. Nat Genet 2005; 37:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/4\">",
"      Ewart AK, Morris CA, Atkinson D, et al. Hemizygosity at the elastin locus in a developmental disorder, Williams syndrome. Nat Genet 1993; 5:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/5\">",
"      Magenis RE, Toth-Fejel S, Allen LJ, et al. Comparison of the 15q deletions in Prader-Willi and Angelman syndromes: specific regions, extent of deletions, parental origin, and clinical consequences. Am J Med Genet 1990; 35:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/6\">",
"      Cooper GM, Nickerson DA, Eichler EE. Mutational and selective effects on copy-number variants in the human genome. Nat Genet 2007; 39:S22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/7\">",
"      Sharp AJ. Emerging themes and new challenges in defining the role of structural variation in human disease. Hum Mutat 2009; 30:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/8\">",
"      Perry GH, Tchinda J, McGrath SD, et al. Hotspots for copy number variation in chimpanzees and humans. Proc Natl Acad Sci U S A 2006; 103:8006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/9\">",
"      Sharp AJ, Cheng Z, Eichler EE. Structural variation of the human genome. Annu Rev Genomics Hum Genet 2006; 7:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/10\">",
"      Sharp AJ, Locke DP, McGrath SD, et al. Segmental duplications and copy-number variation in the human genome. Am J Hum Genet 2005; 77:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/11\">",
"      Sebat J, Lakshmi B, Troge J, et al. Large-scale copy number polymorphism in the human genome. Science 2004; 305:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/12\">",
"      Wong KK, deLeeuw RJ, Dosanjh NS, et al. A comprehensive analysis of common copy-number variations in the human genome. Am J Hum Genet 2007; 80:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/13\">",
"      Wellcome Trust Case Control Consortium, Craddock N, Hurles ME, et al. Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature 2010; 464:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/14\">",
"      Girirajan S, Eichler EE. Phenotypic variability and genetic susceptibility to genomic disorders. Hum Mol Genet 2010; 19:R176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/15\">",
"      Fanciulli M, Petretto E, Aitman TJ. Gene copy number variation and common human disease. Clin Genet 2010; 77:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/16\">",
"      Boone PM, Bacino CA, Shaw CA, et al. Detection of clinically relevant exonic copy-number changes by array CGH. Hum Mutat 2010; 31:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/17\">",
"      Yang Y, Chung EK, Wu YL, et al. Gene copy-number variation and associated polymorphisms of complement component C4 in human systemic lupus erythematosus (SLE): low copy number is a risk factor for and high copy number is a protective factor against SLE susceptibility in European Americans. Am J Hum Genet 2007; 80:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/18\">",
"      Fanciulli M, Norsworthy PJ, Petretto E, et al. FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity. Nat Genet 2007; 39:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/19\">",
"      Fellermann K, Stange DE, Schaeffeler E, et al. A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon. Am J Hum Genet 2006; 79:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/20\">",
"      Sebat J, Lakshmi B, Malhotra D, et al. Strong association of de novo copy number mutations with autism. Science 2007; 316:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/21\">",
"      Stefansson H, Rujescu D, Cichon S, et al. Large recurrent microdeletions associated with schizophrenia. Nature 2008; 455:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/22\">",
"      Sanders SJ, Ercan-Sencicek AG, Hus V, et al. Multiple recurrent de novo CNVs, including duplications of the 7q11.23 Williams syndrome region, are strongly associated with autism. Neuron 2011; 70:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/23\">",
"      Girirajan S, Rosenfeld JA, Coe BP, et al. Phenotypic heterogeneity of genomic disorders and rare copy-number variants. N Engl J Med 2012; 367:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/24\">",
"      Stankiewicz P, Inoue K, Bi W, et al. Genomic disorders: genome architecture results in susceptibility to DNA rearrangements causing common human traits. Cold Spring Harb Symp Quant Biol 2003; 68:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/25\">",
"      Stankiewicz P, Shaw CJ, Dapper JD, et al. Genome architecture catalyzes nonrecurrent chromosomal rearrangements. Am J Hum Genet 2003; 72:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/26\">",
"      Hastings PJ, Lupski JR, Rosenberg SM, Ira G. Mechanisms of change in gene copy number. Nat Rev Genet 2009; 10:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/27\">",
"      1000 Genomes Project Consortium, Abecasis GR, Altshuler D, et al. A map of human genome variation from population-scale sequencing. Nature 2010; 467:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/28\">",
"      Zhang J, Feuk L, Duggan GE, et al. Development of bioinformatics resources for display and analysis of copy number and other structural variants in the human genome. Cytogenet Genome Res 2006; 115:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/29\">",
"      Firth HV, Richards SM, Bevan AP, et al. DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources. Am J Hum Genet 2009; 84:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/30\">",
"      Girirajan S, Brkanac Z, Coe BP, et al. Relative burden of large CNVs on a range of neurodevelopmental phenotypes. PLoS Genet 2011; 7:e1002334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/31\">",
"      Gijsbers AC, Schoumans J, Ruivenkamp CA. Interpretation of array comparative genome hybridization data: a major challenge. Cytogenet Genome Res 2011; 135:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/32\">",
"      Seidman JG, Seidman C. Transcription factor haploinsufficiency: when half a loaf is not enough. J Clin Invest 2002; 109:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/33\">",
"      Wu YQ, Sutton VR, Nickerson E, et al. Delineation of the common critical region in Williams syndrome and clinical correlation of growth, heart defects, ethnicity, and parental origin. Am J Med Genet 1998; 78:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/34\">",
"      Schubert C. The genomic basis of the Williams-Beuren syndrome. Cell Mol Life Sci 2009; 66:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/35\">",
"      Ropers HH. Genetics of intellectual disability. Curr Opin Genet Dev 2008; 18:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/36\">",
"      Wong LJ, Dimmock D, Geraghty MT, et al. Utility of oligonucleotide array-based comparative genomic hybridization for detection of target gene deletions. Clin Chem 2008; 54:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/37\">",
"      Kurth I, Klopocki E, Stricker S, et al. Duplications of noncoding elements 5' of SOX9 are associated with brachydactyly-anonychia. Nat Genet 2009; 41:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/38\">",
"      Russo S, Finelli P, Recalcati MP, et al. Molecular and genomic characterisation of cryptic chromosomal alterations leading to paternal duplication of the 11p15.5 Beckwith-Wiedemann region. J Med Genet 2006; 43:e39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/39\">",
"      Dathe K, Kjaer KW, Brehm A, et al. Duplications involving a conserved regulatory element downstream of BMP2 are associated with brachydactyly type A2. Am J Hum Genet 2009; 84:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/40\">",
"      Ballabio A. Contiguous deletion syndromes. Curr Opin Genet Dev 1991; 1:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/41\">",
"      Punnett HH, Zakai EH. Old syndromes and new cytogenetics. Dev Med Child Neurol 1990; 32:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/42\">",
"      Kang SH, Shaw C, Ou Z, et al. Insertional translocation detected using FISH confirmation of array-comparative genomic hybridization (aCGH) results. Am J Med Genet A 2010; 152A:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/43\">",
"      Nowakowska BA, de Leeuw N, Ruivenkamp CA, et al. Parental insertional balanced translocations are an important cause of apparently de novo CNVs in patients with developmental anomalies. Eur J Hum Genet 2012; 20:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/44\">",
"      Bejjani BA, Theisen AP, Ballif BC, Shaffer LG. Array-based comparative genomic hybridization in clinical diagnosis. Expert Rev Mol Diagn 2005; 5:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/45\">",
"      Cheung SW, Shaw CA, Yu W, et al. Development and validation of a CGH microarray for clinical cytogenetic diagnosis. Genet Med 2005; 7:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/46\">",
"      Lu X, Shaw CA, Patel A, et al. Clinical implementation of chromosomal microarray analysis: summary of 2513 postnatal cases. PLoS One 2007; 2:e327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/47\">",
"      Lu XY, Phung MT, Shaw CA, et al. Genomic imbalances in neonates with birth defects: high detection rates by using chromosomal microarray analysis. Pediatrics 2008; 122:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/48\">",
"      Miller DT, Adam MP, Aradhya S, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet 2010; 86:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/49\">",
"      Stankiewicz P, Beaudet AL. Use of array CGH in the evaluation of dysmorphology, malformations, developmental delay, and idiopathic mental retardation. Curr Opin Genet Dev 2007; 17:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/50\">",
"      Cooper GM, Mefford HC. Detection of copy number variation using SNP genotyping. Methods Mol Biol 2011; 767:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/51\">",
"      Schaaf CP, Scott DA, Wiszniewska J, Beaudet AL. Identification of incestuous parental relationships by SNP-based DNA microarrays. Lancet 2011; 377:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/52\">",
"      Papenhausen P, Schwartz S, Risheg H, et al. UPD detection using homozygosity profiling with a SNP genotyping microarray. Am J Med Genet A 2011; 155A:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/53\">",
"      Shaffer LG, Kennedy GM, Spikes AS, Lupski JR. Diagnosis of CMT1A duplications and HNPP deletions by interphase FISH: implications for testing in the cytogenetics laboratory. Am J Med Genet 1997; 69:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28087/abstract/54\">",
"      Eijk-Van Os PG, Schouten JP. Multiplex Ligation-dependent Probe Amplification (MLPA&reg;) for the detection of copy number variation in genomic sequences. Methods Mol Biol 2011; 688:97.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16647 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.131.41.98-0FBBA5EC0B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_27_28087=[""].join("\n");
var outline_f27_27_28087=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1726355\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16722192\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16722199\">",
"      COPY NUMBER VARIATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12440911\">",
"      Causes of CNVs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12440918\">",
"      Interpreting CNVs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16722227\">",
"      DISEASE MECHANISMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H174214015\">",
"      Contiguous gene syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16722234\">",
"      DETECTION OF GENOMIC DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3390507\">",
"      Array comparative genomic hybridization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1726088\">",
"      Other molecular diagnostic techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1726355\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/16647\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/16647|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/28/41412\" title=\"figure 1\">",
"      Nonhomologous recombination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/63/29687\" title=\"figure 2\">",
"      Schematic CGH for microarray setup",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24473?source=related_link\">",
"      Beckwith-Wiedemann syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18167?source=related_link\">",
"      Chromosomal translocations, deletions, and inversions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=related_link\">",
"      Congenital cytogenetic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28536?source=related_link\">",
"      Cytogenetic and molecular genetic diagnostic tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/8/16516?source=related_link\">",
"      Epidemiology and genetics of Prader-Willi syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/43/37562?source=related_link\">",
"      Epidemiology and pathogenesis of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/13/7386?source=related_link\">",
"      Genetic and environmental causes of birth defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/14/34025?source=related_link\">",
"      Microdeletion syndromes (chromosomes 1 to 11)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/17/37143?source=related_link\">",
"      Microduplication syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33097?source=related_link\">",
"      Pathogenesis of granulomatosis with polyangiitis (Wegener&rsquo;s) and related vasculitides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40774?source=related_link\">",
"      Supravalvar aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4698?source=related_link\">",
"      Terminology, epidemiology, and pathogenesis of autism spectrum disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_27_28088="Causes of chronic cough in children";
var content_f27_27_28088=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Causes of chronic cough in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/27/28088/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/27/28088/contributors\">",
"     Roni Grad, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/27/28088/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/27/28088/contributors\">",
"     George B Mallory, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/27/28088/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/27/28088/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/27/28088/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic cough is typically defined as a cough lasting more than four weeks. This is because most acute respiratory infections in children resolve within this interval. Other schemes define chronic cough as one that last more than eight weeks but also recognize that a relentlessly progressive cough often warrants evaluation prior to eight weeks.",
"   </p>",
"   <p>",
"    The evaluation of a child with chronic cough should include a detailed history, physical examination, chest radiograph, and spirometry (if the child is able). If the initial evaluation provides clues suggesting a specific cause of cough (ie, caused by an underlying disease), further evaluation is focused on that diagnostic possibility (",
"    <a class=\"graphic graphic_algorithm graphicRef74085 \" href=\"UTD.htm?23/57/24471\">",
"     algorithm 1",
"    </a>",
"    ). The steps are detailed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/9/17561?source=see_link\">",
"     \"Approach to chronic cough in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The causes of chronic cough in children are quite different from that of adults, so evaluation and management of children should not be based on adult protocols. The most clinically important causes of cough in children and the initial steps in management are reviewed here. Adolescents 15 years and older may be evaluated using guidelines for adults [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28088/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/18/5418?source=see_link\">",
"     \"Evaluation of subacute and chronic cough in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SPECIFIC COUGH",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cough that is caused by an underlying abnormality or disease is termed a specific cough. The causes of specific chronic cough fall into the following general categories (",
"    <a class=\"graphic graphic_table graphicRef75873 \" href=\"UTD.htm?17/57/18333\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Asthma",
"     </li>",
"     <li>",
"      Persistent bacterial bronchitis",
"     </li>",
"     <li>",
"      Chronic suppurative lung disease and bronchiectasis",
"     </li>",
"     <li>",
"      Airway abnormality (congenital, foreign body, or neoplastic)",
"     </li>",
"     <li>",
"      Aspiration",
"     </li>",
"     <li>",
"      Chronic or less common infections",
"     </li>",
"     <li>",
"      Interstitial lung disease",
"     </li>",
"     <li>",
"      Extrapulmonary causes: cardiac abnormalities, ear conditions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The sequence of evaluation for these disorders is informed by the age and presenting features of the child (",
"    <a class=\"graphic graphic_algorithm graphicRef74085 \" href=\"UTD.htm?23/57/24471\">",
"     algorithm 1",
"    </a>",
"    ). Identification of the presenting features and cough characteristics is important because many are easily recognizable and strongly suggestive of a specific cause; this is less true in adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/9/17561?source=see_link\">",
"     \"Approach to chronic cough in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following causes of cough warrant particular attention:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some children, chronic cough can be the most prominent presenting symptom of asthma. In most cases, there are associated symptoms of wheezing, exertional dyspnea, or atopy. The cough associated with asthma is typically dry. A wet cough does not exclude asthma but should also raise the possibility of persistent bacterial bronchitis or aspirated foreign body. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Persistent bacterial bronchitis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H8\">",
"     'Foreign body'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In our practice, we assess children with any of these symptoms for further evidence of asthma. Asthma in the absence of any of these symptoms, sometimes termed \"cough-dominant asthma\", may present as an apparently nonspecific cough, but this is unusual in children. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Cough-dominant asthma'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The evaluation includes spirometry with bronchodilator testing, chest radiography, and a trial of asthma medications for two to four weeks, followed by reevaluation. If such testing is not available, and if there is no sign of acute infection, it is reasonable to treat with a short course of oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/30/35296?source=see_link\">",
"     prednisolone",
"    </a>",
"    , for three to five days. If the cough is due to asthma, this trial should result in dramatic improvement. However, response to therapy does not fully establish the diagnosis, because nonspecific cough unrelated to asthma frequently resolves spontaneously. Asthma medication should not be continued unless the diagnosis of asthma can be made with confidence. Lack of response to asthma medications usually is sufficient to exclude asthma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26010?source=see_link\">",
"     \"Chronic asthma in children younger than 12 years: Evaluation and diagnosis\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    In cases where it is particularly difficult to establish or exclude the possibility of asthma, an airway hyper-responsiveness challenge test in the pulmonary laboratory may be indicated, if the child is old enough for testing (&gt;6 years). These tests include indirect airway challenges (exercise,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/60/43975?source=see_link\">",
"     mannitol",
"    </a>",
"    , hypertonic saline, adenosine) or direct challenges (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    ). Indirect challenges are now considered superior to direct challenges for the diagnosis of asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28088/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Persistent bacterial bronchitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent bacterial bronchitis (PBB) is increasingly recognized as a cause of chronic wet cough, particularly in young children (&lt;5 years of age). In a series of young children evaluated for chronic cough in a tertiary care center, 45 percent were diagnosed with PBB, based on positive cultures from bronchoalveolar lavage and resolution of the cough with antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28088/abstract/3\">",
"     3",
"    </a>",
"    ]. The most commonly implicated organisms are non-typable Haemophilus influenzae, Streptococcus pneumoniae, and Moraxella catarrhalis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28088/abstract/4\">",
"     4",
"    </a>",
"    ]. Identification and treatment of PBB is important because it may be a precursor to chronic suppurative lung disease. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Chronic suppurative lung disease and bronchiectasis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Children with recurrent PBB or chronic suppurative lung disease should undergo an evaluation for an underlying disorder that predisposes to pulmonary infection, including cystic fibrosis and immune deficiencies such as selective antibody deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28088/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30458?source=see_link\">",
"     \"Approach to the child with recurrent infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17209?source=see_link\">",
"     \"Selective antibody deficiency with normal immunoglobulins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PBB is usually diagnosed based on the presence of an isolated chronic wet-moist cough in a child who otherwise appears well, with resolution of the cough after antibiotic treatment, and absence of symptoms, signs, or laboratory evidence suggestive of an alternative cause of the cough [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28088/abstract/3,6-8\">",
"     3,6-8",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Differential diagnosis of PBB",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical symptoms of PBB can be similar to asthma. Unlike asthma, PBB does not usually respond to bronchodilators, and auscultation typically reveals a rattling sound reflective of airway secretions (expiratory rhonchi) rather than true wheezing. However, asthma and PBB can coexist. If a child with a wet cough and apparent asthma fails to respond to asthma medications, empiric treatment for PBB should be considered [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28088/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The symptoms of PBB may also be indistinguishable from foreign body aspiration. If cough began suddenly after choking, or while eating or playing in a young child, the child should be promptly evaluated for the possibility of a foreign body. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Foreign body'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Treatment of PBB",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of PBB may require a prolonged course of antibiotics, generally two to four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28088/abstract/7,9\">",
"     7,9",
"    </a>",
"    ]. Shorter courses frequently lead to relapse. The antibiotics should be targeted to the most likely causative organisms (empiric), or based on the sensitivities of cultured organisms.",
"   </p>",
"   <p>",
"    Many practitioners use empiric antibiotic treatment for patients with a clinical presentation suspicious for PBB (ie, a child under five years of age with a chronic wet cough), and continue the antibiotics for at least two weeks. Some practitioners may elect to perform bronchoscopy with bronchoalveolar lavage, especially in patients with longer histories and more significant infiltrates on chest radiograph. A few randomized trials support the empiric use of antibiotics to treat children with chronic wet cough [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28088/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Appropriate antibiotic therapy includes",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/26/34214?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    and most second and third generation cephalosporins to cover beta-lactamase producing organisms and S. pneumoniae in the community. Patients with atypical features or who do not respond completely to empiric treatment should be further evaluated with a sweat test, high-resolution CT scan (HRCT), bronchoscopy, and an immune evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Chronic suppurative lung disease and bronchiectasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic suppurative lung disease (CSLD) is characterized by prolonged wet cough that is responsive to antibiotics, symptoms of reactive airway disease, and sometimes by growth failure, clubbing, and chronic hypoxemia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28088/abstract/7\">",
"     7",
"    </a>",
"    ]. The term bronchiectasis is associated with similar clinical symptoms but is based on radiographic signs (irreversible dilatation of peripheral airways, dilated bronchi in the periphery of the lung, and bronchial wall thickening on chest HRCT). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44662?source=see_link\">",
"     \"Clinical manifestations and evaluation of bronchiectasis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relationship between PBB, CSLD, and bronchiectasis is unclear. In some cases, CSLD appears to arise as a consequence of untreated PBB. However, the risk factors and proportion of children with PBB who develop CSLD are unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28088/abstract/7\">",
"     7",
"    </a>",
"    ]. These patients usually require repeated courses of antibiotics, usually in response to exacerbations in symptoms, which are often precipitated by viral respiratory infection. The addition of mucus clearance therapies is often recommended.",
"   </p>",
"   <p>",
"    Patients with chronic suppurative lung disease or bronchiectasis should be evaluated for cystic fibrosis. If there is no evidence of cystic fibrosis, the evaluation should also include HRCT, bronchoscopy, and an immune evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30458?source=see_link\">",
"     \"Approach to the child with recurrent infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Foreign body",
"    </span>",
"    &nbsp;&mdash;&nbsp;A history of onset of the cough after an episode of choking, even if remote in time, or sudden onset of the cough in a young child while eating or playing, raises the possibility of a foreign body. Even if there is no such history, a foreign body remains a possibility and should be considered in any young child with a wet cough.",
"   </p>",
"   <p>",
"    Young children with a wet cough should be evaluated to exclude the possibility of an aspirated foreign body. The minimum evaluation are chest radiographs, taken in both inspiration and expiration (or frontal and both lateral decubitus films). These views will help evaluate for unilateral lung hyperinflation which is suggestive of obstruction by a foreign body. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/9/17561?source=see_link&amp;anchor=H23#H23\">",
"     \"Approach to chronic cough in children\", section on 'Chest radiography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with a history suggestive of foreign body (eg, sudden onset after choking, or while eating or playing) should also be evaluated with bronchoscopy if the chest radiograph is negative. Uncommonly, an aspirated foreign body may go undiagnosed for months or even years, and can cause focal bronchiectasis. This possibility should be considered in otherwise healthy individuals with focal bronchiectasis. The foreign body may not be evident on chest radiograph or even CT evaluation; bronchoscopic evaluation may be necessary to make the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2585?source=see_link\">",
"     \"Airway foreign bodies in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Gastroesophageal reflux",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether gastroesophageal reflux disease (GERD) is an important cause of isolated chronic cough in children is controversial. Most authorities suggest that this is not a common cause except in association with neurologic abnormalities predisposing to aspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28088/abstract/6,11\">",
"     6,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lack of association between acid GERD and chronic cough is supported by a study that used a device to measure ambulatory esophageal pH and cough in 20 children with chronic cough and suspected GERD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28088/abstract/12\">",
"     12",
"    </a>",
"    ]. More than 80 percent of coughs were independent of a reflux event, and when the events coincided, reflux was no more likely to precede than to follow cough. Previous studies showed an increased prevalence of reflux in patients with chronic cough, but did not assess whether there was a temporal association between the events [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28088/abstract/13\">",
"     13",
"    </a>",
"    ]. The role of non-acid GERD in triggering chronic cough is unclear. In a few studies involving small numbers of subjects using impedance manometry (a technique that can detect both acid and non-acid reflux), a temporal association between reflux events and some of the episodes of cough was noted about 50 percent of children with chronic unexplained cough, suggesting a potential association [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28088/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Of note, these studies did not examine the impact of treatment of GERD on cough outcomes in the subjects. &nbsp;",
"   </p>",
"   <p>",
"    In addition, a metaanalysis found that treatment with proton pump inhibitors (PPI) was not efficacious in reducing cough in infants and insufficient evidence to draw conclusions about the efficacy of PPI treatment for chronic cough in adolescents or adults [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28088/abstract/16\">",
"     16",
"    </a>",
"    ]. &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Upper airway cough syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper airway cough syndrome, formerly known as postnasal drip syndrome, is thought to be a common cause of chronic cough in adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/18/5418?source=see_link&amp;anchor=H4#H4\">",
"     \"Evaluation of subacute and chronic cough in adults\", section on 'Upper airway cough syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Underlying reasons for chronic postnasal drip include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Rhinitis &ndash; Allergic rhinitis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28088/abstract/17\">",
"       17",
"      </a>",
"      ], perennial nonallergic rhinitis, and vasomotor rhinitis (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/17/30999?source=see_link\">",
"       \"An overview of rhinitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sinusitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sinusitis is probably not a common cause of chronic cough in children except in association with an immune defect predisposing to chronic infection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28088/abstract/11,18\">",
"     11,18",
"    </a>",
"    ]. However, there are no clinically practical definitive diagnostic tests for sinusitis, so it is difficult to define with accuracy the true incidence of chronic bacterial sinusitis as a cause of chronic cough in children.",
"   </p>",
"   <p>",
"    Sinusitis is commonly diagnosed when radiography reveals opacification of the sinuses. However, this radiographic finding is not specific for bacterial sinusitis: an acute viral respiratory infection can cause transient sinus opacification, and there may be no bacterial infection in an allergic rhinosinusitis.",
"   </p>",
"   <p>",
"    Because of the lack of definitive diagnostic tests, empiric treatment for sinusitis may be appropriate in selected patients with symptoms suggestive of bacterial sinusitis (ie, a chronic nocturnal cough without wheezing, in the absence of other explanations). If a chronic noninfectious rhinitis is suspected (eg, because of chronic clear nasal drainage, and boggy or edematous nasal mucosa), a trial of intranasal glucocorticoids is appropriate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/17/30999?source=see_link\">",
"     \"An overview of rhinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thicker and colored nasal drainage may be caused by either viral or bacterial sinusitis. Many practitioners treat such patients with a three week course of an appropriate antibiotic. However, response to the antibiotic does not necessarily confirm the diagnosis of sinusitis, because persistent bacterial bronchitis would also respond to this intervention, and many other cases of chronic cough will improve or resolve over time regardless of intervention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11273?source=see_link&amp;anchor=H7#H7\">",
"     \"Acute bacterial rhinosinusitis in children: Clinical features and diagnosis\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Postpertussis cough",
"    </span>",
"    &nbsp;&mdash;&nbsp;In infants and young children, Bordetella pertussis infection causes typical whooping cough. In older children, the classic features may not be seen, and the cough may persist for weeks after the infection has cleared. As an example, in a prospective cohort study, an astonishing 37 percent of children with chronic cough had serologic evidence of a recent pertussis infection, although most of the subjects had been fully immunized [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28088/abstract/19\">",
"     19",
"    </a>",
"    ]. Thus, post-pertussis cough should be considered in children with chronic cough regardless of immunization status. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13911?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Bordetella pertussis infections in adolescents and adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16248?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical features and diagnosis of Bordetella pertussis infection in infants and children\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children and adolescents who have cleared the Bordetella pertussis infection (which generally occurs within four weeks of onset of symptoms) but continue to cough do not necessarily require antimicrobial therapy. The chronic cough will usually resolve gradually after several more weeks. Thus, serologic evidence of a recent B. Pertussis infection is mostly useful in establishing the cause of the chronic cough and avoiding further invasive workup. By contrast, positive cultures or polymerase chain reaction (PCR) testing for B. pertussis suggests active infection, and should be treated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/14/25833?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment and prevention of Bordetella pertussis infection in infants and children\", section on 'Treatment indications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39271?source=see_link\">",
"     \"Treatment and prevention of Bordetella pertussis infection in adolescents and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     NONSPECIFIC (ISOLATED) COUGH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many children do not have any evidence of chronic disease based on detailed history, physical examination, radiography, and pulmonary function testing. These patients are described as having chronic nonspecific (or \"isolated\") cough. This type of cough usually resolves gradually, but children should be reevaluated periodically for the emergence of signs or symptoms of specific cough.",
"   </p>",
"   <p>",
"    Possible explanations for nonspecific cough include asthma, postviral cough, increased cough receptor sensitivity, and functional disorders (including habit cough and tic disorders) (",
"    <a class=\"graphic graphic_algorithm graphicRef74085 \" href=\"UTD.htm?23/57/24471\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cough-dominant asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cough-dominant asthma (sometimes known as cough-variant asthma) was first suggested by observations in adults in whom cough was the most prominent presenting symptom of asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28088/abstract/20\">",
"     20",
"    </a>",
"    ]. All of these individuals had other manifestations of disease, namely airway obstruction or atopy.",
"   </p>",
"   <p>",
"    Most studies have suggested that asthma is an uncommon cause of cough in the absence of other asthmatic symptoms, particularly in children [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28088/abstract/18,21,22\">",
"     18,21,22",
"    </a>",
"    ]. This is illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized, placebo-controlled trial of beta agonists and steroids for nonspecific cough showed no benefit over placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28088/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      When a group of children with chronic cough were systematically evaluated for a wide range of causes of cough, only 4 percent were found to have an asthma-like condition [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28088/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Longitudinal studies show that recurrent cough in children in the absence of wheezing generally resolves and that children with nonspecific cough have different risk factors and triggers than classic asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28088/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bronchoconstriction and cough are mediated by different pathways. While bronchoconstriction and cough can be stimulated by common agents, inhibitors of cough do not inhibit bronchoconstriction, and vice versa. Additionally, no correlations have been found between cough receptor sensitivity and airway caliber in children with asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28088/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these caveats, it is still appropriate to consider the possibility of asthma in a child presenting with a chronic cough and no apparent symptoms of asthma. This is because many children in whom cough is the primary complaint may also have unreported wheezing. In addition, much of the literature on nonspecific cough does not address whether the cough is induced by classic asthma triggers.",
"   </p>",
"   <p>",
"    Therefore, we recommend that children presenting with nonspecific chronic cough (particularly if \"dry\") be evaluated for clinical evidence of asthma (eg, wheezing, spirometric indices of obstruction with bronchodilator response, or radiographic findings of hyperinflation and peribronchial thickening) and a trial of anti-asthma medications, as discussed above. Asthma medication should not be continued unless the diagnosis of asthma can be made with confidence. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Asthma'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In cases in which the diagnosis remains unclear, a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    challenge in the pulmonary laboratory may be helpful. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Asthma'",
"    </a>",
"    above.) The possibility of persistent bacterial bronchitis should be considered in young children with a chronic wet cough, even if the symptoms resemble asthma. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Persistent bacterial bronchitis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Increased cough receptor sensitivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some children appear to have increased cough receptor sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28088/abstract/20\">",
"     20",
"    </a>",
"    ]. Indeed, even in children with asthma, increased cough receptor sensitivity may mediate cough. It is unclear how and why some develop this; possibilities include inflammation, stripping of subepithelial cough receptors, or pain-like sensitization of the cough pathway. It is possible that the majority of nonspecific cough is due to increased cough receptor sensitivity, induced by viral illness or other causes.",
"   </p>",
"   <p>",
"    Cough receptor sensitivity can be tested in a research setting, using",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/31/24053?source=see_link\">",
"     capsaicin",
"    </a>",
"    as a stimulant. Such tests suggest that cough receptor sensitivity is highest in younger children, but this may simply reflect more distal deposition of the capsaicin in these younger subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28088/abstract/24\">",
"     24",
"    </a>",
"    ]. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Habit cough",
"    </span>",
"    &nbsp;&mdash;&nbsp;Habit or psychogenic cough is common in a pediatric pulmonology specialty practice, in which it can represent up to 10 percent of children and adolescents with chronic cough of unknown origin that does not respond to observation and primary care interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28088/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. The cough usually is prominent during visits to the clinic, but is absent at night and rarely interrupts play, speech, or eating. The cough is often quite distinctive: it may consist of short, single dry coughs (tics) or may be similar to the cough heard in laryngotracheobronchitis (a barking or honking sound after a short inhalation), and occasionally has different characteristics. It can be very loud and disruptive in a classroom, and may lead to excessive absences from school. Patients complain of tickling in the throat, and indeed, the pattern of the cough supports a laryngeal origin. This cough often begins at the time of an upper respiratory tract infection and fails to resolve; no pathologic cause of the cough can be identified, and there is no response to commonly used antitussive medications. In many cases, the patient has been treated with escalating doses of asthma medications without benefit. Suggestion therapy has been demonstrated to be effective, and when delivered confidently can prevent much ongoing morbidity (",
"    <a class=\"graphic graphic_table graphicRef58800 \" href=\"UTD.htm?41/44/42699\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28088/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Treatment'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p>",
"    Although common, habit cough is a diagnosis of exclusion, and the label should not be applied until all other possible causes have been considered. Cases of Tourette syndrome presenting with chronic cough have been reported, and an evaluation for a tic disorder should be considered if other suggestive signs are present [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28088/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22664?source=see_link\">",
"     \"Tourette syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Otogenic cough",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a minority of individuals, the external ear is innervated by a branch of the vagus nerve. In this case, irritants (eg, cerumen) can cause chronic cough, and removal of the irritants may improve the symptom [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28088/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. This mechanism appears to be a rare cause of chronic cough in children [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28088/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of chronic nonspecific cough is largely one of reassurance and periodic reevaluation for the development of other signs and symptoms, which would suggest underlying chronic disease. Gastroesophageal reflux and sinusitis are uncommon causes of isolated chronic cough in children, and there is no evidence supporting the use of therapies for GERD or rhinitis empirically when no other symptoms are present [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28088/abstract/11\">",
"     11",
"    </a>",
"    ]. However, empiric courses of therapy for asthma, rhinitis, sinusitis, or gastroesophageal reflux can be considered if suggestive findings exist [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28088/abstract/1\">",
"     1",
"    </a>",
"    ]. If empiric treatment is undertaken, the trial should be time-limited, and the medication should not be given chronically unless the underlying diagnosis is firmly established [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28088/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the absence of a specific diagnosis, treatment considerations are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Family expectations and counseling &ndash; The symptom of chronic nonspecific cough is frustrating and disruptive to patients, families, and teachers, and has led to widespread use of cough and cold remedies in the past. Families can be reassured about the excellent prognosis of chronic nonspecific cough and should be advised against the use of nonspecific medications due to lack of efficacy and safety concerns.",
"     </li>",
"     <li>",
"      Cough suppressants and antihistamines &ndash; We recommend against the use of cough suppressants and antihistamines for treatment of chronic cough in children [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28088/abstract/1,18\">",
"       1,18",
"      </a>",
"      ]. This is because there is no evidence that they improve symptoms in this age group, and significant safety concerns have been raised about their use in young children [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28088/abstract/32,33\">",
"       32,33",
"      </a>",
"      ]. The Food and Drug Administration has issued a public health advisory against the use of these drugs for young children [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28088/abstract/34\">",
"       34",
"      </a>",
"      ]. Opioid drugs such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/30/32230?source=see_link\">",
"       codeine",
"      </a>",
"      are effective in suppressing the cough symptom, but are associated with side effects and the potential for abuse; we do not recommend their use [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28088/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bronchodilators &ndash; A trial of asthma therapy is often warranted for children with chronic nonspecific cough, particularly if there are other signs of allergic disease, or if the child's cough is initiated by typical asthma triggers [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28088/abstract/18\">",
"       18",
"      </a>",
"      ]. Our rationale for this approach is that airflow obstruction is not always obvious at the first clinic visit and may not be consistently identified by spirometry. The choice of medication is dictated by the severity, as outlined by the various national asthma treatment guidelines [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28088/abstract/36,37\">",
"       36,37",
"      </a>",
"      ]. If there is no response within two to four weeks, the medication should be stopped. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Asthma'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26010?source=see_link\">",
"       \"Chronic asthma in children younger than 12 years: Evaluation and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Avoidance of tobacco smoke &ndash; There is some evidence that environmental exposure to tobacco smoke increases the risk for chronic cough in children [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28088/abstract/38\">",
"       38",
"      </a>",
"      ]. Parents who smoke should be counseled to stop smoking and guided to support for smoking cessation. Until the parent is able to completely stop smoking, they should not smoke in the presence of children, including in the family car, even with the window open. The provider should also ask adolescent patients about the possibility of tobacco use and provide strong support for smoking cessation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/4/5194?source=see_link\">",
"       \"Secondhand smoke exposure: Effects in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"       \"Overview of smoking cessation management in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Suggestion therapy &ndash; In children with habit or psychogenic cough, various therapies have been successful, including suggestion therapy (",
"      <a class=\"graphic graphic_table graphicRef58800 \" href=\"UTD.htm?41/44/42699\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28088/abstract/27,39\">",
"       27,39",
"      </a>",
"      ], biofeedback, self-hypnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28088/abstract/40\">",
"       40",
"      </a>",
"      ], and mechanical aversive techniques (eg, the bed sheet method) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28088/abstract/39\">",
"       39",
"      </a>",
"      ]. Long-term prognosis appears excellent, but confirmatory data are lacking.",
"     </li>",
"     <li>",
"      Alternative therapies &ndash; In the absence of specific treatments for the chronic symptom, many families will try alternative therapies, including honey and echinacea. Clinical outcomes of these approaches are described separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13146?source=see_link&amp;anchor=H199065619#H199065619\">",
"       \"The common cold in children: Treatment and prevention\", section on 'Other remedies'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/7/13427?source=see_link\">",
"       \"Patient information: Cough in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic cough is usually defined as a cough lasting more than four weeks. The evaluation of a child with chronic cough should include a detailed history, physical examination, chest radiograph, and spirometry (when possible). If the initial evaluation provides clues suggesting a specific cause of cough, further evaluation is focused on that diagnostic possibility (",
"      <a class=\"graphic graphic_algorithm graphicRef74085 \" href=\"UTD.htm?23/57/24471\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/9/17561?source=see_link\">",
"       \"Approach to chronic cough in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Asthma is an uncommon cause of chronic cough in children if other symptoms of asthma are absent. However, it is more likely in children with atopy or a strong family history of asthma. A few children with asthma have cough as the only symptom. If the initial evaluation does not provide specific clues, and the cough is bothersome, then we suggest a trial of asthma medications (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Asthma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Young children with a wet cough should be evaluated to exclude the possibility of an aspirated foreign body. The minimum evaluation is a neck and chest radiograph. Patients with a history suggestive of foreign body (eg, sudden onset after choking, or while eating or playing), should also be evaluated with rigid bronchoscopy, regardless of radiographic findings. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Foreign body'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Persistent bacterial bronchitis (PBB) is the most common cause of chronic wet cough in young children (&lt;5 years of age). After foreign body is excluded, we suggest empiric treatment of such patients with a prolonged course of antibiotics (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Persistent bacterial bronchitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Habit or psychogenic cough typically presents as single dry coughs (tics) or a barking or honking sound after a short inhalation. The cough often is prominent during visits to the clinic, but is absent at night and rarely interrupts when the child is playing, speaking, or eating. It can be very loud and disruptive in a classroom, and may lead to excessive absences from school. A trial of suggestion therapy is warranted. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Habit cough'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend NOT treating chronic cough with cough suppressants or other nonprescription cough medicines (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). There is no evidence that they are effective, and there are some safety concerns. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28088/abstract/1\">",
"      Shields MD, Bush A, Everard ML, et al. BTS guidelines: Recommendations for the assessment and management of cough in children. Thorax 2008; 63 Suppl 3:iii1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28088/abstract/2\">",
"      Anderson SD, Brannan JD. Methods for \"indirect\" challenge tests including exercise, eucapnic voluntary hyperpnea, and hypertonic aerosols. Clin Rev Allergy Immunol 2003; 24:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28088/abstract/3\">",
"      Marchant JM, Masters IB, Taylor SM, Chang AB. Utility of signs and symptoms of chronic cough in predicting specific cause in children. Thorax 2006; 61:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28088/abstract/4\">",
"      Craven V, Everard ML. Protracted bacterial bronchitis: reinventing an old disease. Arch Dis Child 2013; 98:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28088/abstract/5\">",
"      Lim MT, Jeyarajah K, Jones P, et al. Specific antibody deficiency in children with chronic wet cough. Arch Dis Child 2012; 97:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28088/abstract/6\">",
"      Marchant JM, Masters IB, Taylor SM, et al. Evaluation and outcome of young children with chronic cough. Chest 2006; 129:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28088/abstract/7\">",
"      Chang AB, Redding GJ, Everard ML. Chronic wet cough: Protracted bronchitis, chronic suppurative lung disease and bronchiectasis. Pediatr Pulmonol 2008; 43:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28088/abstract/8\">",
"      Zgherea D, Pagala S, Mendiratta M, et al. Bronchoscopic findings in children with chronic wet cough. Pediatrics 2012; 129:e364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28088/abstract/9\">",
"      Marchant JM, Morris P, Gaffney JT, Chang AB. Antibiotics for prolonged moist cough in children. Cochrane Database Syst Rev 2005; :CD004822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28088/abstract/10\">",
"      Marchant J, Masters IB, Champion A, et al. Randomised controlled trial of amoxycillin clavulanate in children with chronic wet cough. Thorax 2012; 67:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28088/abstract/11\">",
"      Chang AB, Asher MI. A review of cough in children. J Asthma 2001; 38:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28088/abstract/12\">",
"      Chang AB, Connor FL, Petsky HL, et al. An objective study of acid reflux and cough in children using an ambulatory pHmetry-cough logger. Arch Dis Child 2011; 96:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28088/abstract/13\">",
"      Khoshoo V, Edell D, Mohnot S, et al. Associated factors in children with chronic cough. Chest 2009; 136:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28088/abstract/14\">",
"      Borrelli O, Marabotto C, Mancini V, et al. Role of gastroesophageal reflux in children with unexplained chronic cough. J Pediatr Gastroenterol Nutr 2011; 53:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28088/abstract/15\">",
"      Blondeau K, Mertens V, Dupont L, et al. The relationship between gastroesophageal reflux and cough in children with chronic unexplained cough using combined impedance-pH-manometry recordings. Pediatr Pulmonol 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28088/abstract/16\">",
"      Chang AB, Lasserson TJ, Gaffney J, et al. Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults. Cochrane Database Syst Rev 2011; :CD004823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28088/abstract/17\">",
"      Higuchi O, Adachi Y, Itazawa T, et al. Relationship between rhinitis and nocturnal cough in school children. Pediatr Allergy Immunol 2012; 23:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28088/abstract/18\">",
"      Chang AB, Glomb WB, ). Guidelines for evaluating chronic cough in pediatrics: ACCP evidence-based clinical practice guidelines. Chest 2006; 129:260S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28088/abstract/19\">",
"      Harnden A, Grant C, Harrison T, et al. Whooping cough in school age children with persistent cough: prospective cohort study in primary care. BMJ 2006; 333:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28088/abstract/20\">",
"      Chang AB. Cough, cough receptors, and asthma in children. Pediatr Pulmonol 1999; 28:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28088/abstract/21\">",
"      Gibson PG, Simpson JL, Chalmers AC, et al. Airway eosinophilia is associated with wheeze but is uncommon in children with persistent cough and frequent chest colds. Am J Respir Crit Care Med 2001; 164:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28088/abstract/22\">",
"      Thomson F, Masters IB, Chang AB. Persistent cough in children and the overuse of medications. J Paediatr Child Health 2002; 38:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28088/abstract/23\">",
"      Wright AL, Holberg CJ, Morgan WJ, et al. Recurrent cough in childhood and its relation to asthma. Am J Respir Crit Care Med 1996; 153:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28088/abstract/24\">",
"      Chang AB, Gibson PG, Willis C, et al. Do sex and atopy influence cough outcome measurements in children? Chest 2011; 140:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28088/abstract/25\">",
"      Butani L, O'Connell EJ. Functional respiratory disorders. Ann Allergy Asthma Immunol 1997; 79:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28088/abstract/26\">",
"      Irwin RS, Glomb WB, Chang AB. Habit cough, tic cough, and psychogenic cough in adult and pediatric populations: ACCP evidence-based clinical practice guidelines. Chest 2006; 129:174S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28088/abstract/27\">",
"      Lokshin B, Lindgren S, Weinberger M, Koviach J. Outcome of habit cough in children treated with a brief session of suggestion therapy. Ann Allergy 1991; 67:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28088/abstract/28\">",
"      Tan H, B&uuml;y&uuml;kavci M, Arik A. Tourette's syndrome manifests as chronic persistent cough. Yonsei Med J 2004; 45:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28088/abstract/29\">",
"      Duncan KL, Faust RA. Tourette syndrome manifest as chronic cough. Int J Pediatr Otorhinolaryngol 2002; 65:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28088/abstract/30\">",
"      Tekdemir I, Aslan A, Elhan A. A clinico-anatomic study of the auricular branch of the vagus nerve and Arnold's ear-cough reflex. Surg Radiol Anat 1998; 20:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28088/abstract/31\">",
"      Jegoux F, Legent F, Beauvillain de Montreuil C. Chronic cough and ear wax. Lancet 2002; 360:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28088/abstract/32\">",
"      Centers for Disease Control and Prevention (CDC). Infant deaths associated with cough and cold medications--two states, 2005. MMWR Morb Mortal Wkly Rep 2007; 56:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28088/abstract/33\">",
"      Schroeder K, Fahey T. Over-the-counter medications for acute cough in children and adults in ambulatory settings. Cochrane Database Syst Rev 2004; :CD001831.",
"     </a>",
"    </li>",
"    <li>",
"     Public Health Advisory. Nonprescription cough and cold medicine use in children. Available at: file://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm051282.html (Accessed on November 07, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28088/abstract/35\">",
"      Chung KF, Chang AB. Therapy for cough: active agents. Pulm Pharmacol Ther 2002; 15:335.",
"     </a>",
"    </li>",
"    <li>",
"     The US guidelines are available online: file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on October 22, 2009).",
"    </li>",
"    <li>",
"     The international guidelines are available online: www.ginasthma.com (Accessed on October 22, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28088/abstract/38\">",
"      Brand PL, Duiverman EJ. [Coughing and wheezing children: improvement after parents stop smoking]. Ned Tijdschr Geneeskd 1998; 142:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28088/abstract/39\">",
"      Weinberger M, Abu-Hasan M. Pseudo-asthma: when cough, wheezing, and dyspnea are not asthma. Pediatrics 2007; 120:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28088/abstract/40\">",
"      Anbar RD, Hall HR. Childhood habit cough treated with self-hypnosis. J Pediatr 2004; 144:213.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6356 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.131.41.98-0FBBA5EC0B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_27_28088=[""].join("\n");
var outline_f27_27_28088=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SPECIFIC COUGH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Persistent bacterial bronchitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Differential diagnosis of PBB",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Treatment of PBB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Chronic suppurative lung disease and bronchiectasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Foreign body",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Gastroesophageal reflux",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Upper airway cough syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Postpertussis cough",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      NONSPECIFIC (ISOLATED) COUGH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cough-dominant asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Increased cough receptor sensitivity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Habit cough",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Otogenic cough",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6356\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6356|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?23/57/24471\" title=\"algorithm 1\">",
"      Chronic cough child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6356|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/57/18333\" title=\"table 1\">",
"      Specific cough child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/44/42699\" title=\"table 2\">",
"      Suggestion therapy for habit cough",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11273?source=related_link\">",
"      Acute bacterial rhinosinusitis in children: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2585?source=related_link\">",
"      Airway foreign bodies in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/17/30999?source=related_link\">",
"      An overview of rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/9/17561?source=related_link\">",
"      Approach to chronic cough in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30458?source=related_link\">",
"      Approach to the child with recurrent infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26010?source=related_link\">",
"      Chronic asthma in children younger than 12 years: Evaluation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16248?source=related_link\">",
"      Clinical features and diagnosis of Bordetella pertussis infection in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13911?source=related_link\">",
"      Clinical manifestations and diagnosis of Bordetella pertussis infections in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44662?source=related_link\">",
"      Clinical manifestations and evaluation of bronchiectasis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/18/5418?source=related_link\">",
"      Evaluation of subacute and chronic cough in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/7/13427?source=related_link\">",
"      Patient information: Cough in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/4/5194?source=related_link\">",
"      Secondhand smoke exposure: Effects in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17209?source=related_link\">",
"      Selective antibody deficiency with normal immunoglobulins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13146?source=related_link\">",
"      The common cold in children: Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22664?source=related_link\">",
"      Tourette syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39271?source=related_link\">",
"      Treatment and prevention of Bordetella pertussis infection in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/14/25833?source=related_link\">",
"      Treatment and prevention of Bordetella pertussis infection in infants and children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_27_28089="Parapneumonic effusion and empyema in adults";
var content_f27_27_28089=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Parapneumonic effusion and empyema in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/27/28089/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/27/28089/contributors\">",
"     Charlie Strange, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/27/28089/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/27/28089/contributors\">",
"     Steven A Sahn, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/27/28089/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/27/28089/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/27/28089/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/27/28089/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parapneumonic effusions are pleural effusions that occur in the pleural space adjacent to a bacterial pneumonia. They occur in at least 40 percent of bacterial pneumonias [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/1\">",
"     1",
"    </a>",
"    ]. The usual parapneumonic effusion is small and resolves with appropriate antibiotic therapy. However, if bacteria invade the pleural space, a complicated parapneumonic effusion or empyema may result, which will necessitate antibiotic therapy plus additional interventions.",
"   </p>",
"   <p>",
"    The pathogenesis, clinical presentation, evaluation, and management of parapneumonic effusions and empyema are reviewed here. The evaluation and management of parapneumonic effusions and empyema in infants and children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/34/9770?source=see_link\">",
"     \"Epidemiology; clinical presentation; and evaluation of parapneumonic effusion and empyema in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27882?source=see_link\">",
"     \"Management and prognosis of parapneumonic effusion and empyema in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parapneumonic pleural effusions are divided into three groups or stages based upon pathogenesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Uncomplicated parapneumonic effusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;An uncomplicated effusion occurs when lung interstitial fluid increases during pneumonia and moves across the adjacent visceral pleural membrane. The pleural fluid is characterized by \"exudative\" chemistries and an influx of neutrophils into the pleural space. Uncomplicated pleural effusions form when the resorptive capacity of the pleural space is exceeded; they resolve with resolution of the pneumonia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9735?source=see_link\">",
"     \"Mechanisms of pleural liquid turnover in the normal state\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36695?source=see_link\">",
"     \"Mechanisms of pleural liquid accumulation in disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with bacteremic pneumococcal pneumonia, pleural effusions are common and are usually sterile. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/4/13386?source=see_link&amp;anchor=H18#H18\">",
"     \"Pneumococcal pneumonia in adults\", section on 'Pulmonary complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Complicated parapneumonic effusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complicated effusions occur when there is persistent bacterial invasion of the pleural space. Bacterial invasion typically leads to an increased number of neutrophils and the development of pleural fluid acidosis, which results from anaerobic utilization of glucose by the neutrophils and bacteria. In addition, lysis of neutrophils increases the LDH concentration in the pleural fluid to values often in excess of 1000",
"    <span class=\"nowrap\">",
"     IU/L.",
"    </span>",
"    Because bacteria can be cleared rapidly from the pleural space, cultures of fluid from complicated parapneumonic effusions are generally negative [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/2\">",
"     2",
"    </a>",
"    ]. This occurs despite the deposition of a dense layer of fibrin on both the visceral and parietal pleurae that can lead to pleural loculation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Thoracic empyema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Formation of empyema is the third stage and is characterized by bacterial organisms seen on Gram stain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the aspiration of pus on thoracentesis. A positive culture is not required for diagnosis, since there are several reasons why bacteria may not be cultured from an empyema (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Bacteriology'",
"    </a>",
"    below):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anaerobic organisms are difficult to culture",
"     </li>",
"     <li>",
"      Sampling is often performed after a patient has received antibiotics",
"     </li>",
"     <li>",
"      Sterile inflammatory fluid may be aspirated adjacent to an infected loculus of infection",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of the adult with parapneumonic effusion or empyema depends upon the patient's timing of presentation and immune competence, and also the specific organisms causing infection. Patients with pneumonia and uncomplicated parapneumonic effusion present earlier in the course of their pneumonia; those with empyema typically present later when bacteria from the untreated pneumonia have had time to colonize the pleural space. Less virulent bacteria favor a later presentation; therefore, many empyemas complicate indolent anaerobic pneumonias that follow aspiration events. However, with severe immune deficiency, as may occur following transplantation or with HIV infection, empyema may present early in the course of pneumonia.",
"   </p>",
"   <p>",
"    Common clinical features of bacterial pneumonia with parapneumonic effusion include cough, fever, pleuritic chest pain, dyspnea, and sputum production. However, patients may only have one or two of these symptoms. In general, the presenting symptoms, other than pleuritic pain and duration of fever, are not helpful in determining which patients have pneumonia versus pneumonia with a parapneumonic effusion or empyema. Patients with empyema may report a longer course with several days of fever and malaise rather than hours.",
"   </p>",
"   <p>",
"    Physical examination may identify the presence of pleural fluid when the fine or coarse crackles, egophony (also known as e to a changes), and increased fremitus (palpable asymmetric increase in vibration with speech) typical of consolidation are replaced by decreased breath sounds and decreased fremitus. Occasionally, egophony will still be present at the upper edge of the effusion. Dullness to percussion is a potential feature of lung consolidation from pneumonia and pleural effusion. These findings are helpful when present; however, they are often absent so radiographic imaging is crucial to the complete evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographic and ultrasound imaging play a key role in the evaluation and management of parapneumonic effusions and empyema [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/4\">",
"     4",
"    </a>",
"    ]. In all patients with pneumonia, the chest X-ray should be evaluated for evidence of pleural fluid. On decubitus views, small effusions are thinner than 1.5 cm, moderate effusions are 1.5 to 4.5 cm thick, and large effusions exceed 4.5 cm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21384?source=see_link\">",
"     \"Imaging of pleural effusions in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of a complicated parapneumonic effusion or empyema is first suggested by a chest radiograph showing a pleural-based opacity that has an abnormal contour or does not flow freely on lateral decubitus views (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73968 \" href=\"UTD.htm?3/31/3575\">",
"     image 1",
"    </a>",
"    ). When these features are noted, we usually proceed to additional imaging with ultrasonography.",
"   </p>",
"   <p>",
"    Ultrasonography permits easy identification of free or loculated pleural effusions, and it facilitates differentiation of loculated effusions from solid masses. It is also helpful to guide site choice for thoracentesis, when the effusion is small in size or loculated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21384?source=see_link&amp;anchor=H7#H7\">",
"     \"Imaging of pleural effusions in adults\", section on 'Ultrasonography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In adults, optimal evaluation of an empyema or loculated effusion requires a chest computed tomography (CT) scan with intravenous contrast. Radiographic contrast enhances the pleural surface and assists in delineating pleural fluid loculi (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80445 \" href=\"UTD.htm?32/41/33439\">",
"     image 2",
"    </a>",
"    ). Thickening of the parietal pleura is suggestive of empyema. Small air bubbles may be noted within the fluid collection, called \"pleural microbubbles.\" The presence of pleural microbubbles may suggest that the fluid collection will be more resistant to chest tube drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/5\">",
"     5",
"    </a>",
"    ]. In addition, airway or parenchymal abnormalities may be detected, such as endobronchial lesions or lung abscesses [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21384?source=see_link&amp;anchor=H6#H6\">",
"     \"Imaging of pleural effusions in adults\", section on 'Computed tomography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     THORACENTESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thoracentesis is performed to guide further management of the effusion (",
"    <a class=\"graphic graphic_table graphicRef59099 \" href=\"UTD.htm?3/38/3693\">",
"     table 1",
"    </a>",
"    ) and to provide fluid for culture and sensitivity studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/9\">",
"     9",
"    </a>",
"    ]. An expert panel report has suggested guidelines for when patients with a parapneumonic effusion should undergo thoracentesis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=see_link\">",
"     \"Diagnostic evaluation of a pleural effusion in adults: Initial testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, a parapneumonic effusion should be sampled if it meets any of the following criteria (",
"    <a class=\"graphic graphic_table graphicRef59099 \" href=\"UTD.htm?3/38/3693\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      It is free-flowing but layers &gt;10 mm on a lateral decubitus film",
"     </li>",
"     <li>",
"      It is loculated",
"     </li>",
"     <li>",
"      It is associated with thickened parietal pleura on a contrast enhanced CT scan, a finding that is suggestive of empyema [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/6-8\">",
"       6-8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      It is clearly delineated by ultrasound",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Ultrasound guidance of thoracentesis is generally helpful. However, with loculation, guidance using ultrasonography or CT scan or both is essential to identify and drain pockets of pleural fluid. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/23/12663?source=see_link\">",
"     \"Diagnostic thoracentesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PLEURAL FLUID ANALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluid obtained by thoracentesis should undergo microbiologic analysis with appropriate stains and cultures (eg, aerobic, anaerobic, mycobacterial). Samples of fluid should be sent for a cell count with differential and chemistries (eg, total protein, lactate dehydrogenase, glucose); pH should be determined with a blood gas analyzer. If a blood gas analyzer is not available, measurement of the glucose concentration of the fluid should be substituted [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=see_link\">",
"     \"Diagnostic evaluation of a pleural effusion in adults: Initial testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, a pH &lt;7.20 or a glucose &lt;60",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    is an indication for drainage of the effusion since such effusions are unlikely to resolve spontaneously. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Management'",
"    </a>",
"    below.) However, these thresholds are not well validated clinically and therefore should not be utilized rigidly. A meta-analysis of pleural fluid chemistries in parapneumonic effusions suggested that the pleural fluid pH is the most useful test in deciding which effusions to drain, although more primary studies were needed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/11\">",
"     11",
"    </a>",
"    ]. A pleural pH between 7.21 and 7.29 appeared to represent the threshold for consideration of drainage of a complicated parapneumonic effusion. In light of this analysis, the American College of Chest Physicians (ACCP) consensus guidelines suggest drainage for pH &lt;7.20 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It should be appreciated, however, that other diseases are associated with pleural fluid acidosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    low glucose, including malignancy, tuberculosis, rheumatoid pleurisy, and lupus pleuritis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/12\">",
"     12",
"    </a>",
"    ]. Appropriate studies to exclude these conditions should be performed when clinically indicated.",
"   </p>",
"   <p>",
"    Novel biomarkers of infection (eg, C-reactive protein, procalcitonin, STREM-1) have been evaluated for possible utility in distinguishing empyemas from uncomplicated pleural effusions, but were found to be less useful than the more traditional pleural chemistries [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     BACTERIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of organisms thought to be responsible for a parapneumonic effusion or empyema are the same as those causing the pneumonia. However, some organisms, particularly anaerobic species, are difficult to isolate by culture of fluid",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    blood [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/15\">",
"     15",
"    </a>",
"    ]. Inoculation of pleural fluid into blood culture bottles in addition to the usual sterile containers used for standard Gram stain and culture may improve the microbiologic yield [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/16\">",
"     16",
"    </a>",
"    ]. In a series of 53 patients with suspected pleural infection and culture data from both standard and blood culture bottles obtained at the same time, the number of patients with identifiable pathogens increased by 21 percent (95 % CI 8.9 to 20.8%). Therefore, we use blood culture bottles in addition to sterile containers for culture of pleural fluid.",
"   </p>",
"   <p>",
"    Putrid odor of empyema fluid is considered diagnostic of anaerobic infection; the Gram stain will also help identify anaerobes because of the unique morphology of anaerobic gram-negative rods. Blood and pleural culture results may be helpful, but are often negative.",
"   </p>",
"   <p>",
"    Anaerobic bacteria have been cultured in 36 to 76 percent of human empyemas [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. The predominant organisms isolated from anaerobic empyemas are Fusobacterium nucleatum, Prevotella sp, Peptostreptococcus, and the Bacteroides fragilis group although B. fragilis is relatively rare [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/17,19,20\">",
"     17,19,20",
"    </a>",
"    ]. The high incidence of anaerobic infection in empyema probably results from the indolent nature of these pneumonias, which permits pleural penetration of bacteria before antibiotics are instituted.",
"   </p>",
"   <p>",
"    Animal models suggest that infection with a mixed bacterial flora containing aerobes and anaerobes is more likely to produce an empyema than infection with a single organism [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Finding an aerobic organism on bacterial culture does not exclude the need for prompt coverage of uncultured anaerobic organisms. This was demonstrated in a study of 197 empyemas that found mixed aerobic and anaerobic infection in 23 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/17\">",
"     17",
"    </a>",
"    ]. Particularly common are the combination of anaerobes with microaerophilic or aerobic streptococci, all components of the normal oral flora.",
"   </p>",
"   <p>",
"    Some centers have begun routine molecular analysis of parapneumonic effusions to detect S. pneumoniae infection by rapid antigen detection assays or broad-range 16S ribosomal DNA polymerase chain reaction. These centers report a much higher detection rate for S. pneumoniae than historical case series [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other bacteria that are prevalent in empyema include Streptococcus milleri, Staphylococcus aureus, and Enterobacteriaceae [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. Patients with diabetes mellitus are at increased risk of empyema secondary to Klebsiella pneumoniae [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/28\">",
"     28",
"    </a>",
"    ]. Methicillin-resistant Staphylococcus aureus (MRSA) often causes a necrotizing pneumonia that is complicated by pleural infection. Streptococcus group A pneumonia is also associated with a high rate of empyema. In patients with influenza, the major causes of bacterial superinfection and empyema have been S. aureus, S. pneumoniae, and S. pyogenes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31514?source=see_link&amp;anchor=H11#H11\">",
"     \"Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults\", section on 'Bacteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a retrospective study, pleural cultures were obtained from 234 patients undergoing video-assisted thoracoscopic drainage of parapneumonic effusions and empyemas because they had failed medical management [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/30\">",
"     30",
"    </a>",
"    ]. Infecting organisms in these refractory effusions included Streptococcus pneumoniae (20 percent), Staphylococcus aureus (21 percent), coagulase negative staphylococcus (17 percent), Pseudomonas (14 percent), Klebsiella (10 percent), and others [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tuberculous empyema should be considered in patients with risk factors for tuberculous infection. Tuberculous empyema is a rare disease in which pus is present in the pleural space and the predominant pleural cell is the polymorphonuclear leukocyte (PMN). Tuberculous empyema should be differentiated from tuberculous pleurisy in which a lymphocytic effusion occurs from the immunologic response to tuberculous proteins. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12856?source=see_link\">",
"     \"Tuberculous pleural effusions in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1324721\">",
"    <span class=\"h1\">",
"     ANTIBIOTIC THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Choice of agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of antibiotic should target the likely cause of the underlying pneumonia, based on the bacteriology described above. Virtually all antibiotics studied adequately penetrate the pleural space. The single exception is that aminoglycosides may be inactivated at low pleural fluid pH [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anaerobic organisms are common, particularly among patients who present with empyema, and are difficult to culture. Therefore, antibiotics are usually selected to treat anaerobic organisms without the benefit of in vitro susceptibility tests. Options for empiric therapy that would cover anaerobic organisms include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    , beta-lactam plus beta-lactamase inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1160?source=see_link\">",
"     ampicillin-sulbactam",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24216?source=see_link\">",
"     piperacillin-tazobactam",
"    </a>",
"    ), and carbapenems (eg, imipenem,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/36/41542?source=see_link\">",
"     ertapenem",
"    </a>",
"    ) (",
"    <a class=\"graphic graphic_table graphicRef73450 \" href=\"UTD.htm?14/18/14637\">",
"     table 2",
"    </a>",
"    ). Single agent therapy with either penicillin or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    is not considered optimal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/39/42617?source=see_link&amp;anchor=H17#H17\">",
"     \"Anaerobic bacterial infections\", section on 'Antibiotic selection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40986?source=see_link\">",
"     \"Treatment of community-acquired pneumonia in adults who require hospitalization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31017?source=see_link&amp;anchor=H11#H11\">",
"     \"Aspiration pneumonia in adults\", section on 'Bacterial infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oral agents with activity against implicated bacteria are probably adequate when drainage is accomplished and vital signs have stabilized.",
"   </p>",
"   <p>",
"    The treatment of candidal and tuberculous empyema is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18055?source=see_link&amp;anchor=H6#H6\">",
"     \"Candida infections of the abdomen and thorax\", section on 'Empyema'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12856?source=see_link&amp;anchor=H17#H17\">",
"     \"Tuberculous pleural effusions in HIV-negative patients\", section on 'Management and outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1324756\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of antibiotic therapy for bacterial empyema is determined on a patient-by-patient basis. Factors that influence the decision include the sensitivity of the organism(s), response to initial therapy, extent of pulmonary parenchymal and pleural disease, adequacy of drainage as assessed by radiographic resolution and cessation of output from a chest tube, and host factors such as immune status. For most patients, we suggest continuing antibiotic therapy until there is radiographic resolution of fluid (pleural thickening may be present). This generally entails continuing antibiotic therapy for two to four weeks following defervescence.",
"   </p>",
"   <p>",
"    The duration of antifungal and antituberculous therapies for empyema is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18055?source=see_link&amp;anchor=H7#H7\">",
"     \"Candida infections of the abdomen and thorax\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/21/19802?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of pulmonary tuberculosis in HIV-negative patients\", section on 'Continuation phase'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17272?source=see_link&amp;anchor=H20#H20\">",
"     \"Monitoring the HIV-infected patient on antituberculous medications\", section on 'Duration of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to appropriate antibiotic therapy, some parapneumonic effusions and all empyemas will need a drainage procedure. The decision about which parapneumonic effusions need drainage depends on the particular type or stage of parapneumonic effusion. Empyemas may need additional intervention beyond single tube thoracostomy (also known as chest tube drainage), including placement of additional drainage tubes under CT guidance, thoracoscopy with lysis of adhesions, and decortication. Patients with persistent air leaks often require surgical or endoscopic repair procedures. These choices are discussed in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Uncomplicated parapneumonic effusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uncomplicated effusions (category 1 or 2 in the 2000 ACCP consensus guidelines) (",
"    <a class=\"graphic graphic_table graphicRef59099 \" href=\"UTD.htm?3/38/3693\">",
"     table 1",
"    </a>",
"    ) generally resolve with antibiotics alone [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/10\">",
"     10",
"    </a>",
"    ]. Serial chest radiographs are usually obtained to assess improvement. Evaluation of fremitus on physical examination may be a useful alternative to serial radiographs; fremitus should decrease as an effusion enlarges and increase as the effusion resolves and underlying consolidated lung moves closer to the chest wall.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Complicated parapneumonic effusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complicated effusions (category 3 in the ACCP consensus guidelines) (",
"    <a class=\"graphic graphic_table graphicRef59099 \" href=\"UTD.htm?3/38/3693\">",
"     table 1",
"    </a>",
"    ) have a variable response to appropriate antibiotic therapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/10\">",
"     10",
"    </a>",
"    ]. Although some patients with a complicated parapneumonic effusion can be managed solely with antibiotics, we believe that early pleural fluid drainage of all loculi of fluid via tube thoracostomy speeds clinical recovery and hospital discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/32\">",
"     32",
"    </a>",
"    ]. This hypothesis remains to be validated in prospective clinical trials. Until clinical trials demonstrate the safety of alternative therapies, these patients should generally be treated with tube thoracostomy drainage under CT or ultrasound guidance [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/10\">",
"     10",
"    </a>",
"    ]. Placement of multiple tubes may be needed when pleural loculations prevent adequate drainage by a single tube. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1226?source=see_link&amp;anchor=H9#H9\">",
"     \"Placement and management of thoracostomy tubes\", section on 'Parapneumonic effusion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Failure to improve after tube thoracostomy drainage may indicate that antibiotic coverage is not adequate or that a loculated area of empyema has developed. If a repeat CT scan demonstrates inadequate drainage of the pleural space, the next step is usually video-assisted thoracoscopic surgery (VATS) for debridement and drainage. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Thoracoscopic debridement'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Empyema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thoracic empyema (category 4 in the ACCP consensus guidelines), defined as pus in the pleural space or an effusion with organisms seen on Gram stain, invariably requires drainage in addition to antibiotic therapy (",
"    <a class=\"graphic graphic_table graphicRef59099 \" href=\"UTD.htm?3/38/3693\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/10\">",
"     10",
"    </a>",
"    ]. Early thoracic surgical consultation is appropriate as many of these patients will require thoracoscopic or open debridement and drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/33\">",
"     33",
"    </a>",
"    ]. Proper management includes all of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sterilization of the empyema cavity with appropriate systemic antibiotics; at least 4 to 6 weeks of therapy are required, and a longer course may be necessary unless there is prompt resolution of fever and leukocytosis.",
"     </li>",
"     <li>",
"      Complete pleural fluid drainage, as evidenced by minimal chest tube output and CT documentation that no residual loculations persist.",
"     </li>",
"     <li>",
"      Obliteration of the empyema cavity by adequate lung expansion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Options for pleural drainage include tube thoracostomy, video-assisted thoracoscopic surgery (VATS), open decortication, and open thoracostomy. These options are discussed in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Tube thoracostomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tube thoracostomy (also known as chest tube) drainage is the least invasive option for drainage of empyema fluid. It is generally preferred over more invasive options for patients with uniloculated effusions and free-flowing fluid, but is also frequently used to drain multiloculated empyemas. The technique of tube thoracostomy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1226?source=see_link\">",
"     \"Placement and management of thoracostomy tubes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When draining empyema fluid, thoracostomy tubes are typically placed using either an ultrasound or CT-guided approach. When multiple loculations are present, we typically place small-bore catheters, as multiple tubes may be needed to drain the multiloculated pleural space.",
"   </p>",
"   <p>",
"    When the empyema is uniloculated, the choice of thoracostomy tube size is more controversial. Traditionally, a larger bore tube was preferred for drainage of more viscous empyema fluid, and smaller bore tubes were reserved for less viscous fluid. However, in a prospective, nonrandomized study of 454 patients who underwent chest tube drainage for empyema as part of the Multi-center Intrapleural Streptokinase Trial (MIST1), no significant difference was found in mortality or need for thoracic surgery between large (15-20F), medium (10-14F), or small (&lt;10F) tubes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/24,34\">",
"     24,34",
"    </a>",
"    ]. Pain, particularly that related to dissection for placement of the tubes, was markedly less with the smaller size tubes.",
"   </p>",
"   <p>",
"    A concern regarding smaller bore tubes is that high viscosity fluid may block the tube. However, periodic flushing (eg, 30 mL of sterile saline every 6 hours via a three way valve), as suggested by the British Thoracic Society guidelines, can help to maintain tube patency [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/35\">",
"     35",
"    </a>",
"    ]. Plugging of smaller bore tubes may explain the failure rate of 80 percent noted in a series of five patients who underwent empyema drainage with small bore tubes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CT imaging performed within 24 hours is crucial to documenting correct position of the chest tube(s) and adequate drainage of the empyema. A high incidence of chest tube failure is seen when initial bedside chest tube placement does not adequately access the pleural fluid collections and pleural fluid drainage is incomplete.",
"   </p>",
"   <p>",
"    Chest tubes are typically left in place until the drainage rate has fallen below 50",
"    <span class=\"nowrap\">",
"     mL/day",
"    </span>",
"    and the empyema cavity has closed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Fibrinolytic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrapleural administration of fibrinolytic agents (eg, streptokinase, urokinase, and tissue plasminogen activator [TPA]) has been assessed as a way to improve drainage of loculated parapneumonic effusions and empyemas [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/37-43\">",
"     37-43",
"    </a>",
"    ]. Data are conflicting regarding the benefit of intrapleural fibrinolytics, as described in the following paragraphs.",
"   </p>",
"   <p>",
"    A number of small trials and a case series found that instillation of a fibrinolytic agent into the pleural space improved outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/39-41,43,44\">",
"     39-41,43,44",
"    </a>",
"    ]. In contrast, a meta-analysis and a large randomized trial did not find significant benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/24,45\">",
"     24,45",
"    </a>",
"    ]. In the trial, 427 patients with pleural pus, pleural pH &lt;7.20 plus sepsis or pleural bacterial invasion were randomly assigned to receive intrapleural streptokinase or saline placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/24\">",
"     24",
"    </a>",
"    ]. There was no difference in mortality, need for surgery, radiographic outcome, or length of hospitalization. A major weakness of the trial was that thrombolytics were used late in the clinical course, with a median time from first symptom to randomization of approximately two weeks. Other concerns include use of small-bore chest tubes and reliance on plain chest radiographs, rather than ultrasound or computed tomography, in the clinical characterization of the fluid collections.",
"   </p>",
"   <p>",
"    A Cochrane review that included the above study (n=761) failed to show a reduction in death among patients who received fibrinolytic therapy (28 versus 33 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/46\">",
"     46",
"    </a>",
"    ]. When surgical intervention was included as a form of treatment failure, fibrinolytics reduced the risk of this specific outcome (RR 0.63; 95% CI 0.46 to 0.85).",
"   </p>",
"   <p>",
"    The reported doses of intrapleural TPA are between 10 and 100 mg daily [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/43\">",
"     43",
"    </a>",
"    ]. Side effects of intrapleural administration of fibrinolytics include chest pain, fever, allergic reactions, and pleural hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/24,47-49\">",
"     24,47-49",
"    </a>",
"    ]. In one study, pleural hemorrhage only occurred in patients who were systemically anticoagulated during intrapleural TPA administration [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/48\">",
"     48",
"    </a>",
"    ]. Intrapleural administration of fibrinolytics does not cause systemic thrombolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/48,50,51\">",
"     48,50,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H824539\">",
"    <span class=\"h3\">",
"     Fibrinolytic and mucolytic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The limited success with intrapleural fibrinolytic agents and the observation that DNA is a main contributor to the viscosity of empyema fluid led to the hypothesis that intrapleural administration of the enzyme deoxyribonuclease (DNase) might reduce empyema fluid viscosity and thus improve the efficacy of pleural drainage.",
"   </p>",
"   <p>",
"    To examine the role of intrapleural DNase with and without concomitant tissue plasminogen activator (TPA) and to clarify the conflicting data concerning fibrinolytic agents, a clinical trial randomly assigned 210 patients with empyema to one of four intrapleural treatments: 10 mg intrapleural TPA twice daily for 3 days, 5 mg intrapleural DNase twice daily for 3 days, both TPA and DNase twice daily for 3 days, or double placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/52\">",
"     52",
"    </a>",
"    ]. Tubes were clamped for 1 hour after each intrapleural administration. Combination TPA-DNase therapy resulted in a greater decrease in radiographic pleural opacity, a lower rate of surgical referral (odds ratio 0.17; 95% CI 0.03 to 0.87), and a shorter hospital stay (-6.7 days; 95% CI, -12.0 to -1.9) compared with placebo. Neither of the individual agents performed better than placebo, although the numbers were small. Two episodes of pleural hemorrhage and one episode of hemoptysis were seen with combined TPA-DNase therapy, although the side effect incidence was not different across study groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Thoracoscopic debridement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Video-assisted thoracoscopic surgery (VATS) is often used to debride multiloculated empyemas or uniloculated empyemas that fail to resolve with antibiotics and tube thoracostomy drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/33,53,54\">",
"     33,53,54",
"    </a>",
"    ]. VATS allows for minimally invasive debridement and drainage and can be followed by or converted to a thoracotomy if adequate pleural fluid drainage and lung expansion are not achieved.",
"   </p>",
"   <p>",
"    The efficacy of VATS in treating empyema has been evaluated in several retrospective studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/55-59\">",
"     55-59",
"    </a>",
"    ]. The endpoints are usually resolution of disease versus need for open thoracotomy, and results are variable. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 178 patients who underwent VATS for pleural empyema, thoracoscopic debridement was successful in 56 percent; conversion to thoracotomy with decortication was necessary in 44 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/55\">",
"       55",
"      </a>",
"      ]. Conversion to thoracotomy was more common in patients with delayed referral (&gt;2 weeks) for VATS and those who had gram-negative bacteria causing empyema.",
"     </li>",
"     <li>",
"      Two retrospective series of thoracoscopic debridement for empyema found that approximately 29 percent of patients ultimately required open decortication [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/56,57\">",
"       56,57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective series of 130 patients who underwent VATS debridement for empyema after failure of antibiotic therapy and chest tube drainage, the rate of conversion to thoracotomy was 3 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Risk factors associated with the need for thoracotomy after thoracoscopy include delayed referral and infection of the pleural space with gram-negative bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thoracoscopy is most commonly used as an alternative to instillation of intrapleural fibrinolytics to facilitate drainage of a multiloculated pleural collection. Several small series suggest that thoracoscopy is superior to intrapleural fibrinolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/60-63\">",
"     60-63",
"    </a>",
"    ]. In contrast, one randomized, single center study in 60 children found no difference in treatment outcomes when intrapleural urokinase and thoracoscopic surgery were compared [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/64\">",
"     64",
"    </a>",
"    ]. Cost favored intrapleural urokinase.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Decortication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pleural fibrosis (also known as a pleural peel) generally begins to regress once the pleural infection is adequately controlled. However, when visceral pleural fibrosis does not regress and limits reexpansion of the lung, an empyema cavity is formed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/53,65,66\">",
"     53,65,66",
"    </a>",
"    ]. In this situation, a total",
"    <span class=\"nowrap\">",
"     pleurectomy/decortication",
"    </span>",
"    may be indicated to achieve lung reexpansion.",
"   </p>",
"   <p>",
"    In general, the outcomes with a thoracoscopic approach are at least as good as with an open thoracotomy, as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a nonrandomized study of 420 patients who underwent either thoracoscopic or open decortication, the operative time and median in-hospital stay were shorter for the thoracoscopic group and the 30 day mortality was slightly lower (8 versus 16 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/67\">",
"       67",
"      </a>",
"      ]. However, the open decortication group had a greater incidence of prior thoracic surgery and a higher rate of muscle flap placement for repair of bronchopleural fistulae, indicating a greater acuity of illness.",
"     </li>",
"     <li>",
"      In another nonrandomized study of decortication by VATS (n = 41) versus open thoracotomy (n = 36), intraoperative blood loss, duration of chest drain, length of hospital stay, and postoperative complication rate were all similar in the two groups [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with relatively more adhesions, greater visceral pleural thickness, or larger empyema cavity size, some surgeons prefer thoracotomy with open decortication to thoracoscopic debridement. Sometimes this decision is made preoperatively; other times it is made at the time of VATS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/55-57\">",
"     55-57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Postsurgical empyema",
"    </span>",
"    &nbsp;&mdash;&nbsp;A special situation is created when empyema complicates a postsurgical space with or without a bronchopleural fistula. These infections once relegated the patient to a life of continued open thoracostomy; however, other options of closure are available to the experienced thoracic surgeon [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28089/abstract/68\">",
"     68",
"    </a>",
"    ]. These include combinations of pleural space sterilization with antibiotic irrigation, space-filling muscle pedicles, and surgical closure of both bronchopleural fistulae and open thoracostomy incisions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32329?source=see_link&amp;anchor=H11#H11\">",
"     \"Sequelae and complications of pneumonectomy\", section on 'Pleural space complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Open thoracostomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Open thoracostomy involves a vertical incision through the chest wall with rib resection to permit open drainage at the inferior border of the empyema cavity. A chest tube is left in place; it is gradually advanced outward as the tract closes, a process that takes approximately 60 to 90 days. Although this procedure is less invasive than decortication, the risks of general anesthesia and the morbidity of prolonged chest tube drainage remain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parapneumonic effusions are pleural effusions that occur in the pleural space adjacent to a bacterial pneumonia. The following subsets are recognized. An uncomplicated parapneumonic effusion has \"exudative\" chemistries, normal pH and glucose, and negative cultures. A complicated parapneumonic effusion typically has \"exudative\" chemistries, a low pleural pH (pH &lt;7.20), a low glucose, and is often loculated. Empyema fluid typically looks like pus and organisms are visible on Gram stain, although cultures may be negative. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In general, all parapneumonic effusions, EXCEPT those that are free flowing and layer less than 10 mm on a lateral decubitus film, should be sampled by thoracentesis. If a small bore catheter is used for thoracentesis, all free-flowing pleural fluid is drained prior to catheter removal. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Pleural fluid analysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with a parapneumonic effusion or an empyema, an empiric, broad spectrum antibiotic that includes coverage for anaerobic organisms should be initiated promptly, as empyemas often harbor multiple species of bacteria, particularly anaerobes. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Choice of agent'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with an uncomplicated parapneumonic effusion that is small to moderate in size, free flowing, and has a pH of 7.20 or greater (eg, category 2) (",
"      <a class=\"graphic graphic_table graphicRef59099 \" href=\"UTD.htm?3/38/3693\">",
"       table 1",
"      </a>",
"      ), we recommend observation rather than drainage of any remaining pleural fluid (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with a large, loculated, or complicated parapneumonic effusion (eg, category 3) (",
"      <a class=\"graphic graphic_table graphicRef59099 \" href=\"UTD.htm?3/38/3693\">",
"       table 1",
"      </a>",
"      ), we recommend prompt drainage of any remaining pleural fluid rather than observation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For further drainage of the pleural space, we suggest tube thoracostomy rather than a more invasive procedure (eg, thoracoscopy, decortication) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). CT or ultrasound-guided placement of multiple tubes may be needed when pleural loculations prevent adequate drainage by a single tube. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Complicated parapneumonic effusions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with a thoracic empyema documented by the presence of pleural pus (eg, category 4) (",
"      <a class=\"graphic graphic_table graphicRef59099 \" href=\"UTD.htm?3/38/3693\">",
"       table 1",
"      </a>",
"      ), we recommend prompt drainage of any remaining pleural fluid rather than observation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Acceptable initial methods for pleural drainage include tube thoracostomy and video-assisted thoracoscopic surgery (VATS) with debridement. The latter may be preferred in patients with multiple loculations and a thick pleural peel. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Empyema'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When tube thoracostomy is used for initial drainage of an empyema, a chest CT scan should be obtained within 24 hours after chest tube placement to document appropriate placement of the tube and assess drainage. For patients who do not have good drainage of empyema fluid from a well-placed chest tube, we suggest intrapleural administration of a combination of tissue plasminogen activator (TPA) 10 mg and deoxyribonuclease (DNase) 5 mg, twice daily for three days rather than no intrapleural therapy or either agent alone (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Fibrinolytic agents'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H824539\">",
"       'Fibrinolytic and mucolytic agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Continued failure of adequate pleural drainage should prompt thoracoscopy or thoracotomy to lyse adhesions, fully drain the pleural space, and optimize chest tube placement. The choice between thoracoscopic debridement and decortication depends on several factors; those favoring decortication include more adhesions, greater visceral pleural thickness, and larger empyema cavity size. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Decortication'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/1\">",
"      Light RW, Girard WM, Jenkinson SG, George RB. Parapneumonic effusions. Am J Med 1980; 69:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/2\">",
"      Mavroudis C, Ganzel BL, Cox SK, Polk HC Jr. Experimental aerobic-anaerobic thoracic empyema in the guinea pig. Ann Thorac Surg 1987; 43:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/3\">",
"      Strange C, Tomlinson JR, Wilson C, et al. The histology of experimental pleural injury with tetracycline, empyema, and carrageenan. Exp Mol Pathol 1989; 51:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/4\">",
"      Heffner JE, Klein JS, Hampson C. Diagnostic utility and clinical application of imaging for pleural space infections. Chest 2010; 137:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/5\">",
"      Smolikov A, Smolyakov R, Riesenberg K, et al. Prevalence and clinical significance of pleural microbubbles in computed tomography of thoracic empyema. Clin Radiol 2006; 61:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/6\">",
"      Aquino SL, Webb WR, Gushiken BJ. Pleural exudates and transudates: diagnosis with contrast-enhanced CT. Radiology 1994; 192:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/7\">",
"      Waite RJ, Carbonneau RJ, Balikian JP, et al. Parietal pleural changes in empyema: appearances at CT. Radiology 1990; 175:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/8\">",
"      Kearney SE, Davies CW, Davies RJ, Gleeson FV. Computed tomography and ultrasound in parapneumonic effusions and empyema. Clin Radiol 2000; 55:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/9\">",
"      Sahn SA, Light RW. The sun should never set on a parapneumonic effusion. Chest 1989; 95:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/10\">",
"      Colice GL, Curtis A, Deslauriers J, et al. Medical and surgical treatment of parapneumonic effusions : an evidence-based guideline. Chest 2000; 118:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/11\">",
"      Heffner JE, Brown LK, Barbieri C, DeLeo JM. Pleural fluid chemical analysis in parapneumonic effusions. A meta-analysis. Am J Respir Crit Care Med 1995; 151:1700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/12\">",
"      Sahn SA. State of the art. The pleura. Am Rev Respir Dis 1988; 138:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/13\">",
"      Porcel JM, Vives M, Cao G, et al. Biomarkers of infection for the differential diagnosis of pleural effusions. Eur Respir J 2009; 34:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/14\">",
"      Porcel JM. Pleural fluid tests to identify complicated parapneumonic effusions. Curr Opin Pulm Med 2010; 16:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/15\">",
"      Kawanami T, Fukuda K, Yatera K, et al. A higher significance of anaerobes: the clone library analysis of bacterial pleurisy. Chest 2011; 139:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/16\">",
"      Menzies SM, Rahman NM, Wrightson JM, et al. Blood culture bottle culture of pleural fluid in pleural infection. Thorax 2011; 66:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/17\">",
"      Brook I, Frazier EH. Aerobic and anaerobic microbiology of empyema. A retrospective review in two military hospitals. Chest 1993; 103:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/18\">",
"      Bartlett JG, Gorbach SL, Thadepalli H, Finegold SM. Bacteriology of empyema. Lancet 1974; 1:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/19\">",
"      Civen R, Jousimies-Somer H, Marina M, et al. A retrospective review of cases of anaerobic empyema and update of bacteriology. Clin Infect Dis 1995; 20 Suppl 2:S224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/20\">",
"      Boyanova L, Gergova G, Petrov D, et al. Anaerobic microbiology in 198 cases of pleural empyema: a Bulgarian study. Anaerobe 2004; 10:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/21\">",
"      Bhattacharyya N, Umland ET, Kosloske AM. A bacteriologic basis for the evolution and severity of empyema. J Pediatr Surg 1994; 29:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/22\">",
"      Chapman SJ, Davies RJ. Recent advances in parapneumonic effusion and empyema. Curr Opin Pulm Med 2004; 10:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/23\">",
"      Le Monnier A, Carbonnelle E, Zahar JR, et al. Microbiological diagnosis of empyema in children: comparative evaluations by culture, polymerase chain reaction, and pneumococcal antigen detection in pleural fluids. Clin Infect Dis 2006; 42:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/24\">",
"      Maskell NA, Davies CW, Nunn AJ, et al. U.K. Controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med 2005; 352:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/25\">",
"      Ahmed RA, Marrie TJ, Huang JQ. Thoracic empyema in patients with community-acquired pneumonia. Am J Med 2006; 119:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/26\">",
"      Maskell NA, Batt S, Hedley EL, et al. The bacteriology of pleural infection by genetic and standard methods and its mortality significance. Am J Respir Crit Care Med 2006; 174:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/27\">",
"      Grijalva CG, Zhu Y, Nuorti JP, Griffin MR. Emergence of parapneumonic empyema in the USA. Thorax 2011; 66:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/28\">",
"      Chen KY, Hsueh PR, Liaw YS, et al. A 10-year experience with bacteriology of acute thoracic empyema: emphasis on Klebsiella pneumoniae in patients with diabetes mellitus. Chest 2000; 117:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/29\">",
"      Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis 2008; 198:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/30\">",
"      Luh SP, Chou MC, Wang LS, et al. Video-assisted thoracoscopic surgery in the treatment of complicated parapneumonic effusions or empyemas: outcome of 234 patients. Chest 2005; 127:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/31\">",
"      Vaudaux P, Waldvogel FA. Gentamicin inactivation in purulent exudates: role of cell lysis. J Infect Dis 1980; 142:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/32\">",
"      Berger HA, Morganroth ML. Immediate drainage is not required for all patients with complicated parapneumonic effusions. Chest 1990; 97:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/33\">",
"      Wozniak CJ, Paull DE, Moezzi JE, et al. Choice of first intervention is related to outcomes in the management of empyema. Ann Thorac Surg 2009; 87:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/34\">",
"      Rahman NM, Maskell NA, Davies CW, et al. The relationship between chest tube size and clinical outcome in pleural infection. Chest 2010; 137:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/35\">",
"      Davies CW, Gleeson FV, Davies RJ, Pleural Diseases Group, Standards of Care Committee, British Thoracic Society. BTS guidelines for the management of pleural infection. Thorax 2003; 58 Suppl 2:ii18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/36\">",
"      Horsley A, Jones L, White J, Henry M. Efficacy and complications of small-bore, wire-guided chest drains. Chest 2006; 130:1857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/37\">",
"      Jerjes-S&aacute;nchez C, Ramirez-Rivera A, Elizalde JJ, et al. Intrapleural fibrinolysis with streptokinase as an adjunctive treatment in hemothorax and empyema: a multicenter trial. Chest 1996; 109:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/38\">",
"      Temes RT, Follis F, Kessler RM, et al. Intrapleural fibrinolytics in management of empyema thoracis. Chest 1996; 110:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/39\">",
"      Davies RJ, Traill ZC, Gleeson FV. Randomised controlled trial of intrapleural streptokinase in community acquired pleural infection. Thorax 1997; 52:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/40\">",
"      Bouros D, Schiza S, Tzanakis N, et al. Intrapleural urokinase versus normal saline in the treatment of complicated parapneumonic effusions and empyema. A randomized, double-blind study. Am J Respir Crit Care Med 1999; 159:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/41\">",
"      Diacon AH, Theron J, Schuurmans MM, et al. Intrapleural streptokinase for empyema and complicated parapneumonic effusions. Am J Respir Crit Care Med 2004; 170:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/42\">",
"      Thomson AH, Hull J, Kumar MR, et al. Randomised trial of intrapleural urokinase in the treatment of childhood empyema. Thorax 2002; 57:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/43\">",
"      Thommi G, Nair CK, Aronow WS, et al. Efficacy and safety of intrapleural instillation of alteplase in the management of complicated pleural effusion or empyema. Am J Ther 2007; 14:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/44\">",
"      Tuncozgur B, Ustunsoy H, Sivrikoz MC, et al. Intrapleural urokinase in the management of parapneumonic empyema: a randomised controlled trial. Int J Clin Pract 2001; 55:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/45\">",
"      Tokuda Y, Matsushima D, Stein GH, Miyagi S. Intrapleural fibrinolytic agents for empyema and complicated parapneumonic effusions: a meta-analysis. Chest 2006; 129:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/46\">",
"      Cameron R, Davies HR. Intra-pleural fibrinolytic therapy versus conservative management in the treatment of adult parapneumonic effusions and empyema. Cochrane Database Syst Rev 2008; :CD002312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/47\">",
"      Ozcelik C, Inci I, Nizam O, Onat S. Intrapleural fibrinolytic treatment of multiloculated postpneumonic pediatric empyemas. Ann Thorac Surg 2003; 76:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/48\">",
"      Gervais DA, Levis DA, Hahn PF, et al. Adjunctive intrapleural tissue plasminogen activator administered via chest tubes placed with imaging guidance: effectiveness and risk for hemorrhage. Radiology 2008; 246:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/49\">",
"      Anevlavis S, Archontogeorgis K, Tzouvelekis A, et al. Intrapleural r-tPA in association with low-molecular heparin may cause massive hemothorax resulting in hypovolemia. Respiration 2011; 81:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/50\">",
"      Skeete DA, Rutherford EJ, Schlidt SA, et al. Intrapleural tissue plasminogen activator for complicated pleural effusions. J Trauma 2004; 57:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/51\">",
"      Davies CW, Lok S, Davies RJ. The systemic fibrinolytic activity of intrapleural streptokinase. Am J Respir Crit Care Med 1998; 157:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/52\">",
"      Rahman NM, Maskell NA, West A, et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N Engl J Med 2011; 365:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/53\">",
"      Potaris K, Mihos P, Gakidis I, Chatziantoniou C. Video-thoracoscopic and open surgical management of thoracic empyema. Surg Infect (Larchmt) 2007; 8:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/54\">",
"      Cassina PC, Hauser M, Hillejan L, et al. Video-assisted thoracoscopy in the treatment of pleural empyema: stage-based management and outcome. J Thorac Cardiovasc Surg 1999; 117:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/55\">",
"      Lardinois D, Gock M, Pezzetta E, et al. Delayed referral and gram-negative organisms increase the conversion thoracotomy rate in patients undergoing video-assisted thoracoscopic surgery for empyema. Ann Thorac Surg 2005; 79:1851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/56\">",
"      Lawrence DR, Ohri SK, Moxon RE, et al. Thoracoscopic debridement of empyema thoracis. Ann Thorac Surg 1997; 64:1448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/57\">",
"      Striffeler H, Gugger M, Im Hof V, et al. Video-assisted thoracoscopic surgery for fibrinopurulent pleural empyema in 67 patients. Ann Thorac Surg 1998; 65:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/58\">",
"      Wurnig PN, Wittmer V, Pridun NS, Hollaus PH. Video-assisted thoracic surgery for pleural empyema. Ann Thorac Surg 2006; 81:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/59\">",
"      Ravaglia C, Gurioli C, Tomassetti S, et al. Is medical thoracoscopy efficient in the management of multiloculated and organized thoracic empyema?. Respiration 2012; 84:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/60\">",
"      Wait MA, Sharma S, Hohn J, Dal Nogare A. A randomized trial of empyema therapy. Chest 1997; 111:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/61\">",
"      Petrakis IE, Kogerakis NE, Drositis IE, et al. Video-assisted thoracoscopic surgery for thoracic empyema: primarily, or after fibrinolytic therapy failure? Am J Surg 2004; 187:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/62\">",
"      Gates RL, Caniano DA, Hayes JR, Arca MJ. Does VATS provide optimal treatment of empyema in children? A systematic review. J Pediatr Surg 2004; 39:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/63\">",
"      Coote N, Kay ES. WITHDRAWN: Surgical versus non-surgical management of pleural empyema. Cochrane Database Syst Rev 2009; :CD001956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/64\">",
"      Sonnappa S, Cohen G, Owens CM, et al. Comparison of urokinase and video-assisted thoracoscopic surgery for treatment of childhood empyema. Am J Respir Crit Care Med 2006; 174:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/65\">",
"      Chan DT, Sihoe AD, Chan S, et al. Surgical treatment for empyema thoracis: is video-assisted thoracic surgery \"better\" than thoracotomy? Ann Thorac Surg 2007; 84:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/66\">",
"      Mandal AK, Thadepalli H, Mandal AK, Chettipally U. Outcome of primary empyema thoracis: therapeutic and microbiologic aspects. Ann Thorac Surg 1998; 66:1782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/67\">",
"      Tong BC, Hanna J, Toloza EM, et al. Outcomes of video-assisted thoracoscopic decortication. Ann Thorac Surg 2010; 89:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28089/abstract/68\">",
"      CLAGETT OT, GERACI JE. A procedure for the management of postpneumonectomy empyema. J Thorac Cardiovasc Surg 1963; 45:141.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6702 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.167.4.114-B6D75EF485-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_27_28089=[""].join("\n");
var outline_f27_27_28089=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Uncomplicated parapneumonic effusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Complicated parapneumonic effusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Thoracic empyema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      IMAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      THORACENTESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PLEURAL FLUID ANALYSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      BACTERIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1324721\">",
"      ANTIBIOTIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Choice of agent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1324756\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Uncomplicated parapneumonic effusions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Complicated parapneumonic effusions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Empyema",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Tube thoracostomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Fibrinolytic agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H824539\">",
"      - Fibrinolytic and mucolytic agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Thoracoscopic debridement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Decortication",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Postsurgical empyema",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Open thoracostomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/6702\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/6702|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/31/3575\" title=\"diagnostic image 1\">",
"      Parapneumonic effusion chest xray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?32/41/33439\" title=\"diagnostic image 2\">",
"      Parapneumonic effusion CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/6702|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/38/3693\" title=\"table 1\">",
"      Parapneumonic effusion drainage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/18/14637\" title=\"table 2\">",
"      Activity of antimicrobiol agents against anaerobes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/39/42617?source=related_link\">",
"      Anaerobic bacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31017?source=related_link\">",
"      Aspiration pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18055?source=related_link\">",
"      Candida infections of the abdomen and thorax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=related_link\">",
"      Diagnostic evaluation of a pleural effusion in adults: Initial testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/23/12663?source=related_link\">",
"      Diagnostic thoracentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31514?source=related_link\">",
"      Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/34/9770?source=related_link\">",
"      Epidemiology; clinical presentation; and evaluation of parapneumonic effusion and empyema in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21384?source=related_link\">",
"      Imaging of pleural effusions in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27882?source=related_link\">",
"      Management and prognosis of parapneumonic effusion and empyema in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36695?source=related_link\">",
"      Mechanisms of pleural liquid accumulation in disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9735?source=related_link\">",
"      Mechanisms of pleural liquid turnover in the normal state",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17272?source=related_link\">",
"      Monitoring the HIV-infected patient on antituberculous medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1226?source=related_link\">",
"      Placement and management of thoracostomy tubes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/4/13386?source=related_link\">",
"      Pneumococcal pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32329?source=related_link\">",
"      Sequelae and complications of pneumonectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40986?source=related_link\">",
"      Treatment of community-acquired pneumonia in adults who require hospitalization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/21/19802?source=related_link\">",
"      Treatment of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12856?source=related_link\">",
"      Tuberculous pleural effusions in HIV-negative patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_27_28090="Pharmacology and side effects of cyclosporine and tacrolimus";
var content_f27_27_28090=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pharmacology and side effects of cyclosporine and tacrolimus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/27/28090/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/27/28090/contributors\">",
"     Colm C Magee, MD, MPH, FRCPI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/27/28090/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/27/28090/contributors\">",
"     Daniel E Furst, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/27/28090/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/27/28090/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/27/28090/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    (formerly FK506) selectively inhibit transcription of interleukin (IL)-2 and several other cytokines, mainly in T-helper lymphocytes. The introduction of cyclosporine in the 1980s and of tacrolimus in the 1990s has significantly improved the survival of transplanted organs.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    are occasionally used in the treatment of various immune-mediated diseases. However, concerns about their long-term toxicity (especially renal dysfunction and hypertension) and the availability of newer biologic agents have restricted the use of cyclosporine and tacrolimus to patients who have not responded to conventional treatment. The renal toxicity of these agents is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=see_link\">",
"     \"Cyclosporine and tacrolimus nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , including dosing for several rheumatic diseases, is reviewed here. The efficacy and use of these agents in specific conditions, including organ transplantation and immune-mediated diseases, are discussed separately in the topic reviews addressing the treatment of each disorder. (See appropriate topic reviews.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     USE OF CYCLOSPORINE AND TACROLIMUS IN RHEUMATIC DISEASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the late 1980s,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    has been used, sometimes with fairly promising results, in the treatment of the following autoimmune disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Adult rheumatoid arthritis (RA) as a single drug [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/1-5\">",
"       1-5",
"      </a>",
"      ], or in combination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]. The microemulsion formulation is approved by the Federal Drug Administration of the United States for treatment of severely active RA.",
"     </li>",
"     <li>",
"      Psoriatic arthritis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Psoriasis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/10-12\">",
"       10-12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Acute ocular Beh&ccedil;et&rsquo;s disease [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/13\">",
"       13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Juvenile idiopathic arthritis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Adult and juvenile polymyositis and dermatomyositis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/14-21\">",
"       14-21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Adult and juvenile systemic lupus erythematosus [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/22-25\">",
"       22-25",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Adult lupus membranous nephritis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/26\">",
"       26",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Systemic sclerosis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/27-29\">",
"       27-29",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Aplastic anemia [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/30,31\">",
"       30,31",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Glucocorticoid-resistant nephrotic syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/9/31898?source=see_link\">",
"       \"Treatment of minimal change disease in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/57/34714?source=see_link\">",
"       \"Treatment of primary focal segmental glomerulosclerosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Atopic dermatitis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42631?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Severe, glucocorticoid-dependent asthma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33354?source=see_link\">",
"       \"Alternative and experimental agents for the treatment of asthma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Severe ulcerative colitis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/32-34\">",
"       32-34",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Pemphigus vulgaris [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/35\">",
"       35",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Myasthenia gravis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/36\">",
"       36",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Dry eye disease, with or without Sj&ouml;gren&rsquo;s syndrome (administered as ophthalmic emulsion) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/37\">",
"       37",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, for many of the above conditions, newer therapies (such as the anti-tumor necrosis factor-alpha agents) are now used instead of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    has been used for therapy of the following disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Adult rheumatoid arthritis, as a single agent [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/38-40\">",
"       38-40",
"      </a>",
"      ] or in combination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/41\">",
"       41",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Adult refractory myositis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/42\">",
"       42",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Systemic sclerosis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/29\">",
"       29",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Crohn's disease [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/43\">",
"       43",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Autoimmune chronic hepatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/44\">",
"       44",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Pediatric autoimmune enteropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/45\">",
"       45",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Uveitis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/46,47\">",
"       46,47",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Steroid-resistant nephrotic syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/57/34714?source=see_link\">",
"       \"Treatment of primary focal segmental glomerulosclerosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Severe, recalcitrant, chronic plaque psoriasis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/48,49\">",
"       48,49",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Atopic dermatitis (administered as ointment) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/50\">",
"       50",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Again, for many of the above conditions, the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    has actually declined, as other agents with a perceived better balance of efficacy and toxicity are used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    is a lipophilic cyclic peptide of 11 amino acids while",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    is a macrolide antibiotic. Both drugs have been isolated from fungi and possess similar suppressive effects on cell mediated and humoral immune responses.",
"   </p>",
"   <p>",
"    Both drugs bind with high affinity to a family of cytoplasmic proteins present in most cells: cyclophilins for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , and FK binding proteins for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    . The drug-receptor complex specifically and competitively binds to and inhibits calcineurin, a calcium and calmodulin dependent phosphatase [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/51-54\">",
"     51-54",
"    </a>",
"    ]. This process inhibits the translocation of a family of transcription factors, NF-AT, leading to reduced transcriptional activation of early cytokine genes for interleukin (IL)-2, tumor necrosis factor alpha (TNF-alpha) IL-3, IL-4, CD40L, granulocyte-macrophage colony-stimulating factor, and interferon-gamma [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/51,52,55,56\">",
"     51,52,55,56",
"    </a>",
"    ]. Ultimately, proliferation of lymphocytes is reduced.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    act primarily on T-helper cells, although some inhibition of T-suppressor and T-cytotoxic cells also seems to occur. Cyclosporine blocks mitogen-induced activation and proliferation of peripheral blood and synovial fluid mononuclear cells in patients with autoimmune arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/57\">",
"     57",
"    </a>",
"    ]. It has a differential effect on T-helper cells in active RA patients shifting the balance from Th1 to Th2 type cytokine expression [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/58\">",
"     58",
"    </a>",
"    ]. In addition, T cell-dependent B cell responses are inhibited by both drugs. Tacrolimus interferes with IgE receptor-mediated histamine and serotonin release from basophils and mast cells. Cyclosporine and tacrolimus have minimal effects upon amplification of the immune response following activation.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    also increases the expression of transforming growth factor-beta, which may be an important mechanism by which it causes renal fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unlike some other immunosuppressive agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and the alkylating agents,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    lack clinically significant myelosuppressive activity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     FORMULATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral, intravenous, ophthalmic, and topical formulations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    are available (",
"    <a class=\"graphic graphic_table graphicRef57518 \" href=\"UTD.htm?4/7/4220\">",
"     table 1",
"    </a>",
"    ). The intravenous forms of both drugs should be used only if enteral administration is not possible, because there is the potential for greater toxicity with intravenous administration. Generic forms of cyclosporine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    are available in many countries, including the United States. In general, patients stabilized on one preparation should not be switched to another, because there are concerns about differences in pharmacokinetics. If a conversion between preparations is necessary, monitoring trough concentrations should be performed until the results are stable [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Dose and administration'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liquid",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    is available in capsules, oral solution, and concentrate for injection.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Liquid-filled capsules (Sandimune&reg;) of 25 mg, 50 mg, and 100 mg are stored at less than 86&ordm;F (30&ordm;C) but not frozen.",
"     </li>",
"     <li>",
"      The oral solution of 100",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      in 50 mL bottles remains stable for two months after opening if stored in the original container at less than 86&ordm;F (30&ordm;C) but does not require refrigeration and should not be frozen.",
"     </li>",
"     <li>",
"      Concentrate for injection of 50",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      in 5 mL ampules should be stored at less 86&ordm;F (30&ordm;C) and protected from light and freezing. Dilutions in 5% glucose or normal saline are stable for 24 hours. Substantial amounts of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      may be lost during intravenous administration through plastic tubing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cyclosporine microemulsion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Capsules and solution are for oral use; no parenteral microemulsion is available.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Capsules (Neoral&reg;): 25 mg and 100 mg stored at 68 to 77&ordm;F (20 to 25&ordm;C)",
"     </li>",
"     <li>",
"      Capsules (Gengraf&reg;): 25 mg and 100 mg stored at 59 to 86&ordm;F (15 to 30&ordm;C)",
"     </li>",
"     <li>",
"      Oral solution (Neoral&reg;): 100",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      in 50 mL bottles, which remains stable for two months after opening if stored in the original container at 68 to 77&ordm;F (20 to 25&ordm; C)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cyclosporine ophthalmic emulsion",
"    </span>",
"    &nbsp;&mdash;&nbsp;An ophthalmic emulsion (Restasis&reg;): 0.05 percent emulsion is available in single vials of 0.4 ml stored at 59 to 77&ordm;F (15 to 25&ordm;C).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Tacrolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral, intravenous, and topical formulations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    are available (",
"    <a class=\"graphic graphic_table graphicRef57518 \" href=\"UTD.htm?4/7/4220\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Capsules (Prograf&reg;): 0.5 mg, 1 mg, and 5 mg are stored at 59 to 86&ordm;F (15 to 30&ordm;C).",
"     </li>",
"     <li>",
"      Concentrate for injection 5",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      in 1 mL ampules is stored at 41 to 77&ordm;F (5 to 25&ordm;C) and is stable for 24 hours in plastic syringes at 75&ordm;F (24&ordm;C). When diluted in glucose or saline solutions, it remains stable for 24 hours in glass but not PVC containers.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       Tacrolimus",
"      </a>",
"      ointment (Protopic&reg;): 0.03 percent and 0.1 percent in 30 g and 60 g tubes, stored at 41 to 77&ordm;F (5 to 25&ordm;C)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PHARMACOKINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whole blood should be used as a sample for both drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. Radioimmunoassay and fluorescence polarization immunoassay are used to determine the blood",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    concentration, while enzyme linked immunoabsorbent assay is performed for measuring blood",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    concentrations. Even with the most specific antibodies currently available, however, there is some cross-reactivity between cyclosporine and tacrolimus metabolites. Thus, the immunoassays tend to slightly overestimate the actual levels of both drugs. High performance liquid chromatography-mass spectrometry remains the reference procedure but is technically demanding. Clinicians prescribing cyclosporine and tacrolimus should be aware of the type of assay used in their institution and the associated reference ranges.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Absorption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    are only partially absorbed with large inter- and intra-individual variability. The oral bioavailability is limited for both drugs (roughly 20 percent for tacrolimus) as a result of poor absorption, partial metabolism by enzymes in the bowel mucosa, and first-pass hepatic metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/65,66\">",
"     65,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The absorption of these agents may vary with ethnicity. The mean",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    exposure after a single 5 mg oral dose in healthy Latin American and African American subjects was 18 and 39 percent less, respectively, than in Caucasians [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both drugs are absorbed in the small intestine, and plasma peak concentrations occur after one to eight hours. The absorption of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , but not",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , is dependent upon bile salts. Thus, the cyclosporine microemulsion may be particularly desirable in patients with biliary diversion or cholestasis. Cyclosporine absorption is increased when ingested with a fatty meal. In contrast, tacrolimus absorption is decreased if administered immediately after a standard breakfast [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, microemulsion formulations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    lead to higher area under the curve (AUC) than the (older) standard preparations. Thus, patients stabilized on either the standard or microemulsion form should generally not be switched from one to the other. If patients are switched, trough cyclosporine concentrations should be closely monitored for several weeks.",
"   </p>",
"   <p>",
"    Patients receiving long-term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ophthalmic emulsion 0.05 percent had no detectable blood cyclosporine levels indicating no significant systemic absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    is minimally absorbed in patients with normal skin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Distribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    are lipophilic and undergo extensive body distribution. In the blood, most of the absorbed amount of each drug is taken up by erythrocytes. In the plasma, cyclosporine binds mainly to lipoproteins whereas tacrolimus binds to proteins.",
"   </p>",
"   <p>",
"    The highest tissue",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    concentration is achieved in thymus, spleen, lymph nodes, marrow, liver, pancreas, kidney, adrenals, lung, and skin.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    accumulates mainly in lung, spleen, heart, kidney, and pancreas.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    penetrates well into synovial fluid but does not cross the blood-brain barrier, even in patients with neurologic manifestations of Beh&ccedil;et&rsquo;s disease. Both drugs cross placenta and appear in breast milk in substantial amounts. Neither cyclosporine nor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    is removed by hemodialysis to a significant extent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    are",
"    <strong>",
"     extensively",
"    </strong>",
"    metabolized by the cytochrome P450 family enzymes in the liver and excreted into the bile. There is also some metabolism in the gut mucosa. The most active cyclosporine metabolites have only 10 to 20 percent of the drug's immunosuppressive activity. In comparison, one of the metabolites of tacrolimus possesses equal immunosuppressive potency to the parent drug.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Elimination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The elimination half-life can vary significantly between patients but is roughly 19 hours for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and 12 hours for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    . Cyclosporine metabolism is age-dependent with a 1.5- to 2.5-fold increase in half-life in adults compared with children. Liver dysfunction prolongs the half-life of both cyclosporine and tacrolimus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/70-73\">",
"     70-73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    are metabolized by hepatic cytochrome P450 3A enzymes, a variety of important drug interactions with drugs that either affect or are metabolized by these enzymes can occur. These interactions are discussed in detail separately on the drug information topics for cyclosporine and tacrolimus, are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef81998 \" href=\"UTD.htm?14/44/15042\">",
"     table 2",
"    </a>",
"    ), and are briefly reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Increased cyclosporine levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following increase",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    blood concentrations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       Diltiazem",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/61/42969?source=see_link\">",
"       Nicardipine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       Verapamil",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       Fluconazole",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       Itraconazole",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"       Ketoconazole",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       Clarithromycin",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       Erythromycin",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/14/3305?source=see_link\">",
"       Lansoprazole",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/18/44327?source=see_link\">",
"       Rabeprazole",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"       Cimetidine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       Methylprednisolone",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"       Allopurinol",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/40/8840?source=see_link\">",
"       Bromocriptine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"       Metoclopramide",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       Colchicine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"     </li>",
"     <li>",
"      Danazole",
"     </li>",
"     <li>",
"      Grapefruit juice",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The proton pump inhibitors",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32009?source=see_link\">",
"     pantoprazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    do not change",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    levels significantly. The effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    on cyclosporine metabolism have led to their use in transplant recipients as a method of lowering the total cyclosporine dose and, therefore, the cost of cyclosporine therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43706?source=see_link\">",
"     \"Maintenance immunosuppressive therapy in renal transplantation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Decreased cyclosporine levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following lower the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    blood concentrations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"       Nafcillin",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"       Rifabutin",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       Rifampin",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       Carbamazepine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"       Phenobarbital",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       Phenytoin",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       Octreotide",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"       Ticlopidine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/32/5638?source=see_link\">",
"       Orlistat",
"      </a>",
"     </li>",
"     <li>",
"      St. John's Wort",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Co-administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    in 30 patients with rheumatoid arthritis resulted in an 18 percent increase of mean methotrexate concentration (area under the curve [AUC]) and an 80 percent decrease of its metabolite, 7-hydroxymethotrexate. Cyclosporine concentration was not affected [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/74\">",
"     74",
"    </a>",
"    ]. The clinical significance of this interaction is unknown.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    (FK506) is also metabolized by cytochrome P450 3A enzymes and should, therefore, be susceptible to many of the drug interactions noted above with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . These relationships are less well-documented than with cyclosporine.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    increases the plasma concentration of the endothelin-1 antagonist,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/16/40200?source=see_link\">",
"     bosentan",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SIDE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    are similar, although tacrolimus is less well-studied. When used for the treatment of autoimmune disorders, the frequency and severity of side effects are lower compared with those seen in transplant recipients. This observation is explained by the lower doses and the option to decrease the dose or discontinue the medication when toxicity appears in patients with autoimmune disorders; these options may not be available in transplant recipients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Nephrotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nephrotoxicity is the most common and clinically significant adverse effect of both drugs.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    nephrotoxicity is manifested as acute azotemia, which is largely reversible after reducing the dose, or as chronic occasionally progressive renal disease, which is usually irreversible. Other renal effects of cyclosporine include tubular dysfunction and, rarely, a hemolytic uremic syndrome (HUS). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=see_link\">",
"     \"Cyclosporine and tacrolimus nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension, caused by renal vasoconstriction and sodium retention, generally develops within the first few weeks of therapy. Studies of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    suggest that stimulation of the renal sodium chloride cotransporter is a potential mechanism by which calcineurin inhibitors may mediate this effect [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/76\">",
"     76",
"    </a>",
"    ]. The blood pressure elevation usually responds to dose reduction, but antihypertensive medications may be required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=see_link\">",
"     \"Cyclosporine and tacrolimus nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Calcium channel blockers are usually considered the drugs of choice if antihypertensive therapy is needed in the setting of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    therapy. As noted above,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    also impairs cyclosporine metabolism, thereby allowing a lower dose to be given. Initiation of diltiazem should prompt immediate reduction in the dose of cyclosporine or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    and careful monitoring of blood concentrations. Diltiazem also reverses the acute vasoconstriction induced by cyclosporine; there is, however, no convincing evidence to date that this prevents chronic cyclosporine nephrotoxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=see_link&amp;anchor=H15#H15\">",
"     \"Cyclosporine and tacrolimus nephrotoxicity\", section on 'Prevention of chronic calcineurin inhibitor nephrotoxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Neurotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurotoxicity associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    may manifest as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/77-81\">",
"     77-81",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mild tremor is common with both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      use, occurring in 35 to 55 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/79,80\">",
"       79,80",
"      </a>",
"      ]. It may improve despite continued therapy.",
"     </li>",
"     <li>",
"      Rarely, patients develop severe headache, visual abnormalities, and seizures. This syndrome is associated with acute hypertension and resembles hypertensive encephalopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/77\">",
"       77",
"      </a>",
"      ]. Posterior leukoencephalopathy is usually seen on brain imaging [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/82\">",
"       82",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43273?source=see_link\">",
"       \"Reversible posterior leukoencephalopathy syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Akinetic mutism, encephalopathy, seizures, focal neurologic abnormalities, and even coma have been reported with intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/78\">",
"       78",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The neurologic side effects are usually reversible following change to an oral preparation, lowering of the drug dose, or drug discontinuation [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/77,78,81\">",
"       77,78,81",
"      </a>",
"      ]. They are probably more common with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/79,80\">",
"       79,80",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Metabolic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucose intolerance occurs more often with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    than with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    in transplant recipients who also receive glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/83\">",
"     83",
"    </a>",
"    ]. As an example, a European trial of liver transplant recipients which compared the efficacy of tacrolimus and cyclosporine reported that hyperglycemia was more frequent with tacrolimus (31 versus 20 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diabetes mellitus resulting from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    also may be more common than with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , particularly among African-Americans compared with Caucasians. The incidence of post-transplant diabetes mellitus was evaluated in 412 patients randomly assigned to tacrolimus or cyclosporine after renal transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/84\">",
"     84",
"    </a>",
"    ]. Among those randomized to tacrolimus, the incidence of diabetes at one year was 37 and 12 percent in African-Americans and Caucasians, respectively.",
"   </p>",
"   <p>",
"    Although initial studies suggested that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    was more likely to induce diabetes mellitus than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , later trials have found a smaller increase or no difference in risk, particularly when tacrolimus is given with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil and low-dose glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. The mechanism underlying the development of diabetes with tacrolimus is unclear. Some evidence suggests that this agent dampens insulin secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    may contribute to bone loss after organ transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/88\">",
"     88",
"    </a>",
"    ]; this effect may be due to the induction of high bone turnover. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9562?source=see_link\">",
"     \"Drugs that affect bone metabolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both drugs cause hyperkalemia and hypomagnesemia, via effects on renal tubular function. Hyperuricemia and exacerbation of gout are well-described with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    but may be less common with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=see_link\">",
"     \"Cyclosporine and tacrolimus nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial, viral (most often cytomegalovirus), and fungal infections often develop in transplant recipients receiving combined immunosuppressive therapy. In the large European trial described above, chronic therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    was associated with infection in approximately 40 percent of patients, sepsis in 20 percent, and cytomegalovirus in 15 to 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/79\">",
"     79",
"    </a>",
"    ]. It should be noted that the majority of transplant recipients requires other immunosuppressive therapy in addition to cyclosporine or tacrolimus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Risk of malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    are associated with an increased risk of squamous cell skin cancer and benign or malignant lymphoproliferative disorders. Spontaneous regression of lymphoma may occur if the drug is discontinued early. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=see_link\">",
"     \"Development of malignancy following solid organ transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The overall level of immunosuppression appears to be the principal factor which increases the risk of post-transplant malignancy. However, evidence from animal models suggests that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    itself may promote cancer progression, principally via the production of transforming growth factor-beta (TGF-beta). In vitro, the administration of cyclosporine results in invasiveness of non-transformed cells in association with striking morphologic changes; in addition, cyclosporine promoted tumor growth in immunodeficient animals [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/89\">",
"     89",
"    </a>",
"    ]. Both the in vitro and in vivo changes were prevented by the administration anti-TGF-beta antibodies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Pregnancy and lactation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Animal and human studies indicate that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    lacks genotoxic effects [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/90\">",
"     90",
"    </a>",
"    ]. Growth restriction and prematurity occur in up to 40 percent of neonates born to mothers with organ transplants who are treated with cyclosporine [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/91\">",
"     91",
"    </a>",
"    ], but no congenital abnormalities have been documented [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. There is also no evidence of increased rates of birth defects in children fathered by patients taking cyclosporine [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/91,93\">",
"     91,93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A paucity of information is available concerning the effects of pregnancy on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    levels. One study found that, compared with levels prior and subsequent to pregnancy, cyclosporine levels declined during pregnancy in five of six allograft recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a paucity of data concerning the effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    on pregnancy. Among 100 pregnancies in 84 women treated with tacrolimus, of whom all but one were organ transplant recipients, 68 progressed to a live birth, with 60 percent of deliveries being premature [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/95\">",
"     95",
"    </a>",
"    ]. Transient neonatal hypoxemia, hyperkalemia, and renal dysfunction were the most frequent side effects. There were four babies with malformations but no consistent pattern of anatomic abnormality.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    should be used during pregnancy only when the potential benefits exceed the possible risk for the fetus. Patients taking cyclosporine or tacrolimus should not breastfeed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Other side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal side effects include anorexia, nausea, vomiting, diarrhea, and abdominal discomfort. These symptoms are more frequent with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    (72 versus 47 percent for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    in one report) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/80\">",
"     80",
"    </a>",
"    ], a finding that is not surprising since tacrolimus is a macrolide. Increased liver enzymes are rare; if present, this abnormality is reversible with dose reduction or discontinuation of the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gingival hyperplasia and hirsutism occur with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/96,97\">",
"     96,97",
"    </a>",
"    ] but not with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    . Poor dental hygiene, higher doses of cyclosporine, and concomitant use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    appear to be the principal risks [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/98\">",
"     98",
"    </a>",
"    ]. Case reports suggest that the gingival hyperplasia can be effectively treated with a two-week course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    (750 mg TID) while cyclosporine is continued [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/99,100\">",
"     99,100",
"    </a>",
"    ]. It is not clear if metronidazole acts in this setting via its antibacterial activity or via another mechanism. Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    (500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for three consecutive days) may also be effective, particularly among those with mild or early disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/101\">",
"     101",
"    </a>",
"    ]. In the transplant setting, the substitution of cyclosporine with tacrolimus was found to significantly ameliorate gingival hyperplasia without increasing the risk of renal allograft dysfunction or rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An uncommon but increasingly recognized complication of immunosuppressive therapy in transplant recipients is alopecia, a finding attributed, in one study, to the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/103\">",
"     103",
"    </a>",
"    ]. At one transplant center, alopecia was noted in 3 to 6 percent of recipients receiving this agent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/104\">",
"     104",
"    </a>",
"    ]. Higher doses were associated with an increased risk. Another study reported an incidence of 30 percent among kidney-pancreas recipients who received tacrolimus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Contraindications and precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypersensitivity to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , or polyoxyl castor oil products (used as solvents for injection preparation of both drugs) is a contraindication to their use. Intravenous cyclosporine or tacrolimus should be used only if the oral route is not feasible.",
"   </p>",
"   <p>",
"    The following conditions have been accepted as contraindications for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    use in rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/41\">",
"     41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Concurrent malignancy (except for nonmelanoma skin carcinoma)",
"     </li>",
"     <li>",
"      Uncontrolled hypertension",
"     </li>",
"     <li>",
"      Renal insufficiency",
"     </li>",
"     <li>",
"      Uncontrolled infections",
"     </li>",
"     <li>",
"      Primary or secondary immune deficiency",
"     </li>",
"     <li>",
"      Hypersensitivity to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    should be used with caution in patients with rheumatoid arthritis and any of the following features [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/41\">",
"     41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age more than 65 years",
"     </li>",
"     <li>",
"      Controlled hypertension",
"     </li>",
"     <li>",
"      Immunodeficiency (except selective IgA deficiency)",
"     </li>",
"     <li>",
"      Abnormally low white blood cell count (unless caused by Felty syndrome)",
"     </li>",
"     <li>",
"      Obesity",
"     </li>",
"     <li>",
"      Use of drugs that interact with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"     </li>",
"     <li>",
"      Concurrent or previous use of alkylating agents",
"     </li>",
"     <li>",
"      Premalignant conditions",
"     </li>",
"     <li>",
"      Active infection, which may require temporary discontinuation",
"     </li>",
"     <li>",
"      Pregnancy and lactation",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     STRATEGIES TO MINIMIZE TOXICITY IN RHEUMATIC DISEASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following approach is recommended when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    is used to treat patients with rheumatic diseases. The issues and tolerance of toxicity are clearly different from transplant recipients, particularly heart, lung, and liver transplant recipients, in whom survival of the graft may be life-saving.",
"   </p>",
"   <p>",
"    A full history and physical examination, complete blood count (CBC) with differential, and electrolyte and chemistry panels should be obtained prior to starting therapy with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    for rheumatic diseases. Three separate blood pressure measurements and two or three normal plasma creatinine levels are also required as a baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Blood pressure, creatinine, BUN, blood glucose, liver function tests, potassium, and magnesium should be monitored every two weeks for the first three months of therapy, as well as every one to two months thereafter. Plasma creatinine is adequate for follow-up of the renal function; an increase above baseline by more than 30 percent (even if it is still in the normal range) requires a decrease of the dose or a temporary discontinuation of the drug. Similarly, hypertension during therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    should prompt reduction in dose or initiation of anti-hypertensive therapy.",
"   </p>",
"   <p>",
"    The lowest effective dose of medication should be used, and changes in the regimen should be made slowly. Twice daily dosing of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    is usually employed, although once a day administration may be acceptable if the total daily dose is low. Monitoring of cyclosporine and tacrolimus blood concentrations is required. Trough (12-hour) concentrations are used to guide dosing. It is important to note that clinically important toxicity (eg, nephrotoxicity) can occur when doses and concentrations are within the \"therapeutic range.&rdquo;",
"   </p>",
"   <p>",
"    Beyond minimizing the dose, there are no specific measures proven to prevent the nephrotoxicity associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    . As noted above, other potential nephrotoxins should be avoided whenever possible (including nonsteroidal antiinflammatory drugs). Calcium channel blockers prevent acute vasoconstriction but are of uncertain benefit over the long-term. Fish oil has been tried, but its efficacy is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=see_link&amp;anchor=H15#H15\">",
"     \"Cyclosporine and tacrolimus nephrotoxicity\", section on 'Prevention of chronic calcineurin inhibitor nephrotoxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     DOSE AND ADMINISTRATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The oral dose should be based on ideal body weight.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    microemulsion (Neoral&reg;, Gengraf&reg;) is preferred to the regular preparation for its superior pharmacokinetic profile and equal price. Cyclosporine should be administered at a consistent time of the day and in relation to meals to decrease the intra-individual blood level variations. Cyclosporine solution can be mixed with milk, chocolate milk, or orange juice (but not grapefruit juice) at room temperature.",
"   </p>",
"   <p>",
"    The dose and target trough concentration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    vary with the disease being treated. The doses used in patients with different types of organ transplants and primary renal diseases are discussed elsewhere in the appropriate topic reviews.",
"   </p>",
"   <p>",
"    Trough concentrations should be checked two to three days after starting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and after any dose change. Typically, after starting cyclosporine, trough concentrations are measured once or twice weekly for the first month, until results are stable. Thereafter, measurement is only required every two to three months. However, if drugs that affect cyclosporine metabolism are added or withdrawn, more frequent measurement of trough concentrations will be required. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Drug interactions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients should be specifically advised not to consume grapefruit juice and to check with their doctor",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pharmacist before starting additional medications, including herbal medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Rheumatoid arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    microemulsion (Neoral&reg;, Gengraf&reg;) in patients with rheumatoid arthritis (RA) is 2.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (in divided doses). The same starting dose is used in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    . This may be increased at one to two month intervals by 0.5 to 0.75",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day if the desired clinical response does not occur and if the drug is well tolerated. The maximum dose is 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day. Cyclosporine should be discontinued if there is no response after six months of therapy, with at least three months on the maximal tolerated dose.",
"   </p>",
"   <p>",
"    Given the adverse effects associated with such doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , lower initial dosing regimens have been evaluated in patients with RA. However, in a randomized prospective study, an initial dose of 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day was no more effective than placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In responders, the dose should be reduced by 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day every one to two months to the lowest effective dose [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/41,107\">",
"     41,107",
"    </a>",
"    ]. If the clinical response is partial, adding another long-acting antirheumatic drug is an option [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Psoriasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial daily dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    microemulsion (Neoral&reg;, Gengraf&reg;) is 2.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    in two divided doses. The dose can be increased to maximum of 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day as for rheumatoid arthritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Endogenous uveitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with endogenous uveitis (including Beh&ccedil;et&rsquo;s disease), the initial dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    is 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day until remission. A maximal dose of 7",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day may be used for a limited time in refractory disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Other rheumatic diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;No dose guidelines have been established for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    in other rheumatic disorders, but the manufacturer recommends that doses be limited to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day or less.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Conversion to microemulsion formulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 1:1 ratio is generally recommended when converting from the original",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    formulation to the microemulsion formulation. However, with the higher end of the dosing range, especially above 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, it is safer to use microemulsion at a dose that is 15 to 20 percent lower than that of the regular cyclosporine. Frequent monitoring and dose adjustment after conversion is necessary to achieve the lowest effective dose [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Intravenous administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients unable to take oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , the intravenous dose should be equal to one-third of the oral dose and should be given twice daily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Ocular administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;One drop of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ophthalmic emulsion 0.05 percent is instilled into each eye twice daily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Tacrolimus",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4397566\">",
"    <span class=\"h3\">",
"     Oral administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Daily doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    between 0.05 to 0.15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    have been used. A single daily dose ranging from 1 mg to 5 mg was used in rheumatoid arthritis trials [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/39,40,108\">",
"     39,40,108",
"    </a>",
"    ] with dose dependent response and side effects. Tacrolimus 0.075",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily in two divided doses was used in polymyositis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/42\">",
"     42",
"    </a>",
"    ]. Tacrolimus should be administered at a consistent manner in relation to the type and timing of meals [",
"    <a class=\"abstract\" href=\"UTD.htm?27/27/28090/abstract/68\">",
"     68",
"    </a>",
"    ]. However, dose-related effectiveness and toxicity of tacrolimus in rheumatic diseases are not established",
"   </p>",
"   <p>",
"    Trough concentrations should be checked three to four days after starting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    and after any dose change. Typically, after starting tacrolimus, trough concentrations are measured once or twice weekly for the first month, until results are stable. Thereafter, measurement is only required every two to three months. However, if drugs that affect tacrolimus metabolism are added or withdrawn, more frequent measurement of trough concentrations will be required. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Drug interactions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients should be specifically advised not to consume grapefruit juice and to check with their doctor",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pharmacist before starting additional medications, including herbal medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Topical application",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    (Protopic&reg;) is applied to the affected areas of skin twice daily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/40/27266?source=see_link\">",
"       \"Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H841472\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      are immunosuppressive agents occasionally used in the treatment of various immune-mediated diseases; the drugs are available in oral, intravenous, ophthalmic, and topical formulations (",
"      <a class=\"graphic graphic_table graphicRef57518 \" href=\"UTD.htm?4/7/4220\">",
"       table 1",
"      </a>",
"      ). Concerns regarding their long-term toxicity, especially renal dysfunction and hypertension, and the availability of safer and effective agents for many of these conditions have led to reduced use. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Use of cyclosporine and tacrolimus in rheumatic diseases'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Formulations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      reduce T-cell activation through the inhibition of calcineurin after forming complexes in the cytoplasm with cyclophilins and FK binding proteins, respectively. Calcineurin inhibition results in reduced transcription of early cytokine genes, including those for interleukin (IL)-2, tumor necrosis factor, and several others. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanism of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      are only partially absorbed, with large inter- and intra-individual variability that also varies with ethnicity. The oral bioavailability is limited for both drugs due to poor absorption, partial metabolism by enzymes in the bowel mucosa, and first-pass hepatic metabolism. Levels are measured in whole blood. The drugs are lipophilic and undergo extensive body distribution. Cyclosporine does not cross the blood-brain barrier. Both drugs cross placenta and appear in breast milk in substantial amounts; neither drug is removed by hemodialysis to a significant extent. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Pharmacokinetics'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Absorption'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Distribution'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      are metabolized by hepatic cytochrome P450 enzymes in the liver and are excreted into the bile. Liver dysfunction prolongs the half-life of both agents. A variety of important drug interactions with drugs that either affect or are metabolized by these enzymes can occur (",
"      <a class=\"graphic graphic_table graphicRef81998 \" href=\"UTD.htm?14/44/15042\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Metabolism'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Elimination'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Drug interactions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Increased cyclosporine levels'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Decreased cyclosporine levels'",
"      </a>",
"      above and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/8/30858?source=see_link\">",
"       \"Cyclosporine (systemic): Drug information\"",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4778?source=see_link\">",
"       \"Tacrolimus (systemic): Drug information\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The side effects of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      are similar. Nephrotoxicity is the most common and clinically significant adverse effect of both drugs, and hypertension, caused by renal vasoconstriction and sodium retention, generally develops within the first few weeks of therapy. Other potential adverse effects include neurotoxicity, metabolic abnormalities, infections, and an increased risk of malignancy. Contraindications to use depend upon the presence of various comorbidities or hypersensitivity to the agents. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Side effects'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=see_link\">",
"       \"Cyclosporine and tacrolimus nephrotoxicity\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H26\">",
"       'Contraindications and precautions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Strategies have been developed to minimize toxicity when using these medications in patients with rheumatic diseases. Patients require close monitoring, the lowest effective dose of medication should be used, and changes in the regimen should be made slowly. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Strategies to minimize toxicity in rheumatic diseases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The dose of medication and route of administration depend upon the specific condition being treated. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Dose and administration'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H29\">",
"       'Cyclosporine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H37\">",
"       'Tacrolimus'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/1\">",
"      Landew&eacute; RB, Goei Th&egrave; HS, van Rijthoven AW, et al. A randomized, double-blind, 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis. Arthritis Rheum 1994; 37:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/2\">",
"      Tugwell P, Bombardier C, Gent M, et al. Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis. Lancet 1990; 335:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/3\">",
"      Bombardier C, Buchbinder R, Tugwell P. Efficacy of cyclosporin A in rheumatoid arthritis: long-term follow-up data and the effect on quality of life. Scand J Rheumatol Suppl 1992; 95:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/4\">",
"      F&oslash;rre O. Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine. Results of a 48-week multicenter study comparing low-dose cyclosporine with placebo. Norwegian Arthritis Study Group. Arthritis Rheum 1994; 37:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/5\">",
"      Pasero G, Priolo F, Marubini E, et al. Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A. Arthritis Rheum 1996; 39:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/6\">",
"      Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med 1995; 333:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/7\">",
"      Stein CM, Pincus T, Yocum D, et al. Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty-eight weeks: an open-label extension study. The Methotrexate-Cyclosporine Combination Study Group. Arthritis Rheum 1997; 40:1843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/8\">",
"      Wagner SA, Peter RU, Adam O, Ruzicka T. Therapeutic efficacy of oral low-dose cyclosporin A in severe psoriatic arthritis. Dermatology 1993; 186:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/9\">",
"      Salvarani C, Macchioni P, Boiardi L, et al. Low dose cyclosporine A in psoriatic arthritis: relation between soluble interleukin 2 receptors and response to therapy. J Rheumatol 1992; 19:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/10\">",
"      Fry L. Psoriasis: immunopathology and long-term treatment with cyclosporin. J Autoimmun 1992; 5 Suppl A:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/11\">",
"      Mahrle G, Schulze HJ, F&auml;rber L, et al. Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. J Am Acad Dermatol 1995; 32:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/12\">",
"      Ellis CN, Fradin MS, Hamilton TA, Voorhees JJ. Duration of remission during maintenance cyclosporine therapy for psoriasis. Relationship to maintenance dose and degree of improvement during initial therapy. Arch Dermatol 1995; 131:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/13\">",
"      Sajjadi H, Soheilian M, Ahmadieh H, et al. Low dose cyclosporin-A therapy in Beh&ccedil;et's disease. J Ocul Pharmacol 1994; 10:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/14\">",
"      Pistoia V, Buoncompagni A, Scribanis R, et al. Cyclosporin A in the treatment of juvenile chronic arthritis and childhood polymyositis-dermatomyositis. Results of a preliminary study. Clin Exp Rheumatol 1993; 11:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/15\">",
"      Reiff A, Rawlings DJ, Shaham B, et al. Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis. J Rheumatol 1997; 24:2436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/16\">",
"      Zeller V, Cohen P, Prieur AM, Guillevin L. Cyclosporin a therapy in refractory juvenile dermatomyositis. Experience and longterm followup of 6 cases. J Rheumatol 1996; 23:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/17\">",
"      Saadeh C, Bridges W, Burwick F. Dermatomyositis: remission induced with combined oral cyclosporine and high-dose intravenous immune globulin. South Med J 1995; 88:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/18\">",
"      Maeda K, Kimura R, Komuta K, Igarashi T. Cyclosporine treatment for polymyositis/dermatomyositis: is it possible to rescue the deteriorating cases with interstitial pneumonitis? Scand J Rheumatol 1997; 26:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/19\">",
"      Tellus MM, Buchanan RR. Effective treatment of anti Jo-1 antibody-positive polymyositis with cyclosporine. Br J Rheumatol 1995; 34:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/20\">",
"      Dawson JK, Abernethy VE, Lynch MP. Effective treatment of anti Jo-1 antibody-positive polymyositis with cyclosporin. Br J Rheumatol 1997; 36:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/21\">",
"      Qushmaq KA, Chalmers A, Esdaile JM. Cyclosporin A in the treatment of refractory adult polymyositis/dermatomyositis: population based experience in 6 patients and literature review. J Rheumatol 2000; 27:2855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/22\">",
"      Tokuda M, Kurata N, Mizoguchi A, et al. Effect of low-dose cyclosporin A on systemic lupus erythematosus disease activity. Arthritis Rheum 1994; 37:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/23\">",
"      Manger K, Kalden JR, Manger B. Cyclosporin A in the treatment of systemic lupus erythematosus: results of an open clinical study. Br J Rheumatol 1996; 35:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/24\">",
"      Caccavo D, Lagan&agrave; B, Mitterhofer AP, et al. Long-term treatment of systemic lupus erythematosus with cyclosporin A. Arthritis Rheum 1997; 40:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/25\">",
"      Fu LW, Yang LY, Chen WP, Lin CY. Clinical efficacy of cyclosporin a neoral in the treatment of paediatric lupus nephritis with heavy proteinuria. Br J Rheumatol 1998; 37:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/26\">",
"      Hallegua D, Wallace DJ, Metzger AL, et al. Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature. Lupus 2000; 9:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/27\">",
"      Clements PJ, Lachenbruch PA, Sterz M, et al. Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients. Arthritis Rheum 1993; 36:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/28\">",
"      Ippoliti G, Miori L, Negri M, et al. Cyclosporine in treatment of progressive systemic sclerosis: clinical and immunologic findings. Transplant Proc 1994; 26:3117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/29\">",
"      Morton SJ, Powell RJ. Cyclosporin and tacrolimus: their use in a routine clinical setting for scleroderma. Rheumatology (Oxford) 2000; 39:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/30\">",
"      Goldenberg NA, Graham DK, Liang X, Hays T. Successful treatment of severe aplastic anemia in children using standardized immunosuppressive therapy with antithymocyte globulin and cyclosporine A. Pediatr Blood Cancer 2004; 43:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/31\">",
"      Locasciulli A, Bruno B, Rambaldi A, et al. Treatment of severe aplastic anemia with antilymphocyte globulin, cyclosporine and two different granulocyte colony-stimulating factor regimens: a GITMO prospective randomized study. Haematologica 2004; 89:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/32\">",
"      Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330:1841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/33\">",
"      Carbonnel F, Boruchowicz A, Duclos B, et al. Intravenous cyclosporine in attacks of ulcerative colitis: short-term and long-term responses. Dig Dis Sci 1996; 41:2471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/34\">",
"      D'Haens G, Lemmens L, Geboes K, et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001; 120:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/35\">",
"      Mobini N, Padilla T Jr, Ahmed AR. Long-term remission in selected patients with pemphigus vulgaris treated with cyclosporine. J Am Acad Dermatol 1997; 36:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/36\">",
"      Ciafaloni E, Nikhar NK, Massey JM, Sanders DB. Retrospective analysis of the use of cyclosporine in myasthenia gravis. Neurology 2000; 55:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/37\">",
"      Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 2000; 107:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/38\">",
"      Gremillion RB, Posever JO, Manek N, et al. Tacrolimus (FK506) in the treatment of severe, refractory rheumatoid arthritis: initial experience in 12 patients. J Rheumatol 1999; 26:2332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/39\">",
"      Furst DE, Saag K, Fleischmann MR, et al. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study. Arthritis Rheum 2002; 46:2020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/40\">",
"      Yocum DE, Furst DE, Kaine JL, et al. Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: a double-blind trial. Arthritis Rheum 2003; 48:3328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/41\">",
"      Panayi GS, Tugwell P. The use of cyclosporin A microemulsion in rheumatoid arthritis: conclusions of an international review. Br J Rheumatol 1997; 36:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/42\">",
"      Oddis CV, Sciurba FC, Elmagd KA, Starzl TE. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 1999; 353:1762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/43\">",
"      Ierardi E, Principi M, Francavilla R, et al. Oral tacrolimus long-term therapy in patients with Crohn's disease and steroid resistance. Aliment Pharmacol Ther 2001; 15:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/44\">",
"      Van Thiel DH, Wright H, Carroll P, et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol 1995; 90:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/45\">",
"      Bousvaros A, Leichtner AM, Book L, et al. Treatment of pediatric autoimmune enteropathy with tacrolimus (FK506). Gastroenterology 1996; 111:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/46\">",
"      Ishioka M, Ohno S, Nakamura S, et al. FK506 treatment of noninfectious uveitis. Am J Ophthalmol 1994; 118:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/47\">",
"      Mochizuki M, Masuda K, Sakane T, et al. A clinical trial of FK506 in refractory uveitis. Am J Ophthalmol 1993; 115:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/48\">",
"      Jegasothy BV, Ackerman CD, Todo S, et al. Tacrolimus (FK 506)--a new therapeutic agent for severe recalcitrant psoriasis. Arch Dermatol 1992; 128:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/49\">",
"      Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. The European FK 506 Multicentre Psoriasis Study Group. Arch Dermatol 1996; 132:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/50\">",
"      Ruzicka T, Bieber T, Sch&ouml;pf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med 1997; 337:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/51\">",
"      Wiederrecht G, Lam E, Hung S, et al. The mechanism of action of FK-506 and cyclosporin A. Ann N Y Acad Sci 1993; 696:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/52\">",
"      Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992; 13:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/53\">",
"      Kahan BD. Cyclosporine. N Engl J Med 1989; 321:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/54\">",
"      Klintmalm GB. FK 506: an update. Clin Transplant 1994; 8:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/55\">",
"      Timmerman LA, Clipstone NA, Ho SN, et al. Rapid shuttling of NF-AT in discrimination of Ca2+ signals and immunosuppression. Nature 1996; 383:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/56\">",
"      Suzuki N, Kaneko S, Ichino M, et al. In vivo mechanisms for the inhibition of T lymphocyte activation by long-term therapy with tacrolimus (FK-506): experience in patients with Beh&ccedil;et's disease. Arthritis Rheum 1997; 40:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/57\">",
"      Guillen C, Prieto A, Perez-Blas M, et al. Cyclosporine A shows immunosuppressor activity on T lymphocytes from the peripheral blood and synovial fluid of patients with autoimmune arthritis. Clin Exp Rheumatol 1996; 14:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/58\">",
"      Kim WU, Cho ML, Kim SI, et al. Divergent effect of cyclosporine on Th1/Th2 type cytokines in patients with severe, refractory rheumatoid arthritis. J Rheumatol 2000; 27:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/59\">",
"      Shin GT, Khanna A, Ding R, et al. In vivo expression of transforming growth factor-beta1 in humans: stimulation by cyclosporine. Transplantation 1998; 65:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/60\">",
"      Slattery C, Campbell E, McMorrow T, Ryan MP. Cyclosporine A-induced renal fibrosis: a role for epithelial-mesenchymal transition. Am J Pathol 2005; 167:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/61\">",
"      Ishida Y, Matsuda H, Kida K. Effect of cyclosporin A on human bone marrow granulocyte-macrophage progenitors with anti-cancer agents. Acta Paediatr Jpn 1995; 37:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/62\">",
"      Spence MM, Nguyen LM, Hui RL, Chan J. Evaluation of clinical and safety outcomes associated with conversion from brand-name to generic tacrolimus in transplant recipients enrolled in an integrated health care system. Pharmacotherapy 2012; 32:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/63\">",
"      Kivist&ouml; KT. A review of assay methods for cyclosporin. Clinical implications. Clin Pharmacokinet 1992; 23:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/64\">",
"      Peters DH, Fitton A, Plosker GL, Faulds D. Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 1993; 46:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/65\">",
"      Kolars JC, Awni WM, Merion RM, Watkins PB. First-pass metabolism of cyclosporin by the gut. Lancet 1991; 338:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/66\">",
"      Hooks MA. Tacrolimus, a new immunosuppressant--a review of the literature. Ann Pharmacother 1994; 28:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/67\">",
"      Mancinelli LM, Frassetto L, Floren LC, et al. The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin Pharmacol Ther 2001; 69:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/68\">",
"      Bekersky I, Dressler D, Mekki Q. Effect of time of meal consumption on bioavailability of a single oral 5 mg tacrolimus dose. J Clin Pharmacol 2001; 41:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/69\">",
"      Small DS, Acheampong A, Reis B, et al. Blood concentrations of cyclosporin a during long-term treatment with cyclosporin a ophthalmic emulsions in patients with moderate to severe dry eye disease. J Ocul Pharmacol Ther 2002; 18:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/70\">",
"      Iwasaki K, Shiraga T, Matsuda H, et al. Further metabolism of FK506 (tacrolimus). Identification and biological activities of the metabolites oxidized at multiple sites of FK506. Drug Metab Dispos 1995; 23:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/71\">",
"      Jusko WJ, Piekoszewski W, Klintmalm GB, et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 1995; 57:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/72\">",
"      Gruber SA, Hewitt JM, Sorenson AL, et al. Pharmacokinetics of FK506 after intravenous and oral administration in patients awaiting renal transplantation. J Clin Pharmacol 1994; 34:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/73\">",
"      Ma&ntilde;ez R, Martin M, Raman D, et al. Fluconazole therapy in transplant recipients receiving FK506. Transplantation 1994; 57:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/74\">",
"      Fox RI, Morgan SL, Smith HT, et al. Combined oral cyclosporin and methotrexate therapy in patients with rheumatoid arthritis elevates methotrexate levels and reduces 7-hydroxymethotrexate levels when compared with methotrexate alone. Rheumatology (Oxford) 2003; 42:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/75\">",
"      Bosentan (Tracleer) for pulmonary arterial hypertension. Med Lett Drugs Ther 2002; 44:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/76\">",
"      Hoorn EJ, Walsh SB, McCormick JA, et al. The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension. Nat Med 2011; 17:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/77\">",
"      Schwartz RB, Bravo SM, Klufas RA, et al. Cyclosporine neurotoxicity and its relationship to hypertensive encephalopathy: CT and MR findings in 16 cases. AJR Am J Roentgenol 1995; 165:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/78\">",
"      Eidelman BH, Abu-Elmagd K, Wilson J, et al. Neurologic complications of FK 506. Transplant Proc 1991; 23:3175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/79\">",
"      Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group. Lancet 1994; 344:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/80\">",
"      A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. The U.S. Multicenter FK506 Liver Study Group. N Engl J Med 1994; 331:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/81\">",
"      Wijdicks EF, Wiesner RH, Krom RA. Neurotoxicity in liver transplant recipients with cyclosporine immunosuppression. Neurology 1995; 45:1962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/82\">",
"      Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996; 334:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/83\">",
"      Weir MR, Fink JC. Risk for posttransplant Diabetes mellitus with current immunosuppressive medications. Am J Kidney Dis 1999; 34:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/84\">",
"      Neylan JF. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group. Transplantation 1998; 65:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/85\">",
"      Johnson C, Ahsan N, Gonwa T, et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 2000; 69:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/86\">",
"      First MR, Gerber DA, Hariharan S, et al. Posttransplant diabetes mellitus in kidney allograft recipients: incidence, risk factors, and management. Transplantation 2002; 73:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/87\">",
"      Filler G, Neuschulz I, Vollmer I, et al. Tacrolimus reversibly reduces insulin secretion in paediatric renal transplant recipients. Nephrol Dial Transplant 2000; 15:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/88\">",
"      Thi&eacute;baud D, Krieg MA, Gillard-Berguer D, et al. Cyclosporine induces high bone turnover and may contribute to bone loss after heart transplantation. Eur J Clin Invest 1996; 26:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/89\">",
"      Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/90\">",
"      Olshan AF, Mattison DR, Zwanenburg TS. International Commission for Protection Against Environmental Mutagens and Carcinogens. Cyclosporine A: review of genotoxicity and potential for adverse human reproductive and developmental effects. Report of a Working Group on the genotoxicity of cyclosporine A, August 18, 1993. Mutat Res 1994; 317:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/91\">",
"      Cockburn I, Krupp P, Monka C. Present experience of Sandimmun in pregnancy. Transplant Proc 1989; 21:3730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/92\">",
"      Armenti VT, Ahlswede KM, Ahlswede BA, et al. National transplantation Pregnancy Registry--outcomes of 154 pregnancies in cyclosporine-treated female kidney transplant recipients. Transplantation 1994; 57:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/93\">",
"      Landewe RB, Goei The HS, van Rijthoven AW, et al. Cyclosporine in common clinical practice: an estimation of the benefit/risk ratio in patients with rheumatoid arthritis. J Rheumatol 1994; 21:1631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/94\">",
"      Thomas AG, Burrows L, Knight R, et al. The effect of pregnancy on cyclosporine levels in renal allograft patients. Obstet Gynecol 1997; 90:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/95\">",
"      Kainz A, Harabacz I, Cowlrick IS, et al. Review of the course and outcome of 100 pregnancies in 84 women treated with tacrolimus. Transplantation 2000; 70:1718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/96\">",
"      Dongari A, McDonnell HT, Langlais RP. Drug-induced gingival overgrowth. Oral Surg Oral Med Oral Pathol 1993; 76:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/97\">",
"      Cutolo M, Giusti M, Villaggio B, et al. Testosterone metabolism and cyclosporin A treatment in rheumatoid arthritis. Br J Rheumatol 1997; 36:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/98\">",
"      Thomas DW, Newcombe RG, Osborne GR. Risk factors in the development of cyclosporine-induced gingival overgrowth. Transplantation 2000; 69:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/99\">",
"      Wong W, Hodge MG, Lewis A, et al. Resolution of cyclosporin-induced gingival hypertrophy with metronidazole. Lancet 1994; 343:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/100\">",
"      Cecchin E, Zanello F, De Marchi S. Treatment of cyclosporine-induced gingival hypertrophy. Ann Intern Med 1997; 126:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/101\">",
"      G&oacute;mez E, S&aacute;nchez-Nu&ntilde;ez M, S&aacute;nchez JE, et al. Treatment of cyclosporin-induced gingival hyperplasia with azithromycin. Nephrol Dial Transplant 1997; 12:2694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/102\">",
"      Thorp M, DeMattos A, Bennett W, et al. The effect of conversion from cyclosporine to tacrolimus on gingival hyperplasia, hirsutism and cholesterol. Transplantation 2000; 69:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/103\">",
"      Talbot D, Rix D, Abusin K, et al. Alopecia as a consequence of tacrolimus therapy in renal transplantation? Transplantation 1997; 64:1631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/104\">",
"      Shapiro R, Jordan ML, Scantlebury VP, et al. Alopecia as a consequence of tacrolimus therapy. Transplantation 1998; 65:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/105\">",
"      Tricot L, Lebb&eacute; C, Pillebout E, et al. Tacrolimus-induced alopecia in female kidney-pancreas transplant recipients. Transplantation 2005; 80:1546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/106\">",
"      Altman RD, Schiff M, Kopp EJ. Cyclosporine A in rheumatoid arthritis: randomized, placebo controlled dose finding study. J Rheumatol 1999; 26:2102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/107\">",
"      Cush JJ, Tugwell P, Weinblatt M, Yocum D. US consensus guidelines for the use of cyclosporin A in rheumatoid arthritis. J Rheumatol 1999; 26:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/27/28090/abstract/108\">",
"      Kremer JM, Habros JS, Kolba KS, et al. Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate: a six-month, open-label study. Arthritis Rheum 2003; 48:2763.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7995 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-B2700F0D78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_27_28090=[""].join("\n");
var outline_f27_27_28090=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H841472\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      USE OF CYCLOSPORINE AND TACROLIMUS IN RHEUMATIC DISEASES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      FORMULATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cyclosporine microemulsion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cyclosporine ophthalmic emulsion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PHARMACOKINETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Absorption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Distribution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Elimination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Increased cyclosporine levels",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Decreased cyclosporine levels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SIDE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Neurotoxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Metabolic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Risk of malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Pregnancy and lactation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Other side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Contraindications and precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      STRATEGIES TO MINIMIZE TOXICITY IN RHEUMATIC DISEASES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      DOSE AND ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Psoriasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Endogenous uveitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Other rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Conversion to microemulsion formulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Intravenous administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Ocular administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4397566\">",
"      - Oral administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Topical application",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H841472\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7995\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7995|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/7/4220\" title=\"table 1\">",
"      Cyclosporine FK506 preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/44/15042\" title=\"table 2\">",
"      Drug interactions with immunosuppressants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33354?source=related_link\">",
"      Alternative and experimental agents for the treatment of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/8/30858?source=related_link\">",
"      Cyclosporine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=related_link\">",
"      Cyclosporine and tacrolimus nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=related_link\">",
"      Development of malignancy following solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9562?source=related_link\">",
"      Drugs that affect bone metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42631?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43706?source=related_link\">",
"      Maintenance immunosuppressive therapy in renal transplantation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/40/27266?source=related_link\">",
"      Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43273?source=related_link\">",
"      Reversible posterior leukoencephalopathy syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4778?source=related_link\">",
"      Tacrolimus (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/9/31898?source=related_link\">",
"      Treatment of minimal change disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/57/34714?source=related_link\">",
"      Treatment of primary focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=related_link\">",
"      Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_27_28091="Ventricular and atrial pacers";
var content_f27_27_28091=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79459&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79459&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Types of cardiac pacemakers and NBG codes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Code",
"       </td>",
"       <td class=\"subtitle1\">",
"        Meaning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        VOO",
"       </td>",
"       <td>",
"        Asynchronous ventricular pacemaker; no adaptive rate control or antitachyarrhythmia functions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        VVI",
"       </td>",
"       <td>",
"        Ventricular \"demand\" pacemaker with electrogram-waveform telemetry; no adaptive rate control or antitachyarrhythmia functions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DVI",
"       </td>",
"       <td>",
"        Multiprogrammable atrioventricular-sequential pacemaker; no adaptive rate control",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DDD",
"       </td>",
"       <td>",
"        Multiprogrammable \"physiologic\" dual-chamber pacemaker; no adaptive rate control or antitachyarrhythmia functions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DDI",
"       </td>",
"       <td>",
"        Multiprogrammable",
"DDI pacemaker (with dual-chamber pacing and sensing but without",
"atrial-synchronous ventricular pacing); no adaptive rate control or",
"antitachycardia functions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        VVIR",
"       </td>",
"       <td>",
"        Adaptive-rate VVI pacemaker with escape interval controlled adaptively by one or more unspecified variables",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DDDR",
"       </td>",
"       <td>",
"        Programmable DDD pacemaker with escape interval controlled adaptively by one or more unspecified variables",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_27_28091=[""].join("\n");
var outline_f27_27_28091=null;
var title_f27_27_28092="Caffeine source amount";
var content_f27_27_28092=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61405&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61405&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Caffeine source and amount*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Source",
"       </td>",
"       <td class=\"subtitle1\">",
"        Caffeine (mg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Coffee (generic brewed; 8 ounces)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drip (8 ounces)",
"       </td>",
"       <td>",
"        95-200",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Regular instant (8 ounces)",
"       </td>",
"       <td>",
"        27-173",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Decaffeinated instant (8 ounces)",
"       </td>",
"       <td>",
"        2-12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Espresso (1 -2 oz)",
"       </td>",
"       <td>",
"        45-100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Decaffeinated espresso (1 ounces)",
"       </td>",
"       <td>",
"        0-20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Starbucks grande (16 oz)",
"       </td>",
"       <td>",
"        330",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Cocoa and chocolate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cocoa from mix (6 ounces)",
"       </td>",
"       <td>",
"        9 (3-12)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Milk chocolate (1 ounce)",
"       </td>",
"       <td>",
"        6-9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Baking chocolate (1 ounce)",
"       </td>",
"       <td>",
"        35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Soft drinks (12 ounces) **",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dr. Pepper",
"       </td>",
"       <td>",
"        41",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Regular cola",
"       </td>",
"       <td>",
"        35-45",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diet cola",
"       </td>",
"       <td>",
"        35-55",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Tea (8 ounces)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1 minute brew",
"       </td>",
"       <td>",
"        9-33",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3 minute brew",
"       </td>",
"       <td>",
"        40-120",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Instant",
"       </td>",
"       <td>",
"        12-28",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Canned iced tea (12 ounces)",
"       </td>",
"       <td>",
"        22-36",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * It is important to remember that these figures are approximate and vary among products. In addition, different types of beans and teas have different caffeine contents, and the way the beverage is brewed also affects the caffeine content.",
"     <br>",
"      <br>",
"       ** US FDA limit for cola and Dr. Pepper soft drinks is 71 mg.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_27_28092=[""].join("\n");
var outline_f27_27_28092=null;
var title_f27_27_28093="Table of intrinsic muscles of the hand";
var content_f27_27_28093=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F66991&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F66991&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Intrinsic muscles of the hand",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Muscle",
"       </td>",
"       <td class=\"subtitle1\">",
"        Proximal attachment",
"       </td>",
"       <td class=\"subtitle1\">",
"        Distal attachment",
"       </td>",
"       <td class=\"subtitle1\">",
"        Innervation*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Main action",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Thenar muscles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Opponens pollicis",
"       </td>",
"       <td rowspan=\"5\">",
"        Flexor retinaculum and tubercles of scaphoid and trapezium",
"       </td>",
"       <td>",
"        Lateral side of 1st metacarpal",
"       </td>",
"       <td rowspan=\"4\">",
"        Recurrent branch of medial nerve (",
"        <strong>",
"         C8",
"        </strong>",
"        , T1)",
"       </td>",
"       <td>",
"        To oppose thumb, it draws 1st metacarpal medially to center of palm and rotates it medially",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Abductor pollicis brevis",
"       </td>",
"       <td rowspan=\"4\">",
"        Lateral side of base of proximal phalanx of thumb",
"       </td>",
"       <td>",
"        Abducts thumb; helps oppose it",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flexor pollicis brevis",
"       </td>",
"       <td>",
"        Flexes thumb",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Superficial head",
"       </td>",
"       <td rowspan=\"5\">",
"        Adducts thumb toward lateral border of palm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Deep head",
"       </td>",
"       <td rowspan=\"4\">",
"        Deep branch of ulnar nerve (C8,",
"        <strong>",
"         T1",
"        </strong>",
"        )",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Adductor pollicis",
"       </td>",
"       <td rowspan=\"2\">",
"        Bases of 2nd and 3rd metacarpals, capitate, adjacent carpals",
"       </td>",
"       <td rowspan=\"3\">",
"        Medial side of base of proximal phalanx of thumb",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Oblique head",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Transverse head",
"       </td>",
"       <td>",
"        Anterior surface of shaft of 3rd metacarpal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Hypothenar muscles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Abductor digiti minimi",
"       </td>",
"       <td>",
"        Pisiform",
"       </td>",
"       <td rowspan=\"2\">",
"        Medial side of base of proximal phalanx of 5th finger",
"       </td>",
"       <td rowspan=\"3\">",
"        Deep branch of ulnar nerve (C8,",
"        <strong>",
"         T1",
"        </strong>",
"        )",
"       </td>",
"       <td>",
"        Abducts 5th finger; assists in flexion of its proximal phalanx",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flexor digiti minimi brevis",
"       </td>",
"       <td rowspan=\"2\">",
"        Hook of hamate and flexor retinaculum",
"       </td>",
"       <td>",
"        Flexes proximal phalanx of 5th finger",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Opponens digiti minimi",
"       </td>",
"       <td>",
"        Medial border of 5th metacarpal",
"       </td>",
"       <td>",
"        Draws 5th metacarpal anterior and rotates it, bringing 5th finger into opposition with thumb",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Short muscles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lumbricals",
"       </td>",
"       <td rowspan=\"2\">",
"        Lateral two tendons of flexor digitorum profundus (as unipennate muscles)",
"       </td>",
"       <td rowspan=\"3\">",
"        Lateral sides of extensor expansions of 2nd-5th fingers",
"       </td>",
"       <td rowspan=\"2\">",
"        Median nerve (C8,",
"        <strong>",
"         T1",
"        </strong>",
"        )",
"       </td>",
"       <td rowspan=\"3\">",
"        Flex metacarpophalangeal joints; extend interphalangeal joints of 2nd-5th fingers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        1st and 2nd",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        3rd and 4th",
"       </td>",
"       <td>",
"        Medial three tendons of flexor digitorum profundus (as bipennate muscles)",
"       </td>",
"       <td rowspan=\"3\">",
"        Deep branch of ulnar nerve (C8,",
"        <strong>",
"         T1",
"        </strong>",
"        )",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dorsal interossei, 1st-4th",
"       </td>",
"       <td>",
"        Adjacent sides of two metacarpals (as bipennate muscles)",
"       </td>",
"       <td>",
"        Bases of proximal phalanges; extensor expansions of 2nd-4th fingers",
"       </td>",
"       <td>",
"        Abduct 2nd-4th fingers from axial line; act with lumbricals in flexing metacarpophalangeal joints and extending interphalangeal joints",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Palmar interossei, 1st-3rd",
"       </td>",
"       <td>",
"        Palmar surfaces of 2nd, 4th, and 5th metacarpals (as unipennate muscles)",
"       </td>",
"       <td>",
"        Bases of proximal phalanges; extensor expansions of 2nd, 4th, and 5th fingers",
"       </td>",
"       <td>",
"        Adduct 2nd, 4th, and 5th fingers toward axial line; assist lumbricals in flexing metacarpophalangeal joints and extending interphalangeal joints; extensor expansions of 2nd-4th fingers",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The spinal cord segmental innervation is indicated (eg, \"",
"     <strong>",
"      C8",
"     </strong>",
"     , T1\" means that the nerves supplying the opponens pollicis are derived from the eighth cervical segment and first thoracic segment of the spinal cord). Numbers in boldface (",
"     <strong>",
"      C8",
"     </strong>",
"     ) indicate the main segmental innervation. Damage to one or more of the listed spinal cord segments or to the motor nerve roots arising from them results in paralysis of the muscles concerned.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moore KL, Dalley AR. Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_27_28093=[""].join("\n");
var outline_f27_27_28093=null;
var title_f27_27_28094="Mandibular advan splint II";
var content_f27_27_28094=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mandibular advancement splint",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 290px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This mandibular advancement splint is manufactured in a laboratory from dental impressions (Klearway appliance, Great Lakes Orthodontics, Inc, Tonawanda, NY). Special features stressed by the manufacturer are the full dental coverage, the low profile of the appliance, and adjustability of mandibular position by means of a screw.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_27_28094=[""].join("\n");
var outline_f27_27_28094=null;
var title_f27_27_28095="Lateral x-ray of intertrochanteric hip fracture";
var content_f27_27_28095=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F52543&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F52543&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lateral x-ray of intertrochanteric hip fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 388px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This lateral plain radiograph shows an intertrochanteric fracture of the hip.&nbsp;On this view, there appears to be no displacement&nbsp;and the hip joint appears intact with the&nbsp;femoral head&nbsp;properly seated in the acetabulum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bucholz RW, MD and Heckman JD, MD. Rockwood &amp; Green's Fractures in Adults, 5th ed. Lippincott Williams &amp; Wilkins, 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_27_28095=[""].join("\n");
var outline_f27_27_28095=null;
